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ABSTRACT
BAYESIAN ADAPTIVE DESIGNS AND VERSATILE SOFTWARE PLATFORM
FOR EARLY PHASE CLINICAL TRIALS
Yanhong Zhou, M.S.
Advisory Professors: J. Jack Lee, Ph.D. & Ying Yuan, Ph.D.

This research is dedicated to improve the efficiency of Bayesian adaptive designs for
early phase clinical trials. Phase I clinical trials can be conducted using algorithmbased (also known as rule-based), model-based, or model-assisted designs. Numerous
studies have shown that model-assisted designs have the simplicity of algorithm-based
designs while possessing the great performance of the model-based designs. Despite
the desirable properties of current model-assisted designs, their use is still limited.
More importantly, they can fall short of tackling some emerging challenges brought
by the development of novel therapies. Thus, there is a pressing need for modelassisted designs that can complement the current designs. In this work, we first clarify some mis-conceptions between algorithm-based designs and the model-assisted
designs with the purpose to eliminate the confusion caused by the designs’ similarity
in their appearance. Second, we develop a class of novel model-assisted designs that
aim to accommodate the urgent need to utilize readily available historical data or
real-word evidence to further improve the efficiency of the Phase I model-assisted designs. Third, we construct a seamless Phase I/II design that addresses the challenges
emerging along with the vast development of immunotherapy and targeted therapy.
Fourth, we develop a versatile software platform to provide user-friendly web-based
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applications to facilitate the use of a series of well-performed model-assisted designs
that are built on sound statistical foundations and have superior operating characteristics (e.g., have high probability of identify the MTD and treat a large number
of patients on the MTD). In addition to the important issues addressed for Phase I
model-assisted designs, we also include the examination of a critical topic in Phase II
clinical trials: sequential monitoring. We thoroughly study the connections between
different sequential monitoring approaches theoretically. Furthermore, we conduct
extensive simulations to examine the impact of different types of prior distributions
on the false positive rate and power to test the efficacy of a treatment, and provide
practical recommendations for Phase II sequential monitoring. Our research will
greatly advance drug development as it not only provides a wide range of innovative
designs, but also creates user-friendly versatile software platforms to facilitate the
implementation of the novel designs.
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CHAPTER 1

Background

A clinical trial is defined by the National Institutes of Health (NIH) as a
research study in which human subjects are prospectively assigned to receive an
intervention (e.g., a new drug) in order to evaluate the effect of this intervention
on “health-related biomedical or behavioral outcomes” [76]. In a clinical trial, the
outcome used to objectively measure the effect of the intervention is referred to as
endpoint. Common endpoints are dose limiting toxicity (DLT), tumor response, and
survival.
Traditionally, clinical trials for drug development involve several critical stages:
Phase I, Phase II, Phase III, and Phase IV, each with a different objective. A Phase
I trial primarily aims at identifying the maximum tolerated dose (MTD), defined
as the highest dose with acceptable level of toxicity. After the toxicity profile has
been investigated and the MTD for the new treatment has been determined, a Phase
II clinical trial is conducted at the MTD to evaluate whether the new treatment is
efficacious. Once the efficacy of the drug is confirmed in a Phase II study based on
pre-selected short-term endpoint (e.g., tumor response), a confirmatory trial (i.e.,
Phase III) will be conducted. In Phase III, the most desirable outcome is to get the
drug approved by relevant regulatory agents (e.g., Food and Drug Administration in
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the U.S.). The primary endpoint is often time to a certain adverse event (e.g., death)
and the approval of the drug requires comparing the new treatment to a standard of
care with a certain improvement margin (e.g., on overall survival). Once the drug is
approved based on the results of a Phase III study and released into the market, a
Phase IV trial may be conducted to continuously monitor the long-term side effect
of the drug.
Our research work is primarily focused on Bayesian adaptive designs for early
phase (Phase I or II) clinical trials. The main purpose of Phase I studies is to evaluate the safety (or study the toxicity profile) of a new drug and identify the MTD.
In general, the endpoint in Phase I trials is binary, i.e., whether or not a patient
experiences a dose-limiting toxicity (DLT), which refers to side effects caused by the
treatment under investigation that are severe enough to prevent an increase in the
dosage of the drug. The corresponding parameter of interest (i.e., any numerical
quantity that tells us something about the effect of the new intervention) is the proportion of patients who experience at least one DLT. The earliest class of designs
proposed to identify the MTD is rule-based [4] or algorithm-based [119]. Rule or
algorithm-based means that there is no assumption on the true dose-toxicity curve
and that dose assignment in the trial is based on a set of ad hoc prespecified rules.
Classical examples include the conventional 3+3 design originated in the 1940s [19],
the pharmacologically guided dose escalation design [17], and the accelerated titration design [89] proposed in the 1990s, among others. The eminent advantages of the
algorithm-based designs are that they are easy to implement and require no special
software. However, they are typically rigid and also have undesirable properties, such
as the implicit target DLT probability, poor accuracy to identify the MTD, and the
likeliness of assigning patients to sub-therapeutic doses [114].
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Other good alternatives for finding the MTD are model-based designs. Modelbased designs assume that dose-toxicity curve is monotonically increasing with dose
levels. The most widely used or cited model-based design are continual reassessment
method (CRM [77]) and its extensions: escalation with overdose control (EWOC
[2]), Bayesian logistics regression model (BLRM [74]), and Bayesian model averaging
CRM (BMA-CRM [111]), among others [53, 63, 68]. Compared to algorithm-based
designs, the model-based designs generally have better operating characteristics, including greater accuracy to identify the MTD and a larger number of patients assigned to the MTD [119]. However, because the model-based designs require repeat
model fitting during trials to guide dose assignment, they are perceived to be “black
boxes” that are hard for practitioners to comprehend. Due to such a perception
along with the inconvenience of the implementation, their use is quite limited. Thus,
despite the conventional 3+3 design has well-documented flaws, it remains dominant
in Phase I clinical trials.
To combine the simplicity of algorithm-based designs and the superior performance of model-based designs, a series of model-assisted designs have been proposed,
including the Bayesian optimal interval design (BOIN [65]), keyboard [105], modified
toxicity probability interval design (mTPI [43]), among a few others ([31, 60]). Similar to the model-based designs, the model-assisted designs utilize a statistical model
to derive efficient decision rules for real-time decision making. The difference between
model-assisted and model-based designs is that the dose escalation and de-escalation
rules in the former can be pre-determined before the onset of a trial. Thus, modelassisted designs are as simple as the conventional 3+3 to implement. Many studies
have conducted comprehensive comparisons among algorithm-based, model-based,
and model-assisted designs. The studies found that the easy-to-use model-assisted
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designs greatly outperform the 3+3 design and have comparable performance to the
more complicated model-based designs [85, 124, 125]. Among the model-assisted
designs, BOIN and keyboard stand out with their greater accuracy, safety, and reliability. Here, accuracy is quantified using the probability of correctly identifying
the MTD and the number of patients treated at the MTD; safety is measured by
the percentage of treating patients above MTD and of selecting overly toxic dose as
MTD; and reliability is measured by the probability of assigning 50% or more patients at doses above the MTD and the probability of assigning less than six patients
at the MTD.
Despite the marvelous performance of the model-assisted designs, the designs can sometimes fall short of tackling the emerging challenges in recent early
phase trials. Additionally, the lack of user-friendly software has limited the use of
those designs. Thus, there is a pressing need for developing model-assisted designs
that can complement the current designs and for building reliable, interactive, and
freely available software to facilitate the use of the novel designs. In this work, we
first clarify some mis-conceptions between algorithm-based designs and the modelassisted designs with the purpose to eliminate the confusion caused by the designs’
similarity in their appearance. Second, we develop a class of novel model-assisted
designs that aim to accommodate the urgent need to utilize readily available historical data or real-word evidence to further improve the efficiency of the model-assisted
Phase I designs. Third, we construct a seamless early phase trial design that addresses the challenges emerging along with the vast development of immunotherapy
and targeted therapy. Fourth, we develop a versatile software platform to provide
user-friendly web-based applications to facilitate the use of a series of well-performed
model-assisted designs that are built on sound statistical foundations and have su-
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perior operating characteristics (e.g., have high probability of identify the MTD and
treat a large number of patients at the MTD). In addition to the important issues
addressed for model-assisted Phase I designs, we also include the examination of a
critical topic in Phase II clinical trials: sequential monitoring. We thoroughly studied the connections between different sequential monitoring approaches theoretically.
Furthermore, we conduct extensive simulations to examine the impact of different
type of prior distributions on the false positive rate and power to test the efficacy of
a treatment, and provide practical recommendations for Phase II sequential monitoring. Our research will greatly advance drug development as it not only provides
a wide range of innovative designs, but also creates user-friendly versatile software
platforms to facilitate the implementation of the novel designs. In the text below,
we provide an overview of each of the five projects.
1.1

Model-assisted design versus algorithm-based design
Comprehensive comparisons among algorithm-based, model-based, and model-

assisted designs have been conducted in previous studies [85, 124, 125]. The studies
showed that model-assisted designs (e.g., BOIN and keyboard) outperform algorithmbased designs in terms of the accuracy, safety, and reliability, and have comparable
performance to more complicated model-based designs. BOIN is a well validated
design and has gained a lot of popularity in various types of Phase I clinical trials
[114]. The most well-known hallmark of the BOIN design is its concise decision rule:
making the decision of dose escalation and de-escalation by simply comparing the
observed DLT probability at the current dose with a pair of optimal dose escalation
and de-escalation boundaries. Recently, an interval 3+3 (i3+3) design has been proposed and shown to have comparable performance to BOIN in the original paper
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[60]. The i3+3 design is an algorithm-based dose-finding design using a BOIN-like
decision rule with some modifications. The similarity in the appearance of the two
designs has caused substantial confusions among practitioners. In this project, we
aim to demystify the i3+3 design by elucidating its links with the BOIN design and
compare their similarities and differences, as well as pros and cons. The comparison is illustrated in both their theoretical foundations and operating characteristics
based on extensive simulation studies.
1.2

Use informative prior to improve the efficiency of model-assisted
Phase I clinical trial designs
Incorporating historical data or real-world evidence has a great potential to

improve the success of Phase I clinical trials and accelerate drug development. For
model-based Phase I designs such as CRM [77], this can be conveniently carried out
by specifying a “skeleton”, i.e., the prior estimate of DLT probability at each dose.
In contrast, little work has been done to incorporate historical data or real-world evidence into model-assisted designs, such as BOIN, keyboard, and mTPI designs. This
has led to the misconception that model-assisted designs cannot incorporate informative prior information. To improve the efficiency of the model-assisted designs, we
propose a unified framework that allows incorporating historical data or real-world
evidence into the derivation of the decisions rules in these designs. The proposed
approach adapts the well-established “skeleton” approach, combined with the concept of prior effective sample size. It is easy to understand and use. In addition, this
approach maintains the hallmark of the model-assisted design: simplicity−the dose
escalation/de-escalation rules can be tabulated prior to the trial conduct [114].
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1.3

Seamless Phase I/II design for identifying optimal biological dose
In the era of targeted therapy and immunotherapy, the objective of dose

finding is to identify the optimal biological dose (OBD) instead of the MTD. The
OBD is typically the most desirable dose that considers the trade-off between toxicity
and efficacy. Thus, traditional Phase I trials that evaluate toxicity information alone
by assuming the monotonicity of dose-toxicity curve may fail to find the optimal dose
for subsequent trials. This is because the monotonicity assumption for dose-toxicity
relationship implies a dose-response curve that also monotonically increases with
dose level. Although it is reasonable to assume that toxicity increases with the dose,
the same is not necessarily true for efficacy, since clinical research has shown that
the dose-response curve can plateau or even decrease after a certain level of doseage
of some immunotherapies or targeted therapies [83]. Thus considering both toxicity
and efficacy should be an ideal approach, which indicates the need for seamless
Phase I/II designs [118]. There are three general optimization approaches in Phase
I/II designs to deal with the trade-off between toxicity and efficacy [117]. The first
approach is to set an upper limit on acceptable DLT probability, identify doses with
estimated DLT probability less than the limit, and select the optimal dose as the
one with the largest efficacy probability; or set a lower limit on acceptable efficacy
probability, identify doses with efficacy probability greater than the limit, and select
the optimal dose as the one with the smallest DLT probability. The second strategy
is to map the joint probability of efficacy and toxicity to a numerical value that
quantifies the desirability of the dose, where the numerical value is determined by
certain prior specifications and model fitting. Another great alternative is to assign
a numerical utility value to all the possible combinations of the toxicity endpoint

7

and efficacy endpoint, where a model is assumed for all the joint outcomes. The
utility quantifies how useful each outcome is for patients using a prespecified scale
(e.g., 0-10, or 1-100). With the posterior DLT probability obtained for all doses,
the expected posterior mean utilities for the doses are easily determined and used to
guide dose assignment in the trial.
One of the classical Phase I/II designs is the EffTox design [97, 96] that
uses the second strategy to measure the treadoff between binary toxicity and efficacy. Yuan and Yin [118] proposed the time-to-event EffTox (TTE-EffTox) that
jointly models toxicity and efficacy as time-to-event outcomes. Both of the designs
are model-based with certain parametric assumption on the dose-toxicity and doseresponse curves. And their decision rules cannot be tabulated. Additionally, quantifying the trade-off based on model fitting is also sensitive to the prior specifications.
To overcome the limitations, we propose a model-assisted Phase I/II design
that jointly evaluates toxicity and efficacy using a utility function to measure riskbenefit (i.e., toxicity-efficacy) trade-off after sufficient data are accumulated in stage
I using the BOIN design (the design is referred to as U-BOIN). The advantage of the
utility-based approach is that it is more straightforward to elicit from clinicians and
is also applicable for trials with ordinal or time-to-event outcomes. Specifically, the
U-BOIN design consists of two seamlessly connected stages. In stage I, the U-BOIN
design quickly explores the dose space and collects preliminary toxicity and efficacy
data. In stage II, a multinomial-Dirichlet model is utilized to model toxicity and
efficacy endpoints jointly and a utility function elicited from clinicians is employed
to measure the dose risk-benefit trade-off. Based on the accumulating efficacy and
toxicity from both stages I and II, U-BOIN continuously updates the posterior estimate of the utility for each dose after each cohort, and uses this information to
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direct the dose assignment and selection. Compared to existing Phase I/II designs,
one prominent advantage of the U-BOIN design is its simplicity for implementation.
Once the trial is designed, it can be easily applied using predetermined decision tables, without complex model fitting and parameter estimation. Our simulation study
shows that, despite its simplicity, the U-BOIN design is robust and has high accuracy
to identify the OBD. In this project, we also extend the design to accommodate delayed efficacy by leveraging the short-term endpoint (e.g., immune activity or other
biological activity of targeted agents), and using it to predict the delayed responses
to facilitate real-time decision making.
1.4

Versatile software platform of Bayesian adaptive designs for early
phase clinical trials
It has been shown in previous studies [124, 125] that the model-assisted de-

signs BOIN and keyboard have greater operating characteristics in that they both
perform better than 3+3 in terms of accuracy and reliability, and are safer than
model-based designs such as CRM and other model-assisted designs (e.g., mTPI).
Moreover, the use of the designs can result in larger success rate in later phases [85].
The standard BOIN and keyboard designs can be used only in single-agent trials
with binary endpoint and requires fully observed toxicity outcomes for all patients
in the trial in order to make dose assignment decisions. Researchers have extended
the two designs to accommodate commonly encountered challenges in Phase I clinical trials, such as fast accrual or delayed toxicity outcomes [116, 57], evaluation of
drug combinations [121, 56], identification of the OBD instead of the MTD [126],
and incorporation of historical or real-world evidence [127]. All these designs are
model-assisted and easy to implement once the decisions rules are determined before
trials start. However, the conventional 3+3 still remains as the dominant method
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used in Phase I clinical trials to identify the MTD, despite the well-documented flaws
of this design. The lack of reliable, robust, and easy-to-use software has limited the
use of these novel designs in clinical trials, since it is not convenient for practitioners
to evaluate the accuracy and reliability of the designs and they are likely to continue
to use the approach they are already familiar with. Lee and Chu [39] suggested
that “the availability of accompanying software for the implementation of Bayesian
methods is crucial for the use of these methods in clinical trials”. Some software
applications have been developed to make model-based designs easier to implement
[79, 100, 102]. But few works have been done to make the aforementioned modelassisted designs more accessible for practitioners, even though there are existing R
packages, such as BOIN package. The use of a R package would require a certain
level of programming knowledge, which is not easy for everyone. Thus, it remains
a challenge for practitioners to evaluate the operating characteristics of the designs
without programming skills. A broader use of the model-assisted designs requires
robust yet user-friendly interactive software.
To facilitate the use of model-assisted designs for designing and conducting Phase I clinical trials and make it more accessible for clinicians who may not
have expertise in statistical programming, we develop a web-based software platform
for BOIN design and its extensions (BOIN suite), and Keyboard and its extensions (Keyboard suite), respectively. Compared to other existing web-based applications, one distinct feature of our software platform is that each of the two suites
includes multiple model-assisted designs that can accommodate different challenges
in Phase I clinical trials. The BOIN suite includes designs for single-agent trials
using non-informative prior (standard BOIN [65]) or incorporating historical data
(iBOIN [127]); for single-agent trials with fast accrual or delayed toxicity (TITE-
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BOIN [116]); for drug-combination (BOIN COMB) to find a single MTD [56] or a
MTD contour [121]; for finding OBD based on risk-benefit trade-offs in immunothearpy and targeted therapy trials (U-BOIN [126]). The Keyboard suite includes
designs for single-agent trials without delayed outcomes (KEYBOARD [105]) or delayed outcomes (TITE-KEYBOARD [57]); and for combination trials to find a single
MTD (KEYBOARD COMB [80]). In addition to the interactive and self-explanatory
interface of the web-based applications, extensive help files have also been provided
to aid the understanding of the designs and navigate the use of the applications.
1.5

Sequential monitoring in Phase II designs
Phase II clinical trials play a critical role in drug development, as their ob-

jective is to evaluate the therapeutic effect of a new treatment, and to screen out
in-efficacious ones. If the new treatment shows promising treatment effect, further
large-scale confirmatory trials can be carried forward. In general, Phase II trials use
a short-term and dichotomous endpoint to characterize the patient clinical response
to treatment. For example, a binary objective response endpoint can be used to
indicate whether a patient has achieved complete or partial response within a predefined treatment course. A Phase II study can be performed using either frequentist
or Bayesian designs. Regardless of the type of designs, interim analysis has been
the common feature of Phase II clinical trials to prevent from overdosing patients
or exposing patients to sub-therapeutic treatment. Most of the frequentist Phase II
designs only have two or three stages with the design parameters determined based
on numerical searching. When the number of interim analyses exceeds three or when
a continuous endpoint is considered, it is computationally infeasible to determine
the optimal design parameters for the frequentist designs. Moreover, the frequentist
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designs are rigid in the sense that they do not allow any deviation from the original
design. For example, for the Simon’s two-stage design [88], the “go/no-go” decisions
can only be made at the predetermined interim times, and it will not stop the trial
early even when early observed data have already indicated that the drug is indeed
futile. To safe guard patients from futile treatments and accelerate the development
of efficacious drugs, it is critical to make adaptive decisions based on the accumulated data throughout the trial in a timely fashion such that the trial can be stopped
earlier for futility or efficacy.
When more interim analyses are desired, Bayesian methods becomes particularly appealing due to its “we learn as we go” nature [39]. As a result, Bayesian
designs usually are more flexible in making multiple interim decisions.

Due to

the appealing feature of flexibility, recent years have witnessed vast development in
Bayesian Phase II clinical trial designs [32, 45, 49, 86, 94, 98, 99, 103, 122]. Overall,
existing Bayesian sequential monitoring approaches can be divided into two categories: posterior (or predictive) probability based (PB) [98, 49] or Bayesian hypothesis test based (TB) [45]. For the PB approach, the “go/no-go” decisions are made
based on the Bayesian posterior (or predictive) probability that the treatment is futile or effective. If such a probability is greater than a prespecified upper probability
cutoff, then the trial can be terminated early, because the experimental treatment
is likely to be futile or promising; Otherwise (i.e., this probability is small), there is
not adequate information to deliver any conclusion, and the trial continues to collect
more data. On the other hand, the TB approach makes the adaptive “go/no-go”
decisions based on the Bayesian hypothesis testing framework with the Bayes factor.
Although Johnson and Cook [45] argued that the use of Bayes factor in sequential
monitoring can gain more efficiency compared to the PB approach and can also elim-
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inate a potential source of bias often caused by prior-data conflict, the research on
the TB approach for Phase II trials is lacking. Limited examples include the twostage Bayes factor-based design [20] and the design to identify the maximum effective
dose [30]. To get more insight into the TB monitoring, we studied and showed the
connection between the TB and PB approaches.
Although the Bayesian approaches gain in popularity in Phase II clinical
trials, an issue that has been largely overlooked is the choice of prior distributions.
For the TB monitoring approach, a prior distribution is required to quantify the
initial uncertainty of the unknown parameter under the alternative hypothesis. The
prior distributions for TB monitoring can be classified into local priors and nonlocal
priors [46]. A local prior refers to a probability density that has positive density
to regions of the parameter space that are consistent with the null hypothesis. In
contrast, a nonlocal prior will not overlap with the null hypothesis. The commonly
used Beta distribution for the response rate falls into the category of local priors and
the inverse moment density (iMOM) is an nonlocal prior. We extensively examined
the effects of local and nonlocal priors on the TB monitoring procedure under various
trial settings and provide recommendations for practical use. To facilitate sequential
TB monitoring, we also develop a web-based software to help clinicians to obtain
decision tables and prepare trial protocols.
The five projects introduced above make significant contributions to drug
development.
1) The thorough comparison between the BOIN and the recently proposed i3+3
provides practitioners the pros and cons of the designs, clarifies some confusions
among practitioners, and helps practitioners to choose an appropriate design for
early phase trials in order to increase the success of drug development at later
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phases.
2) The proposed model-assisted designs (e.g., iBOIN) overcomes the limitation of
the current model-assisted designs and efficiently make use of the historical data
and real-world evidence into the design of Phase I clinical trials.
3) The U-BOIN design serves as a novel Phase I/II model-assisted design that
uses a utility function to measure dose desirability and can be reliably used for
finding the OBD in trials for immunotherapy and targeted therapies.
4) The development of versatile software platforms for Phase I Bayesian adaptive designs provides a critical hub for designing and implementing early phase
clinical trials. The availability of the free software platforms with regular maintenance allows researchers easily to compare and contrast different designs, and
enables clinicians to evaluate the accuracy and safety of the designs easily without knowing any programming knowledge.
5) The examination of sequential monitoring in Phase II clinical trials reveals the
connection between PB monitoring and TB monitoring and provides practical
recommendations for the choice of prior distributions. Along with the userfriendly software, this project complements the existing tools for Phase II trial
monitoring.
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CHAPTER 2

A comparative study of Bayesian optimal interval (BOIN)
design with interval 3+3 (i3+3) design for Phase I oncology
dose-finding trials

2.1

Introduction
The objective of Phase I oncology trials is to identify the maximum tolerated dose (MTD)

of a new drug, which is defined as the dose with a dose limiting toxicity (DLT) probability that
is closest to the target DLT probability. Phase I dose-finding designs can be conducted using
algorithm-based designs, model-based designs, or model-assisted designs [36, 48, 115].
Algorithm-based designs determine dose assignment (escalation or de-escalation), based on
a set of prespecified rules. Examples include the 3+3 design, accelerated titration design [89], the
biased-coin design [21], and its variations [38, 92]. Recently, Liu et al. [60] proposed an algorithmbased design, called interval 3+3 (i3+3), which guides dose escalation and de-escalation by comparing the observed DLT probability with a prespecified toxicity equivalence interval. Algorithm-based
designs are simple and easy to implement, but their decision rules are chosen mostly in an ad hoc
way and lack of statistical justification. As a result, their statistical properties are often not well
defined, leading to poor operating characteristics.
Model-based designs are a class of dose-finding designs that employ a statistical model
to describe the dose-toxicity curve and guide dose transition. The most well known model-based
design is the continual reassessment method (CRM [77]). The CRM begins with a prior dosetoxicity curve. As information accrues during the trial, it continuously updates the estimate of the
model after each cohort, and then uses it to determine the dose assignment for the next cohort
of patients. Various extensions of the CRM have been proposed, including dose escalation with
overdose control [2], bivariate CRM [5], time-to-event CRM [13], partial order CRM [101], and
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Bayesian model averaging CRM [111]. Cheung provides a comprehensive review of the CRM and
its related methods [12]. Compared to algorithm-based designs, model-based designs have solid
statistical foundation and yield better operating characteristics. However, for appropriate use,
the CRM requires specialized expertise to choose and calibrate the dose-toxicity model, and to
re-estimate the model at each decision of dose escalation/de-escalation. It remains a challenge to
communicate to clinicians how the design works, leading them to perceive the dose allocation rules
as coming from a “black box” [67]. The complexity and lack of understanding of the model-based
designs result in underutilization of the model-based designs[15, 84].
Model-assisted designs were developed to combine the advantages of algorithm-based designs and model-based designs. Similar to model-based designs, the model-assisted designs use a
statistical model (e.g., the binomial model for the number of patients who experience at least one
DLT) to derive the decision rules; but like the algorithm-based designs, model-assisted designs can
have their dose escalation and de-escalation rules determined before the onset of the trial, and thus
can be implemented as simple as the algorithm-based designs. Examples of model-assisted Phase
I designs include the modified toxicity probability interval (mTPI) design [42], Bayesian optimal
interval (BOIN) design [65, 112], and keyboard design [106] or its equivalent version of mTPI extension (mTPI-2 [31]). Comprehensive reviews and numerical studies have been conducted to compare
the model-assisted designs with the 3+3 design and several model-based designs (e.g., CRM), and
the results show that the model-assisted designs substantially outperform the 3+3 design, yielding
performance comparable to model-based designs [85, 125, 124].
The objective of this chapter is to review and compare the recently proposed algorithmbased i3+3 design with the model-assisted BOIN design. From both theoretical and practical
viewpoints, we elucidate their links, similarities, and differences, and pros and cons, supported by
extensive simulation studies. The reason we choose to focus on these two designs is that they share
considerable similarity in their decision rules, which has caused substantial confusions among practitioners. Our goal is to clarify these confusions, delineate their differences, and provide guidance on
choosing appropriate design framework for Phase I clinical trials. We do not include other designs
(such as CRM, mTPI and keyboard) in our comparison as comprehensive reviews and comparisons
have been provided in Zhou et al. [124, 125] and Ruppert and Shoben [85]. We refer interested
readers to these papers.
The remainder of this chapter is organized as follows. In section 2.2, we review the BOIN
and i3+3 designs, and delineate their links and difference. In section 2.3, we describe and report
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the results of our simulation study. In section 2.4, we conclude with some further discussion of our
findings.

2.2

Method
Consider a Phase I trial with J prespecified doses of a drug under examination, d1 < · · · <

dJ . Let pj to denote the DLT probability that corresponds to dj , and φ denote the target DLT
probability for the MTD. Let nj denote the number of patients who have been assigned to dj , and
yj denote the number of patients who have experienced DLTs at dj , for j = 1, . . . , J. The maximum
sample size is N , and patients are enrolled sequentially and treated in cohorts. We assume that the
cohort size is prespecified, typically ranging from 1 to 3. Cohort size of 1 leads to a fully sequential
trial where the decision of dose escalation and de-escalation is made after each patient is treated.
We assume that the DLT can be ascertained quickly such that when a new cohort of patients are
ready for enrollment and dose assignment, the DLT outcomes of enrolled patients have been fully
observed. In what follows, we first review the BOIN design, followed by the i3+3 design.
2.2.1

Bayesian optimal interval design
Compared to other novel model-based designs (e.g., CRM and BLRM) and model-assisted

designs (e.g., mTPI and keyboard), the hallmark of BOIN design is its simple and transparent
decision rule: the dose escalation and de-escalation is determined by simply comparing the observed
DLT rate p̂j = yj /nj at the current dose with a pair of prespecified, optimized dose escalation
boundary λe and de-escalation boundary λd (see panel (A) in Figure 2.1). Table 2.1 provides the
optimal values of λe and λd for commonly used target DLT probabilities. The BOIN design is
described as follows:
1. Treat the first patient or cohort of patients at the lowest dose or a prespecified starting dose.
2. Let j denote the current dose level. Follow the following algorithm to assign a dose to the
next patient or cohort of patients.
• If p̂j ≤ λe , escalate the dose to level j + 1;
• If p̂j ≥ λd , de-escalate the dose to level j − 1;
• Otherwise, i.e., λe < p̂j < λd , stay at the current dose level j.
3. Repeat step 2 until the maximum sample size N is exhausted or an prespecified early stopping
rule is satisfied. At that point, select the MTD as the dose whose isotonic estimate of the
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DLT probability is closest to the target φ (note that no MTD is selected if the first dose is
eliminated due to safety issues).

(A) BOIN
Compute the DLT rate at
the current dose
Within
Escalate the
dose

Retain the
current dose

De-escalate the
dose

(B) i3+3
Compute the DLT rate at
the current dose
Within
Escalate the
dose

Retain the
current dose

Yes

<
No
De-escalate the
dose

Figure 2.1: Dose escalation and de-escalation algorithm in BOIN and i3+3. DLT rate is the
observed DLT probability. The main difference between two designs is that i3+3 adds a “deescalation modification rule” (in red).

Table 2.1: The optimal escalation/de-escalation boundaries (λe , λd ) under the BOIN design for
different target DLT probabilities.
Optimal
Target DLT probability φ
boundaries
0.15
0.20
0.25
0.30
0.35
0.40
λe
0.118
0.157
0.197
0.236
0.276
0.316
λd
0.179
0.238
0.298
0.359
0.419
0.480
Note. The boundaries (λe , λd ) are calculated using the default under-dosing toxicity probability
φ1 = 0.6φ and overdosing toxicity probability φ2 = 1.4φ in Liu and Yuan [65].
The BOIN design is derived based on the optimal design theory. Let 0 < λe (dj , nj , φ) < 1
and 0 < λd (dj , nj , φ) < 1 denote the generalized dose escalation and de-escalation boundaries that
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are unspecified functions of the dose level (i.e., dj ), the number of patients treated (i.e., nj ), and
the target DLT probability (i.e., φ). The derivation of the BOIN design starts from defining a class
of nonparametric designs, denoted as Cnp , with the following dose transition rule:
• If p̂j ≤ λe (dj , nj , φ), escalate the dose to level j + 1;
• If p̂j ≥ λd (dj , nj , φ), de-escalate the dose to level j − 1;
• Otherwise, i.e., λe (dj , nj , φ) < p̂j < λd (dj , nj , φ), stay at the current dose level j.
Because λe (dj , nj , φ) and λd (dj , nj , φ) can freely vary with the dose level dj , the number of treated
patients nj , and the target φ, this class of designs are extremely broad and contain all possible
nonparametric designs that do not impose the parametric assumption on the dose-response curve
and make dose escalation and de-escalation based on Dj = (yj , nj ). The mTPI, keyboard/mTPI-2,
BOIN, and i3+3 designs all belong to Cnp . This provides the first link between i3+3 and BOIN
designs. For notation brevity, we use λej ≡ λe (dj , nj , φ) and λdj ≡ λd (dj , nj , φ) hereafter.
The BOIN design is obtained by minimizing the probability of making incorrect decisions
of dose escalation and de-escalation within Cnp . In other words, the BOIN is the optimal design
among Cnp with the smallest decision errors. To derive the standard BOIN, Liu and Yuan [65] first
define three point hypotheses: H0 : pj = φ, H1 : pj = φ1 , and H2 : pj = φ2 , where φ1 indicates that
the dose is substantially under-dosing (i.e., below the MTD) such that escalation is required, and
φ2 indicates that the dose is substantially overdosing such that de-escalation is required. Let S, E
and D denote stay (at the current dose), escalation, and de-escalation, respectively. Under H0 , the
correct decision is S, and incorrect decisions are E and D; under H1 , the correct decision is E, and
incorrect decisions are S and D; and under H2 , the correct decision is D, and incorrect decisions
are S and E. Assuming a non-informative prior that the three hypotheses have equal probability
of being true, i.e., Pr(H0 ) = Pr(H1 ) = Pr(H2 ) = 1/3, under the dose transition rule of Cnp , the
probability of making incorrect decision (i.e, decision error) is given by

α = Pr (H0 ) Pr (E or D|H0 ) + Pr (H1 ) Pr (S or D|H1 ) + Pr (H2 ) Pr (S or E|H2 )
1
1
1
Pr (p̂j ≤ λej or p̂j ≥ λdj |H0 ) + Pr (p̂j > λej |H1 ) + Pr (p̂j < λdj |H2 )
3
3
3
1
1
= {Bin(nj λej ; nj , φ) + 1 − Bin(nj λdj − 1; nj , φ)} + {1 − Bin(nj λej ; nj , φ1 )}
3
3
1
+ Bin(nj λdj − 1; nj , φ2 ),
3
=

(2.1)
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where yj is assumed to follow a Binomial model, i.e., yj ∼ Binomial(nj , pj ), and Bin(b; m, ξ) is
the cumulative density function of the binomial distribution, with size and probability parameters
m and ξ, respectively. Liu and Yuan [65] proved that the optimal escalation and de-escalation
boundaries (λe , λd ) that minimize the decision error α are given by,


(2.2)

λej




1 − φ1
log
1−φ

,
= λe =
φ (1 − φ1 )
log
φ1 (1 − φ)

λdj


1−φ
log
1 − φ2

.
= λd =
φ2 (1 − φ)
log
φ (1 − φ2 )

Remarkably, the optimal escalation and de-escalation boundaries are independent of dj and nj ,
resulting in BOIN’s hallmark conciseness: dose escalation and de-escalation is made by a simple
comparison of p̂j with λe and λd .
Such simplicity might lead one to think that the BOIN decision rule does not consider
the variance of p̂j (or equivalently the sample size nj ). This, however, is not true. As shown by
equation (2.1), in the BOIN design, the derivation and minimization of the decision error α depends
on the sampling distribution of p̂j , thus directly taking the uncertainty of p̂j into account. Liu and
Yuan [65] further proved that λe and λd are also the boundaries corresponding to the likelihood
ratio test and Bayes factor, which certainly account for data variability or equivalently sample size
nj . In other words, nj being cancelled out should not be confused with ignoring nj . In contrast,
as described later, ignoring the variation of p̂j is a deficiency of the i3+3 design. The values of φ1
and φ2 can be elicited from physicians and should not be set as too close to φ as the small sample
size of Phase I trial provides very limited power to distinguish a very small difference. Liu and
Yuan [65] recommend the default values φ1 = 0.6φ and φ2 = 1.4φ, which generally yield a design
with good operating characteristics. In some cases, the values of φ1 and φ2 can be calibrated to fit
specific trial needs. For example, if a stronger overdose control is needed, we may set φ2 = 1.2φ to
encourage easier dose de-escalation.
Similarly, because λe and λd are independent of nj , one might concern that λe and λd
will not converge to φ asymptotically. This concern overlooks the basic fact that when studying
the asymptotic property, it is not meaningful to consider fixed alternative hypotheses, but should
consider local hypotheses, where H1 and H2 converge to H0 [50]. Thus, to study the convergence of
√
√
BOIN, appropriate hypotheses are H1 : φ1 = φ − d1 / nj and H2 : φ1 = φ + d2 / nj , where d1 and
d2 are constants. Under these local hypotheses, λe and λd (and thus the BOIN design) converge
to φ. As one of the most important features of Phase I trials is small sample size, the asymptotic
property is mainly of the theoretical interest with little practical relevance.
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For patient safety, BOIN imposes an overdose control/early stopping rule: if Pr(pj >
φ | nj , yj ) > C and at least 3 patients have been treated, the current dose dj and higher doses are
eliminated from the trial, where C is a probability cutoff, typically set as C = 0.95. The trial is
terminated if the lowest dose is eliminated. The posterior probability Pr(pj > φ | nj , yj ) is evaluated
based on the beta-binomial model with yj |pj ∼ Binomial(nj , pj ) and pj ∼ Beta(1, 1).
2.2.2

Interval 3+3 design
The i3+3 design is an algorithm-based design and consisted of a set of prespecified rules.

It requires the specification of a MTD equivalence interval (EI), defined as [φ − 1 , φ + 2 ], where
1 and 2 are small margins, such as 0.05. EI represents a range of toxicity probability (or dose)
that can be viewed as practically equivalent to the target DLT probability φ (or MTD). That is,
EI represents a proper dosing interval. For ease of exposition, define δe ≡ φ − 1 and δd ≡ φ + 2 .
The i3+3 design is consisted of the following rules (also shown in panel (B) of Figure 2.1).
1. Treat the first patient or cohort of patients at the lowest dose or a prespecified starting dose.
2. Let j denote the current dose level. Follow the following procedure to assign a dose to the
next patient or cohort of patients.
• If p̂j < δe , escalate the dose to level j + 1;
• If p̂j > δd , de-escalate the dose to level j − 1;
– (De-escalation modification rule)
However, if (yj − 1)/nj < δe , stay at the current dose level j.
• Otherwise, i.e., δe ≤ p̂j ≤ δd , stay at the current dose level j.
3. Repeat step 2 until the maximum sample size N is exhausted or the prespecified early stopping
rule is reached. At that point, select the MTD as the dose whose isotonic estimate of the
DLT probability is closest to the target φ but not greater less than δd .
The i3+3 design employs a similar overdose control/early stopping rule as described previously.
Suppose that the decision is to escalate the dose from level j to j + 1, if Pr(pj+1 > φ | nj+1 , yj+1 ) >
0.95, then dose dj+1 and higher doses are eliminated from the trial. The trial is terminated if the
lowest dose is eliminated.

21

2.2.3

Comparison of BOIN and i3+3 designs
Contrasting the decision rule of the i3+3 design with that of the BOIN design (see Figure

2.1), several links, similarities, and differences become clear. First, despite its name, the i3+3
design has very little to do with the conventional 3+3 design. Instead, its decision rule is strikingly
akin to the BOIN’s hallmark decision rule−make the decision of dose escalation and de-escalation
by comparing p̂j with a pair of dose escalation and de-escalation boundaries (Figure 2.1). The
difference between the two designs is that the dose escalation de-escalation boundaries of the BOIN
design (i.e., λe and λd ) are derived based on rigorous statistical theory and optimized to minimize
the probability of making incorrect dose assignment decisions, whereas those of the i3+3 design (i.e.,
δe and δd ) are ad hoc and subjectively picked. Such difference stems from the different frameworks
on which the two designs are based. The i3+3 design takes the algorithm-based framework and
thus inevitably inherits its deficiency−the decision rules are ad hoc and often arbitrarily chosen
without any formal statistical justification to ensure statistical properties. As a result, such type of
designs have been widely criticized for the lack of consistence and reproducibility because anyone
can arbitrarily add, remove or modify rules without rigorous justification. The i3+3 can have
similar desirable performance to BOIN in some cases when δe = λe and δd = λd , otherwise, it could
result in undesirable outcomes due to the subjectivity of the specifications for the EI.
Moreover, the use of statistically unfounded ad hoc rule leads to deeper statistical issues.
The cornerstone of the i3+3 design is the definition of EI, which says that when the true DLT
probability pj ∈ [δe , δd ], the drug is dosed properly and can be accepted as the MTD. Therefore,
when pj < δe , the drug is under-dosing and thus should be escalated, and when pj > δd , the drug
is overdosing and thus should be de-escalated. Note that in this definition, pj is the true DLT
probability. After defining the EI, the i3+3 design directly replaces pj with its point estimate p̂j to
make the decision of dose escalation and de-escalation. Because of ignoring the difference between
pj and p̂j , the i3+3 design fails to account for the variation of p̂j . To alleviate this problem, the
i3+3 design adds an additional ad hoc rule, i.e., the “de-escalation modification rule”. However,
this rule does not really address the problem, but instead causes more problems, as described below.
In contrast, the BOIN design rigorously accounts for data variability through its derivation and
optimization of the dose escalation and de-escalation boundaries as demonstrated in (2.1). It does
not need such an additional rule, making BOIN more concise and transparent than i3+3 (Figure
2.1).
Structure-wise, the main difference between BOIN design and i3+3 design is that the latter
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adds a “de-escalation modification rule”: if p̂j > δd and (yj − 1)/nj < δe , then rather than deescalating the dose, the dose stays at the current dose level. Liu et al. [60] claimed that this rule
accounts for data variability (i.e, the sampling variance of p̂j ). Unfortunately, this ad hoc rule does
not serve its intended purpose, but instead causes a series of logical and scientific flaws. First, it
is odd that the data variability is considered only when the dose de-escalation criteria is met, but
omitted when the dose escalation or stay criteria is met. This contradicts with the clinical practice
that extra caution should be taken when performing dose escalation, not when performing dose
de-escalation. Also, it is difficult to understand why using (yj − 1)/nj , but not others, such as
(yj − 2)/nj , or more naturally the variance of p̂j , to account for the uncertainty of p̂j .
Secondly, the “de-escalation modification rule” directly contradicts with the essence of the
i3+3 design itself, which says that if the observed DLT rate is greater than the upper limit of
EI, the dose is regarded as overdosing and thus should be de-escalated. Suppose the target DLT
probability φ = 0.1 with EI=[0.05, 0.15], then when p̂j = 1/3 = 33% patients has DLT, the “deescalation modification rule” will force the design staying at that dose to treat patients even through
p̂j is much greater than 0.15, and more precisely Pr(pj > 0.1|nj = 3, yj = 1) = 94.8% based on the
beta-binomial model assuming a uniform prior for pj .
Thirdly, numerically it can be shown that the “de-escalation modification rule” is rarely
triggered. For example, when target φ = 0.3 and EI= [0.25, 0.35], this rule will never be triggered
when the commonly cohort size (e.g., 3) is used; and when target φ = 0.2 and EI= [0.15, 0.25],
this rule is triggered only when 1/3 patients experience DLT. In other words, this “de-escalation
modification rule” is largely redundant, playing little role but unnecessarily complicating the design.
Moreover, as shown later in the simulation study, adding the “de-escalation modification rule”
actually impairs the performance of the design.
All aforementioned issues highlight the deficiency of the algorithm-based design framework
that the 3+3 and i3+3 designs are based on: arbitrarily specifying decision rules without rigorous
statistical reasoning and theory. These rules often do not serve the purposes they are intended to,
but often cause a series of scientific and logistical flaws.
In contrast to the algorithm-based i3+3 design, the BOIN design takes the model-assisted
framework. Its decision rule is rigorously derived based on well established statistical theory. This
makes the BOIN design more reliable with well known statistical properties [65]. More importantly,
the BOIN is also simpler and has been well validated in practice. It has been used in a variety of
oncology trials, including trials for pediatric tumors, adult tumors, solid tumors, and liquid tumors.
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A list of specific trials can be found in Yuan et al. [115].

2.3
2.3.1

Simulation study
Simulation configuration
To avoid cherry-picking and provide objective comparison, the dose-toxicity scenarios used

for comparing the i3+3 and BOIN designs were randomly generated using the pseudo-uniform
scenario algorithm proposed by Clertant and O’Quigley [16]. Given a target toxicity rate φ and J
dose levels, we generated scenarios as follows:
1). Select one of the J dose levels as the MTD with equal probabilities.
2). Sample M ∼ Beta(max{J − j, 0.5}, 1), where j denotes the selected dose level.
3). Set an upper bound B = φ + (1 − φ) × M for the toxicity probabilities.
4). Repeatedly sample J toxicity probabilities uniformly on [0, B] until these correspond to a
scenario in which dose level j is the MTD.
To ensure that MTD is uniquely and meaningfully defined, we required that the true DLT probability of the MTD is within [φ − 0.05, φ + 0.05], and the distance between the MTD and its adjacent
doses is greater than 0.05 and less than 0.3, , i.e., 0.05 < pj+1 − pj < 0.3 and 0.05 < pj − pj−1 < 0.3.
We considered target DLT probabilities of φ = 0.2, 0.3 or 0.4, each with J = 5 dose
levels, and a maximum sample size of N = 30 with the cohort size of 1 or 3. Under each setting, we
generated 1000 scenarios. Figure A2.1 displays 50 randomly chosen scenarios for each φ, which cover
a variety of dose-toxicity curve shapes and spacing. For each of the 1000 scenarios, we simulated
1000 trials and calculated the following performance metrics:
(a) Percentage of correct selection (PCS): the percentage of simulated trials in which the MTD
is correctly selected.
(b) Patient allocation: the average number of patients assigned to the MTD.
(c) Overdose control : the percentage of patients assigned to the doses that are above the MTD.
For the i3+3 designs, we set the EI as δe = φ − 0.05 and δd = φ + 0.05, which is reasonable
based on its authors’ recommendation. For the BOIN design, we used its default optimal boundaries
with φ1 = 0.6φ and φ2 = 1.4φ.
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Figure 2.2: Performance difference between BOIN and i3+3 under 1000 randomly generated scenarios. A positive value for “Correct selection (%)” and “Number of patients treated on MTD”
indicates that BOIN outperforms i3+3, while a negative value of “Patients treated above MTD
(%)” indicates that BOIN is safer.
2.3.2

Results
To summarize the results, we calculate the difference between BOIN and i3+3 in each of

the performance metrics, defined as (the performance metric of BOIN) − (the performance metric
of i3+3). For metrics (a) and (b), a positive value indicates that BOIN outperforms i3+3, while
for metric (c), a negative value indicates that BOIN outperforms i3+3. As 1000 scenarios were
considered, there were 1000 values for the difference in each performance metric.
Figure 2.2 shows the results, with each performance metric summarized by boxplots. In

25

general, BOIN has better accuracy to correctly identify the MTD than i3+3. For example, compared
to i3+3, the average percentage of correct selection for BOIN is 5.4% higher when the target DLT
probability is 0.3 and the cohort size is 1, and 5.3% higher when the target DLT probability is 0.4
and the cohort size is 3. In addition, BOIN is also safer than i3+3 with better overdose control.
For example, i3+3 has 6.4% and 18.3% higher probability of treating patients at the doses above
the MTD, when the target DLT probability is 0.2 and cohort size is 1, and when the target DLT
probability is 0.4 and cohort size is 3, respectively. On average, the two designs have similar
performance in terms of the number of patients treated at the MTD. Figure A2.2 provides the
absolute (rather than relative) performance of BOIN and i3+3.
To facilitate a close-up examination on the operating characteristics of the two designs,
Table 2.2 shows 15 representative scenarios, 5 for each of the target DLT probabilities (φ = 0.2,
0.3, or 0.4), with the MTD located at different dose levels. Table 2.3 shows the simulation results,
which are generally consistent with those from 1000 random scenarios, showing that BOIN has
higher accuracy to identify the MTD and better overdose control than i3+3.
Table 2.2: Fifteen representative randomly generated scenarios

Scenario

1

1
2
3
4
5

0.23
0.12
0.06
0.04
0.03

6
7
8
9
10

11
12
13
14
15

Dose level
3

2

4

5

Target DLT probability
0.49
0.52
0.19
0.27
0.15
0.23
0.06
0.13
0.05
0.08

φ = 0.2
0.53
0.38
0.66
0.20
0.11

0.89
0.47
0.71
0.30
0.17

0.31
0.03
0.08
0.05
0.02

Target DLT probability
0.42
0.53
0.27
0.46
0.11
0.30
0.08
0.13
0.03
0.06

φ = 0.3
0.54
0.48
0.55
0.30
0.15

0.81
0.58
0.66
0.39
0.31

0.36
0.18
0.10
0.16
0.02

Target DLT probability
0.45
0.60
0.36
0.50
0.15
0.40
0.19
0.22
0.06
0.10

φ = 0.4
0.63
0.60
0.50
0.37
0.22

0.73
0.66
0.52
0.51
0.38
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Table 2.3: Operating characteristics of BOIN and i3+3 under the 15 representative scenarios shown
in Table 2.2.

Scenario

Percentage of correct
selection of MTD

Number of patients
treated on MTD

Percentage of patients
treated above MTD

BOIN

BOIN

BOIN

i3+3

i3+3

i3+3

Cohort size = 1
1
2
3
4
5

61.8
38.0
50.6
40.4
71.2

63.9
36.9
55.0
45.7
73.3

17.2
8.6
12.1
9.5
15.9

16.2
7.9
14.2
10.2
18.5

26.9
45.1
9.9
24.9
0

33.9
54.4
13.4
33.0
0

6
7
8
9
10

54.1
62.6
68.1
49.2
69.3

50.4
61.1
70.9
49.8
72.2

15.2
13.7
13.7
10.6
16.1

13.3
12.8
14.1
10.7
17.5

41.9
35.4
20.8
28.0
0

49.6
40.7
24.0
32.9
0

11
12
13
14
15

42.4
52.0
54.9
49.3
76.1

36.6
47.7
46.9
53.0
78.0

13.9
12.1
11.8
9.6
16.0

10.1
10.3
9.7
10.6
19.1

48.8
35.8
27.8
21.2
0

63.2
49.0
44.3
33.4
0

Cohort size = 3
1
2
3
4
5

64.1
39.3
45.3
37.3
54.0

63.2
38.0
48.0
37.5
62.4

19.7
9.9
8.4
6.4
7.6

19.2
10.1
9.8
7.0
9.5

15.8
22.9
5.3
10.8
0

18.2
28.2
6.0
14.3
0

6
7
8
9
10

57.5
67.9
69.9
48.6
71.1

57.4
67.1
69.6
48.8
71.1

17.6
15.1
12.9
9.1
11.5

17.5
15.0
12.9
9.1
11.5

32.5
27.0
15.4
17.1
0

32.9
27.2
15.4
17.1
0

11
12
13
14
15

55.4
61.3
63.8
46.6
69.9

39.8
46.5
43.1
49.6
77.4

19.6
14.4
12.0
6.6
9.1

11.8
10.4
9.2
8.2
14.6

30.4
19.3
11.8
7.1
0

58.6
45.0
37.7
29.1
0
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2.3.3

The role of “de-escalation modification rule”
One main difference between i3+3 and BOIN is that the former adds the “de-escalation

modification rule” (see Figure 2.1). Liu et al. (2019) claimed that this rule is a main contribution
and the key for the performance of the design. To understand the role of that rule, we compared the
performance of the i3+3 design (with the rule) to its counterpart without the rule (denoted as the
i3+3s design, where “s” means simplified) under the 1000 random scenarios described previously.
That is, the two designs are exactly same except that i3+3s removes the “de-escalation modification
rule”. For each scenario, we simulated 1000 trials and calculated the difference between i3+3s and
i3+3 in each of the performance metrics, defined as (the performance metric of i3+3s) − (the
performance metric of i3+3).
Figure 2.3 shows the results. We can see that the “de-escalation modification rule” has
virtually no, and sometimes detrimental, effect on the design performance. In terms of the percentage of correct selection, the mean difference between i3+3 and i3+3s is less than 1.6% in all the
simulation settings. This is particularly obvious when the target DLT probability is 0.3 and the
cohort size is 3. In this case, the two designs are exactly same as the “de-escalation modification
rule” is never triggered. The same pattern is observed for the number of patients treated at the
MTD, i.e., the mean difference between i3+3s and i3+3 is less than 0.4 (i.e., 1.3%), suggesting that
adding the rule provides virtually no gain in this metric either. For safety, adding the rule actually
led to substantially worse performance, and resulted in treating 2.7% to 13.4% more patients on
the toxic doses above the MTD, except when the target DLT probability is 0.3 and the cohort size
is 3 (as noted above, the two designs are equivalent in this case).
These results validate the previous theoretical analysis, showing that the “de-escalation
modification rule” is not only redundant, but often detrimental. This exemplifies the risk of arbitrarily adding rules without careful and formal statistical and scientific justification for algorithmbased designs. Removing the “de-escalation modification rule” from i3+3 improves the performance
of the design. The dilemma is that the resulting design (i.e., i3+3s) then is a trivial variation of
BOIN. From this perspective, i3+3 is simply a downgraded version of BOIN.

2.4

Summary
We have elucidated the similarity and difference between the recently proposed algorithm-

based i3+3 design and the model-assisted BOIN design. We showed that the i3+3 design adopted
very similar decision rules as the BOIN design, but because of taking the algorithm-based design
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Figure 2.3: Performance difference between i3+3s (i.e., the counterpart of i3+3 with the “deescalation modification rule” removed) and i3+3 under 1000 random scenarios. A positive value for
“Correct selection (%)” and “Number of patients treated on MTD” indicates that i3+3s outperforms
i3+3, while a negative value of “Patients treated above MTD (%)” indicates that i3+3s is safer.
framework, it suffers from a series of scientific and logical deficiencies inherited in algorithm-based
designs. We further showed that the “de-escalation modification rule” used by i3+3 to differentiate
it from BOIN does not improve, but often impair the design performance. Simulation studies show
that compared to the i3+3 design, the BOIN design has better accuracy to identify the MTD and is
safer with a lower risk of overdosing patients. In addition, BOIN is also simpler, more transparent,
and has been widely validated in a variety of clinical trials. Thus, we believe BOIN provides a
better choice for Phase I oncology trials.
The solid statistical foundation underlying the BOIN design provides its ability to be
extended to handle more complicated clinical applications. Under the model-assisted framework,
the BOIN design has been extended to accommodate drug-combination [56], late-onset toxicity
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[116], efficacy-toxicity based Phase I/II trials [93, 126]. More details for these extended designs are
provided in Chapters 4 and 5.
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A
A2.0.1

Appendix

A subset of random scenarios when comparing BOIN to i3+3
Figure A2.1 shows a random sample of the 1000 random scenarios used for comparing

BOIN and i3+3 design under each target DLT probabilities.

Figure A2.1: A sample of 50 randomly generated scenarios given the target DLT probability φ=0.2,
0.3 or 0.4.
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A2.0.2

The simulation results for BOIN and i3+3 designs under 1000 random scenarios
Figure A2.2 shows the simulation results for BOIN and i3+3 designs under 1000 random

scenarios, under different target DLT probabilities. Both designs were implemented under their
default/recommended settings. As shown, BOIN has larger probability of correctly identifying the
MTD and is safer in that it assigns less patients on doses above MTD. The number of patients
treated on MTD is comparable between the two designs, but i3+3 is still more aggressive than
BOIN and assigns more patients on doses above MTD, an undesirable consequence caused by
i3+3’s “de-escalation modification rule”.
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Figure A2.2: Performance of BOIN and i3+3 designs under 1000 randomly generated scenarios
given different target DLT probability (φ) and cohort size.
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CHAPTER 3

Incorporating historical information to improve phase I
clinical trial designs

3.1

Introduction
Recently, there is tremendous interest to use prior information, such as historical data or

real-world evidence, as an effective way to improve the efficiency of clinical trials. In May 2019,
Food and Drug Administration (FDA) released a draft guidance on submitting documents using
real-world data or evidence to FDA for drugs and biologics [24]. When designing phase I trials,
prior information is often available from previous studies. For example, the drug to be investigated
has been studied previously in other indications, or similar drugs belonging to the same class have
been studied in earlier phase I trials [128]. Another example is the proposal of bridging phase I
trials to extend a drug from one ethnic group (e.g., Caucasian) to another (e.g., Asian) [63], or from
adult patients to pediatric patients [81]. In this case, dose-toxicity data from the original trial in
one ethnic group or adult can be used to inform the design of the subsequent bridging trials, see
for example Morita [68], Liu et al. [63], and Li and Yuan [53].
Various Phase I trial designs have been proposed to find the the maximum tolerated dose
(MTD). These designs can be classified into algorithm-based, model-based, and model-assisted
designs, depending on their statistical foundations and implementation approaches. Algorithmbased designs, such as the 3+3 design, are ad-hoc, simple to implement, but rigid and have poor
accuracy to identify the MTD. It is difficult, if not impossible, to incorporate prior information into
algorithm-based designs. Model-based designs assume a dose-toxicity model and determine the dose
escalation/de-escalation by continuously updating the estimate of the model based on accrued data.
Typical examples of the model-based design are the continual reassessment method (CRM [77])
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and its variations, such as escalation with overdose control (EWOC[2]), Bayesian logistic regression
model (BLRM [74]), and Bayesian model averaging CRM (BMA-CRM [111]). Model-based designs
yield better performance than the 3+3 design in identifying the MTD and allocating more patients
to the MTD. Another important strength of model-based designs is that it is straightforward to
incorporate prior information. In particular, for the CRM, the prior information can be easily
incorporated by specifying a “skeleton” of the dose-toxicity model—the prior estimate of dose
limiting toxicity (DLT) probability for each dose. More details are provided later. Along that
line, Morita [68] proposed to incorporate informative prior to the CRM; Liu et al. [63] proposed
to bridge CRM for phase I clinical trials in different ethnic populations based on Bayesian model
averaging; Li and Yuan [53] proposed the continuous reassessment method for pediatric phase I
oncology trials (PA-CRM) to leverage trial information from adult trials to pediatric trials.
Model-assisted designs were developed to combine the simplicity of algorithm-based designs
with the superior performance of model-based designs. Similar to model-based designs, modelassisted designs use a statistical model (e.g., the binomial model) to derive decision rules for efficient
decision making; like algorithm-based designs, model-assisted designs can have their dose escalation and de-escalation rules determined before the onset of a trial, and thus can be implemented
as simple as algorithm-based designs. Examples of model-assisted designs include the Bayesian
optimal interval (BOIN) design [65], modified toxicity probability interval design (mTPI [42]), and
keyboard design [105] (or mTPI-2 [31]). Extensive numerical studies show that the model-assisted
designs yield superior performance comparable to more complicated model-based designs, and are
increasingly used in practice [115].
Model-assisted designs were developed assuming non-informative prior. Little research has
been done on how to incorporate informative prior information into the derivation of these designs.
This has led to the misconception that model-assisted designs cannot incorporate informative prior
information, which is sometimes cited as their weakness, compared to model-based designs.
In this chapter, we propose a unified framework to incorporate informative prior information
into model-assisted designs, including BOIN and keyboard/mTPI-2 designs. Our method utilizes
the skeleton approach same as in the CRM, combined with the concept of prior effective sample size
(PESS) [69]. The method is intuitive and easy to understand, and more importantly, maintains the
simplicity of the model-assisted designs in the sense that their dose escalation/de-escalation rule
can still be determined and included in the protocol before the onset of a trial. Numerical studies
show that incorporating appropriate informative prior information can improve the performance of
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the model-assisted designs in a similar way as that of the CRM.
The remainder of the paper is organized as follows. In section 3.2, we propose the methodology of incorporating informative prior information through skeleton and PESS for CRM, BOIN
and keyboard designs. In section 3.3, we provide the software to implement the proposed designs.
In section 3.4, we conduct extensive simulation to evaluate operating characteristics of the proposed
methodology. We conclude the study with a brief summary in section 3.5.

3.2
3.2.1

Method
Incorporate prior information in CRM
We first describe how to incorporate prior information in the CRM. Let j = 1, · · · , J, denote

the J doses under investigation, and pj denote the true DLT probability of dose j. The objective of
the trial is to find the MTD, whose DLT probability is equal or the closest to a prespecified target
DLT probability φ.
To incorporate prior information on the dose-toxicity relationship, we elicit the prior estimate of (p1 , · · · , pJ ), denoted as (q1 , · · · , qJ ), known as “skeleton”. The skeleton should be specified
by clinicians based on their clinical experience or estimated using historical data or real-world evidence. We link pj with the skeleton through a parametric model

(3.1)

exp(α)

pj = qj

,

for

j = 1, · · · , J,

where α is an unknown parameter, which controls the discrepancy between the prior estimate
qj and the true DLT probability pj . Under the Bayesian paradigm, we assign α a normal prior
f (α) = N (0, σ 2 ), where σ 2 is a prespecified hyperparameter. As a result, a priori the dose-toxicity
curve (p1 , · · · , pJ ) centers around the skeleton (q1 , · · · , qJ ). The value of σ 2 controls how much
information contained in the prior that can be borrowed from historical data (i.e., the skeleton). A
smaller value leads to stronger borrowing. If σ 2 = 0, the prior completely dominates the observed
data and pj ≡ qj regardless of the observed data.
Let D = (D1 , · · · , DJ ) denote the observed data, where Dj = (nj , yj ) denotes the data
observed at dose level j with nj being the number of patients treated and yj the number of patients
who experienced DLTs at dose j. To make the decision of dose escalation and de-escalation, the
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CRM updates the posterior estimate of pj as follows,
Z
p̂j =

where L(D | α) =

QJ

j=1

exp(α)

qj

R

L(D | α)f (α)
dα,
L(D | α)f (α)dα

n
oyj n
onj −yj
exp(α)
exp(α)
qj
1 − qj
is the likelihood function, and f (α) =

N (0, σ 2 ) is the prior distribution of α. Then, the CRM assigns the next cohort of patients at the
dose whose p̂j is closet to φ. In practice, we typically impose safety rules, such as starting at the
lowest dose level and no dose skipping during dose escalation.
Given a specific skeleton and prior f (α) = N (0, σ 2 ), it is of great importance to quantify
how much information is borrowed from historical data. This is, however, rarely discussed in the
dose-finding literature. In what follows, we propose a simple and intuitive approach to formally
quantify the information borrowed through the skeleton using the concept of “prior effective sample
size (PESS)”, which represents the sample size that the prior information is equivalent to. Morita
et al. [69] proposed a general methodology to determine PESS, but requires complicated derivation
and intensive simulation.
Our approach is simpler and more intuitive, and built upon the following observation:
assuming yj follows a binomial distribution Binom(nj , pj ), if pj follows a beta prior distribution
Beta(a, b), then a + b can be interpreted as the PESS. Our strategy is to approximate the prior
distribution of pj , induced by model (3.1) and f (α), with a beta distribution by matching the first
and second moments. Therefore, the PESS can be easily determined. Specifically, given skeleton
(q1 , · · · , qJ ) and prior f (α), let µj and τj2 denote the prior mean and variance of pj , respectively,
with
Z
µj =

pj f (pj )dpj ,

τj2 =

Z

p2j f (pj )dpj − u2j ,

where f (pj ) is the prior distribution of pj induced by the prior distribution of f (α) = N (0, σ 2 ),
given by
 h 
i2 
log(pj )




log log(qj )
1
1
f (pj ) = −
exp −
.
2


2π
2σ

 pj log(pj )
Matching the first and second comments of pj by a beta distribution Beta(aj , bj ), we obtain that
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the PESS of the skeleton is aj + bj , where

(3.2)

aj =

µ2j (1 − µj )
a(1 − µj )
− µj , bj =
.
2
τj
µj

This reveals a property of the CRM that is barely discussed in the literature but of great
implication in practice. Because pj is a non-linear function of α, once prior f (α) is specified,
the PESS for each dose is automatically determined. For example, given skeleton (q1 , · · · , q5 ) =
(0.10, 0.19, 0.30, 0.42, 0.54) and prior f (α) = N (0, 0.72), the PESS is (3, 3, 3, 3.1, 3.4) for the five
doses. As a result, the CRM does not allow users to specify dose-specific prior information or PESS.
However, in practice, we often have unequal amount of prior information for different doses. For
example, we often have more data at the doses that are below and around the MTD from historical
phase I trials. In this case, it is highly desirable to be able to specify different PESS for different
doses according to the historical data.

3.2.2

Incorporate prior information in BOIN
We now discuss how to use the skeleton, coupled with the PESS, to incorporate prior

information into model-assisted designs such as the BOIN design. To do so, we first briefly describe
the genesis of the BOIN design, which lays the ground for the proposed approach. Consider a class
of nonparametric designs Cnp as follows.
(a) Patients in the first cohort are treated at the lowest or a prespecified starting dose level.
(b) At the current dose level j, let p̂j = yj /nj denote the observed DLT probability, and
λe (j, nj , φ) and λd (j, nj , φ) denote arbitrary functions of j, nj and φ, serving as the dose
escalation and de-escalation boundaries, respectively, with 0 ≤ λe (j, nj , φ) < λd (j, nj , φ) ≤ 1.
Use the following procedure to assign a dose to the next cohort of patients.
• Escalate the dose level to j + 1, if p̂j < λe (j, nj , φ);
• De-escalate the dose level to j - 1, if p̂j > λd (j, nj , φ);
• Stay the same dose level, j, if λe (j, nj , φ) ≤ p̂j ≤ λd (j, nj , φ).
(c) This process is continued until the maximum sample size is reached.
Note that λe (j, nj , φ) and λd (j, nj , φ) can vary with dose level j, the number of patients treated
nj , and the target φ. This class of nonparametric designs includes all possible designs that do not
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impose a parametric assumption on the dose-toxicity curve. For notational brevity, in what follows,
we suppress arguments in λe (j, nj , φ) and λd (j, nj , φ) and denoted them as λe and λd .
The BOIN design is obtained by choosing the optimal dose escalation and de-escalation
boundaries λe and λd to minimize the probability of making incorrect dose escalation and deescalation decisions. The optimization is carried out under three point hypotheses:

H1 : pj = φ;

H2 : pj = φ1 ;

H3 : pj = φ2 ,

where φ1 denotes the DLT probability that is deemed substantially lower than the target (i.e.,
underdosing) such that dose escalation should be made, and φ2 denotes the DLT probability that
is deemed substantially higher than the target (i.e., overdosing) such that dose de-escalation is
required. Thus, the correct decision under H1 , H2 and H3 is stay, escalation, and de-escalation,
respectively; and other decisions are incorrect. For example, under H1 , escalation or de-escalation
are incorrect decisions. Liu and Yuan (2015) showed that optimal dose escalation and deescalation
boundaries that minimize incorrect decisions are given by

λe

=

max




log



0,

1−φ1
1−φ

(3.3)

λd

=

min

log
1,





+ n−1
j log
n
o

log


φ(1−φ1 )
φ1 (1−φ)

log

φ2 (1−φ)
φ(1−φ2 )







1−φ
1−φ2

+ n−1
j log
n
o



π2j
π1j




,




π1j
π3j




,



where πkj = Pr(Hk ) is the prior probability that the hypothesis Hk is true at dose level j, where
k = 1, 2, 3. As a result, the BOIN is the optimal design with the lowest decision errors among all
nonparametric designs. Liu and Yuan (2015) recommended default values φ1 = 0.6φ φ2 = 1.4φ
that lead to desirable operating characteristics and the decision rule that fits most clinical practice.
When there is no reliable prior information available, we can take the non-informative
prior approach and assign the equal probability to each of the three hypotheses being true, i.e.,
π1j = π2j = π3j = 1/3. Then, the optimal boundaries (3.3) become

(3.4)



1
log 1−φ
1−φ
n
o
λ∗e =
1)
log φ(1−φ
φ1 (1−φ)

and



1−φ
log 1−φ
2
n
o,
λ∗d =
φ2 (1−φ)
log φ(1−φ2 )

which have the desirable feature that they are independent to the dose level j and the number of
patients treated nj . This means that the same pair of dose escalation and de-escalation boundaries
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(λd , λe ) can be used throughout of the trial to make the decision of dose escalation and de-escalation,
making the BOIN design particularly simple to implement. That is, if p̂j < λ∗e , escalate the dose;
if p̂j > λ∗d , de-escalate the dose; otherwise, stay at the current dose.
When prior information is available, we propose the following procedure to incorporate it
into the design:
1. Elicit skeleton (q1 , · · · , qJ ) and corresponding PESS (n01 , · · · , n0J ), where n0j is the desirable
PESS for dose level j, j = 1, · · · , J.
2. Determine informative prior for Hk , i.e., πkj , as

(3.5)

πkj =

n0
X
x=0

φxk (1 − φk )n0 −x
P3

k0 =1

φxk0 (1 − φk0 )n0 −x




n0 x
q (1 − qj )n0 −x .
x j

3. Make decision of dose escalation and de-escalation according to the boundaries given in (3.3)
with πkj determined in step 2.
The derivation of πkj in step 2 is provided in section A3.0.1. We refer to the resulting design (with
informative prior) as iBOIN.
Because of the incorporation of the prior information, the escalation and de-escalation
boundaries λe and λd of iBOIN depend on the dose level j, as well as nj . Figure 3.1 contrasts
the boundaries under non-informative prior and those under informative prior for a trial with 5
doses and the elicited skeleton (0.10, 0.19, 0.30, 0.42, 0.54) when PESS is 3 and 5, respectively.
For example, because the prior information says that the lowest dose is under the MTD (with the
prior toxicity probability of 0.1), its escalation boundary λe thus is lower than that of the noninformative prior to encourage dose escalation. On the contrary, because the prior information says
the highest dose is above the MTD (with the prior toxicity probability of 0.54), its de-escalation
boundary λd thus is lower than that of the non-informative prior to encourage dose de-escalation.
When (n01 , · · · , n0J ) = 0, iBOIN becomes the standard BOIN (with non-informative prior).
Compared to the CRM, iBOIN is more flexible and allows users to accurately incorporate
prior information by specifying a PESS for each of the dose. For example, given a phase I trial with
5 doses, if historical data provide more information on the first 2 doses than the last 2 doses and
most information on dose level 3, we could specify the PESS for 5 doses as (3, 3, 6, 1, 1) to reflect
that. As described previously, this is very difficult, if not impossible, under the CRM.
The other advantage of the iBOIN is that its the dose escalation and de-escalation rule can
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Figure 3.1: Escalation and de-escalation boundaries (λe , λd ) of iBOIN given different prior DLT
probability (q) and PESS = 3 or 5, in comparison to the boundaries determined using noninformative prior in standard BOIN.

be pre-tabulated and included in the trial protocol. Table 1 shows the decision table of iBOIN with
skeleton (0.10, 0.19, 0.30, 0.42, 0.54) and the effective sample size n01 = · · · = n05 = 3.
This decision table is equivalent to the rule based on λe and λd , but easier to use in practice.
The user only need to identify the row corresponding to the current dose level, and then can use
the boundaries listed in that row to easily make the decision of dose escalation and de-escalation.
In summary, the iBOIN design can be described as follows:
1. Patients in the first cohort are treated at the lowest dose d1 , or the physician-specified dose.
2. Given data (nj , yj ) observed at the current dose level j, make the decision of escalation/de-
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Table 3.1: iBOIN decision boundaries up to 30 patients with a cohort size of 3, given the skeleton (q1 , · · · , q5 ) = (0.10, 0.19, 0.30, 0.42, 0.54) and PESS n01 = · · · = n05 = 3. The target DLT
probability φ = 0.3.

Dose level

Action∗

3
Escalate if no. of DLT ≤
1
1
De-escalate if no. of DLT ≥
2
Escalate if no. of DLT ≤
0
2
De-escalate if no. of DLT ≥
2
Escalate if no. of DLT ≤
0
3
De-escalate if no. of DLT ≥
2
Escalate if no. of DLT≤
0
4
De-escalate if no. of DLT ≥
1
Escalate if no. of DLT ≤
0
5
De-escalate if no. of DLT ≥
1
*When neither “Escalate” nor “De-escalate” is
treating the next cohort of patients.

Number of patients treated at current
6
9
12
15
18
21
24
1
2
3
4
4
5
6
3
4
5
7
8
9
10
1
2
3
3
4
5
5
3
4
5
6
7
8
9
1
2
2
3
4
4
5
3
4
5
6
7
8
9
1
1
2
3
3
4
5
2
3
4
6
7
8
9
0
1
2
2
3
4
5
2
3
4
5
6
7
8
triggered, stay at the current dose for

dose
27
6
11
6
11
6
10
6
10
5
10

30
7
12
7
12
7
11
6
11
6
11

escalation according to the iBOIN decision table (e.g., Table 3.1) for treating the next cohort
of patients.
3. Repeat step 2 until the prespecified maximum sample size is reached, and then select the
MTD as the dose whose isotonically transformed estimate of pj is closest to φ.
For the purpose of overdose control, following BOIN, the iBOIN design imposes a dose
elimination rule: if Pr(pj > φ | yj , nj ) > 0.95 and nj ≥ 3, dose level j and higher are eliminated from
the trial, and the trial is terminated if the lowest dose level is eliminated, where Pr(pj > φ | nj , yj )
is evaluated based on the beta-binomial model with uniform prior. As the objective of the dose
elimination rule is to protect patients from excessively toxic doses, it is sensible to use uniform prior
to evaluate this rule to avoid potential bias due to the misspecification of the prior.
At the end of the trial, iBOIN uses isotonic estimate of pj to select the MTD (i.e., Step
3). As determining dose escalation/de-escalation and selecting the MTD are two independent
components, when the trial is completed, other methods can also be used to determine the MTD.
For example, when desirable, we can fit a dose-toxicity model (e.g., a logistic model) as the CRM
to select the MTD.

3.2.3

Incorporate prior information in keyboard/mTPI-2 design
Keyboard design is another model-assisted design, developed to address the overdosing

issue of mTPI design. Guo et al. [31] proposed a modification of mTPI, known as mTPI-2, which
is statistically equivalent to the keyboard design but less transparent and relies on a perplexing
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statistical concept and method (e.g., Occam’s razor and model selection). Thus, we here only
present the keyboard design. The methodology and simulation results described below are directly
applicable to the mTPI/mTPI-2.
The keyboard design starts by specifying a proper dosing interval I ∗ = (δ1 , δ2 ), referred to
as the “target key,” and then populates this interval toward both sides of the target key, forming
a series of keys of equal width that span the range of 0 to 1. For example, given a target rate of
φ = 0.30, the proper dosing interval or target key may be defined as (0.25, 0.35), then on its left
side, we form 2 keys of width 0.1, i.e., (0.15, 0.25) and (0.05, 0.15); and on its right side, we form
6 keys of width 0.1, i.e., (0.35, 0.45), (0.45, 0.55), (0.55, 0.65), (0.65, 0.75), (0.75, 0.85) and (0.85,
0.95). We denote the resulting intervals/keys as I1 , · · · , IK .
The keyboard design assumes a beta-binomial model,

yj | nj , pj

∼

Binom(nj , pj )

pj

∼

Beta(aj , bj ),

(3.6)

where aj and bj are hyperparameters. The posterior distribution of pj arises as,

(3.7)

pj | Dj ∼ Beta(yj + aj , nj − yj + bj ), for j = 1, . . . , J.

By default, the keyboard design set aj = bj = 1 to obtain a uniform prior. To make the decision of
dose escalation and de-escalation, given the observed data Dj = (nj , yj ) at the current dose level
j, the keyboard design identifies the interval Imax that has the largest posterior probability, i.e.,

Imax = argmaxI1 ,··· ,IK {Pr(pj ∈ Ik | Dj ); k = 1, · · · , K}.
Imax represents the interval that the true value of pj is most likely located, referred to as the
“strongest” key by Yan et al. [105]. Suppose j is the current dose level. The keyboard design
determines the next dose as follows.
• Escalate the dose to level j + 1, if the strongest key is on the left side of the target key;
• Stay at the current dose level j, if the strongest key is the target key;
• De-escalate the dose to level j − 1, if the strongest key is on the right side of the target key.
The trial continues until the prespecified sample size is exhausted, and the MTD is selected based
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on isotonic estimates of pj . During the trial conduct, the keyboard design imposes the same dose
elimination/early stopping rule as the BOIN design.
As in the beta-binomial model (3.6), aj + bj can be interpreted as the PESS. We propose
the following procedure to incorporate prior information into the keyboard design:
1. Elicit skeleton (q1 , · · · , qJ ) and corresponding PESS (n01 , · · · , n0J ), where n0j is the desirable
PESS for dose level j, j = 1, · · · , J.
2. Determine hyperparameter aj and bj in the beta prior (3.6) as follows:

(3.8)

aj = n0j qj ;

bj = n0j (1 − qj ),

j = 1, · · · , J

3. Make dose escalation and de-escalation based on the resulting posterior given by equation
(3.7).
We refer the keyboard design with informative prior as iKeyboard design. Given a fixed maximum
sample size, all possible outcomes Dj = (nj , yj ) can be enumerated, and for each possible outcome,
the posterior distribution f (pj |Dj ) can be calculated. Therefore, the dose escalation/de-escalation
rule of the iKeyboard can be tabulated. The decision table for the ikeyboard design can also be
pre-tabulated as that for iBOIN. The above approach is directly applicable to the mTPI design for
incorporating prior information. As the keyboard/mTPI-2 design outperforms the mTPI design in
both safety and accuracy (Yan et al., [105]; Zhou et al. [124]; Guo et al. [31]), we will not discuss
the mTPI.
3.2.4

Robust prior
The performance of aforementioned designs is affected by whether the informative prior

is correctly specified. When the informative prior correctly specified, it improves the accuracy of
identifying the MTD. However, when the informative prior is misspecified and conflicts with the
true dose-toxicity relationship, it may compromise the accuracy of identifying the MTD. In the
numerical study described later, we found that when prior is severely misspecified, the prior that
sets the MTD at higher doses has more impact on the design performance than the prior that sets
the MTD at lower doses, in particular when the true MTD is higher than the prior MTD. For
example, consider two cases: in case 1, the prior sets dose level 3 as the MTD while the true MTD
is dose level 5; and in case 2, the prior sets dose level 1 as the MTD while the true MTD is dose
level 3. Although both priors are misspecified, iBOIN and iKeyboard designs have lower probability
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to identify the true MTD in case 1 than case 2. This is because in case 2, the prior MTD is dose
level 1, when data cumulates, they eventually will override the prior and escalate to the MTD.
In contrast, in case 1, because the MTD is dose level 5, the sample size is often exhausted before
enough data are cumulated at dose level 3 (i.e., prior MTD) to override the prior.
This observation motivated us to propose a robust prior, which is useful when there is large
uncertainty on the prior information. Given the elicited skeleton (q1 , · · · , qJ ) with dose level j ∗ as
the prior estimate of the MTD (i.e., qj ∗ = φ), the robust prior is the same as the prior described
above if when j ∗ < J/2, but modify the PESS to (n01 , · · · , n0j ∗ , 0, · · · , 0) when j ∗ ≥ J/2. In
other words, when prior MTD j ∗ ≥ J/2, the robust prior uses informative prior information for
the dose up to the prior estimate of the MTD, and after that uses non-informative prior. This
modification facilitates overriding prior when the data conflict with the prior, and thus alleviates
the impact of the prior misspecification. Our simulation study described later shows that iBOIN
and iKeyboard designs are robust to moderate misspecification of priors, and using robust prior
proves their robustness when the prior is severely misspecified.

3.2.5

Choose PESS
PESS should be chosen to reflect the appropriate amount of prior information to be incor-

porated, which depends on the reliability of prior information and varies from trial to trial. When
there is strong evidence that the prior is most likely correctly specified, it is appropriate to use a
large PESS to borrow more information; when there is large uncertainty on whether the prior is
most likely correctly specified, we may use a small PESS to avoid bias. In practice, there is often
sizable uncertainty on the reliability of the prior information. Thus, PESS should be chosen carefully to achieve an appropriate balance between design performance and robustness. Using a large
PESS improves the design performance (i.e., the accuracy to identify the MTD) when the prior is
correctly specified, but may lead to substantial loss of performance when the prior is misspecified.
Based on numerical study, we recommend PESS ∈ [1/3(N/J), 1/2(N/J)] as default value which
improves trial performance while maintaining reasonably robust. For example, when J = 5 and
N = 30, the recommended value for PESS is n0j = 2 or 3 (i.e., across 5 doses, the total PESS is
10 or 15). The value of n0j can be further calibrated by simulation using the software described
below.
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3.3

Software
We have developed online software “BOIN Suite”, freely available at https://www.trialdesign.

org, to allow users to design trials, conduct simulation, and generate protocol template. The software has an intuitive graphical user interface and rich documents to help with navigating through
the process, see Figure A3.1 for the user interface of the software. A trial can be easily designed by
the following 3 steps:
Step 1. Specify the design parameters, e.g., sample size, cohort size, target DLT probability, skeleton, PESS, etc.
Step 2. Use the software to produce decision table and design diagram, and conduct simulation to
obtain operating characteristics of the design. The software also generates sample texts and
protocol template to facilitate the protocol write-up.
Step 3. Use the design decision table to conduct the trial.
After a trial is completed, the app can be used to select the MTD.

3.4

Simulation
We conducted extensive simulation to evaluate the operating characteristics of the proposed

designs. We assume J = 5 doses and the target DLT probability φ = 0.3. The maximum sample
size is N = 30 with a cohort size of 3. We considered the CRM with an informative prior (denoted
as iCRM), iBOIN and iKeyboard, as well as their counterparts with non-informative prior. We also
considered BOIN and Keyboard designs with the robust prior, denoted as iBOINR and iKeyboardR ,
respectively. For iBOIN and iKeyboard, we set PESS n0j = 3 for j = 1, · · · 5, and for iCRM, the
prior is chosen such that the PESS at the prior MTD is 3. All the designs use the same skeletons
(i.e., the prior DLT probabilities), provided in Table 3.2.

3.4.1

Fixed scenarios
We evaluated the performance of the designs in ten scenarios, as shown in Table 3.2. In

the first five scenarios, the MTD is located at dose level 1, 2, 3, 4 and 5, respectively; and the
prior MTD is correctly specified and matches the true MTD. To reflect the practice, we do not
assume that the prior (at each dose level) exactly matches the truth. Here, we call a prior correctly
specified if the prior MTD matches the true MTD. Scenarios 6-10 consider the cases that the prior
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is mis-specified. Specifically, in scenarios 6 and 7, the prior MTD is one level off the true MTD,
and in scenarios 8-10, the prior MTD is two levels off the true MTD.
Table 3.2: Ten dose-toxicity scenarios with target DLT probability φ = 0.30. The prior MTDs are
correctly specified in scenarios 1-5 and misspecified in scenarios 6-10.

1

2

Dose level
3
4

5

1

2

Dose level
3
4

True Pr(DLT)
Prior Pr(DLT)

0.30
0.30

0.42
0.42

Scenario 1
0.50
0.60
0.54
0.64

0.65
0.73

0.09
0.01

0.12
0.04

Scenario 6
0.15 0.30
0.10
0.19

0.45
0.30

True Pr(DLT)
Prior Pr(DLT)

0.15
0.19

0.27
0.30

Scenario 2
0.40
0.50
0.42
0.54

0.65
0.64

0.08
0.19

0.15
0.30

Scenario 7
0.31 0.45
0.42
0.54

0.55
0.64

True Pr(DLT)
Prior Pr(DLT)

0.08
0.10

0.15
0.19

Scenario 3
0.31 0.45
0.30 0.42

0.55
0.54

0.08
0.01

0.15
0.04

Scenario 8
0.31 0.45
0.10
0.19

0.55
0.30

True Pr(DLT)
Prior Pr(DLT)

0.09
0.04

0.12
0.10

Scenario 4
0.15 0.30
0.19 0.30

0.45
0.42

0.04
0.04

0.08
0.09

Scenario 9
0.10
0.18
0.30 0.40

0.27
0.45

True Pr(DLT)
Prior Pr(DLT)

0.05
0.01

0.08
0.04

Scenario 5
0.10
0.14
0.10
0.19

0.30
0.30

0.08
0.30

Scenario 10
0.10 0.28 0.40
0.42
0.54
0.64

0.45
0.73

5

Table 3.3 shows the results, including (1) percentage of correct selection (PCS), defined
as the percentage of simulated trials in which the MTD is correctly identified; (2) percentage of
patients treated at MTD; (3) percentage of patients treated above the MTD; (4) risk of overdosing,
defined as the percentage of simulated trials that assigned 50% or more patients to the doses above
the MTD; and (5) risk of poor allocation: defined as the percentage of simulated trials that assigned
less than 6 patients to the MTD. As noted by Zhou et al. [125], metrics (4) to (5) measure the
reliability of the design, i.e., the likelihood of a design demonstrating extreme problematic behaviors
(e.g., treating 50% or more patients at toxic doses, or fewer than 6 patients at the MTD), which
are of great practical importance. Note that the percentage of patients overdosed (i.e., metric (3))
does not cover the risk of overdosing (i.e., metric (4)). Two designs can have a similar percentage
of patients overdosed, but rather different risks of overdosing 50% of the patients.
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Operating characteristics of iCRM, iBOIN and iKeyboard, in comparison
with their counterparts with non-informative priors. iBOINR and iKeyboardR are
iBOIN and iKeyboard using robust prior.
Table 3.3:

Design

% Correct
selection

% Patients
at MTD

CRM
iCRM

54.8
63.1

59.9
65.2

BOIN
iBOIN
iBOINR

59.2
64.2
64.2

59.6
66.2
66.2

Keyboard
iKeyboard
iKeyboardR

59.2
64.2
64.2

59.3
50.7
50.7

CRM
iCRM

51.6
53.3

36.1
42.4

BOIN
iBOIN
iBOINR

50.6
57.8
57.8

41.1
47.6
47.6

Keyboard
iKeyboard
iKeyboardR

50.2
59.6
59.6

41.1
37.8
37.8

CRM
iCRM

57.2
60.2

37.8
40.4

BOIN
iBOIN
iBOINR

52.3
59.8
58.9

35.7
41.3
38.2

Keyboard
iKeyboard
iKeyboardR

52.4
62.5
59.7

35.7
35.8
35.6

CRM
iCRM

52.0
56.6

30.0
33.8

BOIN
iBOIN
iBOINR

51.5
59.7
57.6

28.6
36.1
32.4

Keyboard
iKeyboard

52.1
65.1

28.7
31.7

% Patients
above MTD

Risk of
overdosing

Risk of
poor allocation

23.2
19.4

12.2
9.8

29.0
22.4
22.4

23.6
12.8
12.8

10.2
4.5
4.5

29.3
39.6
39.6

23.6
34.2
34.2

10.2
17.8
17.8

29.5
23.7

25.2
16.8

6.0
3.7
3.7

23.0
10.4
10.4

17.1
8.6
8.6

6.0
6.6
6.6

23.0
35.1
35.1

16.7
23.6
23.6

17.3
15.3

21.6
18.8

17.0
14.5
17.7

7.9
3.5
9.1

19.2
10.9
15.2

17.1
28.8
29.0

7.9
18.7
19.4

18.9
19.1
19.7

10.3
8.6

33.4
26.5

13.1
12.1
15.7

1.2
0.6
3.2

24.6
12.8
19.0

13.1
25.6

1.2
11.2

24.6
18.9

Scenario 1
27.8
24.9

Scenario 2
7.7
5.6

Scenario 3
22.1
20.9

Scenario 4
15.3
14.4
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Table 3.3 Continued:

% Correct
selection

% Patients
at MTD

% Patients
above MTD

Overdose
(%)

% Poor
allocation

iKeyboardR

62.4

31.7

25.6

11.2

18.9

CRM
iCRM

72.7
75.8

38.6
41.7

0
0

23.4
19.7

BOIN
iBOIN
iBOINR

71.0
76.8
76.8

35.2
42.2
42.2

0
0
0

0
0
0

16.8
9.6
9.6

Keyboard
iKeyboard
iKeyboardR

71.0
75.8
75.8

35.2
47.1
47.1

0
0
0

0
0
0

16.8
5.2
5.2

CRM
iCRM

50.7
57.3

29.9
33.8

9.3
13.0

32.9
28.2

BOIN
iBOIN
iBOINR

51.5
58.6
58.6

28.6
35.5
35.5

13.1
18.4
18.4

1.2
3.8
3.8

24.6
11.8
11.8

Keyboard
iKeyboard
iKeyboardR

52.1
56.5
59.5

28.6
35.4
30.8

13.1
27.9
27.9

1.2
11.2
11.2

24.6
17.9
17.9

CRM
iCRM

58.0
59.8

38.1
38.0

17.3
13.4

21.8
21.3

BOIN
iBOIN
iBOINR

52.3
61.6
61.6

35.6
33.0
33.0

17.0
10.9
10.9

7.9
2.2
2.2

19.2
14.8
14.8

Keyboard
iKeyboard
iKeyboardR

52.4
56.4
56.4

35.7
45.4
45.4

17.1
15.3
15.3

7.9
3.6
3.6

18.9
6.8
6.8

CRM
iCRM

57.8
58.7

37.0
41.5

17.2
21.3

22.9
20.3

BOIN
iBOIN
iBOINR

52.3
54.3
54.3

35.6
36.2
36.2

17.0
28.6
28.6

7.9
19.9
19.9

19.2
19.8
19.8

Keyboard
iKeyboard

52.4
46.8

35.7
33.0

17.1
37.8

7.9
34.4

18.9
25.2

Design

Scenario 5
0
0

Scenario 6
14.6
17.0

Scenario 7
21.7
18.3

Scenario 8
21.6
25.5

49

Table 3.3 Continued:

% Correct
selection

% Patients
at MTD

% Patients
above MTD

Overdose
(%)

% Poor
allocation

iKeyboardR

46.8

33.0

37.8

34.4

25.2

CRM
iCRM

67.5
64.8

36.5
35.3

0
0

30.0
31.8

BOIN
iBOIN
iBOINR

69.4
51.4
68.8

33.8
25.7
36.7

0
0
0

0
0
0

22.4
35.3
21.2

Keyboard
iKeyboard
iKeyboardR

69.4
58.7
71.7

33.8
39.8
39.8

0
0
0

0
0
0

22.4
17.8
17.8

CRM
iCRM

54.2
60.6

36.5
40.0

28.3
15.2

26.1
18.1

BOIN
iBOIN
iBOINR

53.1
65.5
65.5

37.5
36.1
36.1

0.1
0.0
0.0

14.6
3.1
3.1

17.2
13.4
13.4

Keyboard
iKeyboard
iKeyboardR

52.6
66.5
66.5

37.5
37.9
37.9

0.1
0.1
0.1

14.6
3.8
3.8

17.1
7.0
7.0

Design

Scenario 9
0
0

Scenario 10
0.0
0.0

In scenarios 1 to 5, the prior is correctly specified. iCRM and iBOIN outperform their
counterparts using non-informative priors. Specifically, compared to the CRM, iCRM improves the
PCS and percentage of patients treated at the MTD by 2-8% and 3-6%, respectively. Compared
to the BOIN, iBOIN improves the PCS and percentage of patients treated at the MTD by 5-8%
and 5-7%, respectively. iCRM and iBOIN yield comparable PCS and the percentage of patients
assigned to the MTD, but iBOIN is more reliable with lower risk of overdoing. For example, in
scenarios 2 and 3, the risk of overdosing for iBOIN is about half of that of iCRM. Compared to its
non-informative counterpart, iKeyboard has 5-10% increase in PCS, but the percentage of patients
treated at the MTD is often lower and the risk of overdosing is substantially increased by more
than 10% in most scenarios. The proposed robust prior works well. iBOINR and iKeyboardR yield
the performance very similar to iBOIN and iKeyboard, respectively.
Scenarios 6 and 7 consider the cases, where the prior is misspecified with the prior MTD
one level off the true MTD. iCRM and iBOIN are robust to this moderate prior misspecification and
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outperform their counterparts. For example, in scenario 6, the PCS of iCRM and iBOIN are 57.3%
and 58.6%, respectively, about 6.6% and 7.1% higher than CRM and BOIN. Compared to iCRM,
iBOIN has lower risk of overdosing. Scenarios 8 and 9 examine the cases where the prior is severely
misspecified with the prior MTD two levels off the true MTD. When the prior MTD is higher than
the true MTD (i.e., scenario 8), iCRM and iBOIN perform well, yielding performance comparable
to their non-informative counterparts. The PCS of the iKeyboard is lower than keyboard. When
the prior MTD is lower than the true MTD (i.e., scenario 9), the prior misspecification has more
impact on the performance of the designs. The PCS of iCRM and iBOIN is lower than their noninformative counterparts. Scenario 9 is a difficult scenario because the true MTD is the highest dose.
The sample size often exhausted before enough data are accumulated to overcome the misspecified
prior to reach the highest dose (i.e., MTD). In this scenario, the iCRM performs better than iBOIN
because the iCRM tends to escalate dose more aggressively, as demonstrated by its relatively high
risk of overdosing. The proposed robust prior addressed this issue. iBOINR yield higher PCS that
is comparable to the BOIN using non-informative prior. In the case that the prior MTD is two
levels lower than the true MTD but the true MTD is not the highest dose, the iCRM and iBOIN
outperform their non-informative counterparts (see scenario 10).

3.4.2

Random scenarios
To validate the above results, we repeated the simulation using a large number of scenarios

randomly generated using a pseudo-uniform algorithm [16]. Two large sets of random scenarios
were constructed. The first set was used to examine the operating characteristics of the designs
when the prior is correctly specified. We generated 2000 random scenarios with MTD located at
dose level 1, 2, 3, 4, and 5, with equal probability, and assume that the prior MTD is correctly
specified for each of the scenarios. The second set was used to evaluate the performance of the
designs when prior is misspecified. We considered two types of misspecification: the prior MTD
is one level off the true MTD, and the prior MTD is two levels off the true MTD. For each type
of misspecification, we generated 4000 random scenarios with half of them having the prior MTD
(one or two levels) lower than the true MTD, and the other half having the prior MTD (one or two
levels) higher than the true MTD. We simulated 2000 trials for each scenario. Details on random
scenarios generation and configuration are provided in section A3.0.3 of the Appendix.
Figure 3.2 shows the simulation results when the prior MTD is correctly specified, which
are generally consistent with the results based on the fixed scenarios. That is, iCRM and iBOIN
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Figure 3.2: Operating characteristics of iCRM, iBOIN, and iKeyboard, in comparison to their
counterparts with non-informative priors, under 2000 random scenarios when the prior is correctly
specified. iBOINR and iKeyboardR are iBOIN and iKeyboard using robust prior, respectively. The
number under each boxplot is the average value with the standard deviation shown in parenthesis.
outperform their non-informative counterparts with higher PCS and higher percentage of patients
assigned to the MTD. For example, averaging over 2000 random scenarios, the PCS of iCRM is 6%
higher than that of the CRM, and the PCS of iBOIN is 8% higher than that of BOIN. iCRM and
iBOIN yield similar PCS and the percentage of patients to the MTD, but iBOIN has lower risk
of overdosing and poor allocation. iKeyboard design yields higher PCS than its non-informative
counterpart, but increases the risk of overdosing due to its aggressive dose escalation.
Figure 3.3 shows the simulation results when prior is misspecified by one dose level. iCRM
and iBOIN are robust to such moderate prior misspecification. The PCS of iCRM and iBOIN are
both 56%, offering 3% and 5% improvement over their non-informative counterparts, respectively.
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The risk of overdosing and poor allocation of iCRM are respectively 5% and 6% higher than the
iBOIN. iKeyboard design offered 3% improvement over its non-informative counterpart, but the
risk of overdosing is 8% higher. When the prior is severely misspecified with prior MTD being two
levels off the true MTD (see Figure 3.4), iCRM is more robust than the iBOIN, however, by using
the proposed robust prior, iBOINR shows competitive performance. In addition, when the prior
is likely to be severely misspecified, at the first place we should avoid using prior information and
non-informative prior is a more sensible choice.
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Figure 3.3: Operating characteristics of iCRM, iBOIN and iKeyboard, in comparison to their
counterparts with non-informative priors, under 4000 random scenarios when the prior MTD is one
dose off the true MTD. iBOINR and iKeyboardR are iBOIN and iKeyboard using robust prior,
respectively. The number under each boxplot is the average value with the standard deviation
shown in parenthesis.
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Figure 3.4: Operating characteristics of iCRM, iBOIN and iKeyboard, in comparison to their
counterparts with non-informative priors, under 4000 random scenarios when the prior MTD is two
doses off the true MTD. iBOINR and iKeyboardR are iBOIN and iKeyboard using robust prior,
respectively. The number under each boxplot is the average value with the standard deviation
shown in parenthesis.
3.4.3

Unequal prior information across doses
Lastly, we briefly investigated the case that different amount of prior information is available

for different doses. We assume that more prior data are available at lower dose than higher doses,
and more prior data are available around the prior MTD, as we often observed in (historical) phase
I trials. As described in section 3.2, iBOIN can easily accommodate that by specifying different
PESS at different doses. Figure 3.5 shows the simulation results under scenarios 1 to 5. We control
the total PESS over 5 doses are the same for iBOIN and CRM. We see that, compared to the CRM,
iBOIN offers higher PCS and allocates higher percentage of patients at the MTD, as well as lower
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Figure 3.5: Operating characteristics of iBOIN and iCRM when different amount of prior information (i.e., PESS) is available for different doses under scenarios 1 to 5.
risk of overdosing and poor allocation. The CRM does not allow specifying dose-specific PESS as
it uses a single parameter to control prior information in all doses, thus cannot take full advantage
of the prior information.

3.5

Summary
In this chapter, we propose a unified framework to incorporate historical data or real-world

evidence to improve the efficiency of phase I trial designs, especially model-assisted designs. By
using skeleton and PESS, our method is intuitive and easy to interpret. More importantly, our
approach maintains the hallmark of the model-assisted design: simplicity—the dose escalation/deescalation rule can be tabulated prior to the trial conduct. For example, implementing the proposed
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iBOIN only involves simple comparison of the number of DLT observed at the current dose with
the prespecified dose escalation and de-escalation boundaries (e.g., Table 3.1). Extensive simulation studies show that the proposed method, in particular iBOIN, can effectively incorporate prior
information and yield comparable performance as the model-based CRM design and greater reliability. Moreover, iBOIN is more transparent and easier to implement. In addition, iBOIN is
more flexible and allows specifying dose-specific prior information to more accurately reflect available prior information. The iBOIN design is generally robust to prior misspecification. When
there is high likelihood that prior is severely misspecified, the proposed robust prior can be used
with iBOIN to enhance its robustness. Actually, in this case, there is little rationale to incorporate prior information and it may be more appropriate to use non-informative prior. When
non-informative prior is used, iBOIN becomes the standard BOIN. Freely available software is
provided at www.trialdesign.org to facilitate the use of proposed designs.
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A
A3.0.1

Appendix

Determining informative prior for BOIN
Suppose at dose level j, the prior estimate of DLT probability is qj with PESS of n0 . This

prior information can be transformed into the prior distribution of the three hypothesis employed
by BOIN (i.e., H1j : pj = φ,

H2j : pj = φ1 ,

H3j : pj = φ2 ) as follows: for k = 1, 2 and 3,

πkj = Pr(Hkj | n0 , qj )
=

(A3.1)

=
=
=

n0
X

Pr(Hkj | x)Pr(x | n0 , qj )

x=0
n0
X
x=0
n0
X
x=0
n0
X
x=0

Pr (x | Hkj ) Pr (Hkj )
P3

k0 =1

Pr (x | Hkj ) Pr (Hkj )

Pr (x | Hkj )
P3

k0 =1

Pr (x | Hkj )

Pr(x | n0 , qj ).

φxk (1 − φk )n0 −x
P3

k0 =1

Pr(x | n0 , qj )

0 n0 −x
φ0x
k (1 − φk )




n0 x
q (1 − qj )n0 −x .
x j

By doing so, the prior information is incorporated into the dose escalation and de-escalation boundaries, as given by equation (2.3).
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A3.0.2

iBOIN Shiny app interface

Figure A3.1: User interface of iBOIN software
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A3.0.3

Random scenario configuration

A3.0.4

Generate random scenarios where prior MTD is correctly specified
To examine how the informative designs perform, we generated 2000 random scenarios with

MTD located at dose level 1, 2, 3, 4, and 5, with equal probability. The random scenarios were
generated using the following pseudo-uniform algorithm [16]. Given a target DLT probability φ
and J dose levels,
1. Select one of the j ∈ (1, · · · , J) with probability 1/J.
2. Sample M ∼ Beta(max{J − j, 0.5}, 1).
3. Repeatedly sample J toxicity probabilities uniformly on [0, B] until these correspond to a
scenario in which dose level j is the MTD, where B = φ + (1 − φ) × M is the upper bound of
DLT probability.
In these scenarios, the MTD is the dose with the DLT probability closest to the target φ but
not necessarily equal to the target φ. It is possible to obtain scenarios in which all the doses have
DLT probabilities below or above the target φ. To ensure that MTD is uniquely and meaningfully
defined, we required that the true DLT probability of the MTD is within [φ − 0.05, φ + 0.05], and
the distance between the MTD and its adjacent doses is greater than 0.05 and less than 0.3, i.e.,
0.05 < pj+1 − pj < 0.3 and 0.05 < pj − pj−1 < 0.3. The generating process stops until we obtained
2000 random scenarios that satisfied the specification. Figure A3.2 shows 50 scenarios from the
2000 random scenarios generated. The plot shows that the scenarios cover a wide range of possible
dose-toxicity scenarios that we may encounter in practice. Each of 2000 the scenarios has their
prior MTD correctly specified. The five prior skeletons utilized are presented in scenarios 1-5 in
Table 3.2.
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Figure A3.2: 50 randomly selected scenarios from the 2000 scenarios generated
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A3.0.5

Generate random scenarios with different levels of mis-specification
To assess the performance of the informative designs when prior is mis-specified (i.e., prior

MTD is not corresponding to the true MTD), we conduct extensive simulation for random scenarios
with different levels of severity for mis-specification. Below is the configuration of the scenarios.
1. The prior MTD is one dose below the true MTD. Generate 2000 scenarios with true MTD
located at dose level 2, 3, 4, and 5 with equal probability. The corresponding prior skeletons
are in scenarios 1, 2, 3, and 4 in Table 3.2.
2. The prior MTD is one dose above the MTD. Generate 2000 scenarios with true MTD located
at dose level 1, 2, 3, and 4 with equal probability. The corresponding prior skeletons are in
scenarios 2, 3, 4, and 5 in Table 3.2.
3. The prior MTD is two doses below the true MTD. Generate 2000 scenarios with true MTD
located at dose level 3, 4, and 5 with equal probability. The corresponding prior skeletons are
in scenarios 1, 2, and 3 in Table 3.2.
4. The prior MTD is two doses above the MTD. Generate 2000 scenarios with true MTD located
at dose level 1, 2, and 3 with equal probability. The corresponding prior skeletons are in
scenarios 3, 4, and 5 in Table 3.2.
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CHAPTER 4

A utility-based Bayesian optimal interval (U-BOIN) Phase
I/II design to identify the optimal biological dose for
targeted and immune therapies

4.1

Introduction
This chapter is based on an article published in Statistics in Medicine in 2019 and entitled

“A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal
biological dose for targeted and immune therapies” [126], for which I was the first-author. It was
a joint work with J. Jack Lee and Ying Yuan. The journal has granted the permission to use this
article in the dissertation.
Immunotherapy and targeted therapies have revolutionized cancer treatment. Unlike conventional chemotherapy, immunotherapy drugs do not target the tumor directly. Instead, they
work by reactivating the immune system and, hence, reestablishing its capacity to combat tumors.
A major class of immunotherapy drugs are monoclonal antibodies, known as immune checkpoint
inhibitors (ICI) (e.g., nivolumab, pembrolizumab, and ipilimumab). Checkpoint proteins are receptors on immune cells that can be activated to block immune response, for example checkpoint
proteins on T cells (e.g., PD-1 and CTLA-4). The ICI bind to the checkpoint receptors on T cells
and release “brake” such that T cells can kill cancer cells, achieving treatment efficacy. Nivolumab
and pembrolizumab are PD-1 inhibitors, and ipilimumab is CTLA-4 inhibitor.
Traditional dose-finding designs developed for chemotherapy aim to find the maximum
tolerated dose (MTD). The underlying assumption is that both toxicity and efficacy monotonically
increase with the dose and, thus, the MTD presents the most efficacious dose that is safe. This
assumption, however, is often questionable for immunotherapy and targeted agents. Although it
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is reasonable to assume that toxicity increases with the dose, the same is not necessarily true for
efficacy. For example, once the checkpoint binding is saturated, further incrementing the ICI dose
does not increase treatment efficacy. For some monoclonal antibodies, it is observed that higher
doses actually lead to lower efficacy [83]. In addition, while increasing the dose of immunotherapy
agents (or targeted biological agents) may improve efficacy, it still may cause substantial toxicity,
due to over-activation of the immune system. When the overall benefit is limited, the value of
increasing the dose becomes questionable.
To optimize the treatment benefit of immunotherapy and targeted therapy, therefore, it is
important to consider toxicity and efficacy simultaneously and their risk-benefit trade-off during
dose finding. The objective of dose finding for targeted therapy and immunotherapy is to identify
the optimal biological dose (OBD), defined as the dose that has the highest desirability in terms
of the risk-benefit trade-off. Our research is motivated by a Phase I/II trial to identify the OBD
of a novel humanized anti-TROP2 monoclonal antibody in patients with an advanced solid tumor. Trophoblast cell-surface antigen 2 (TROP2) is associated with increased tumor growth. It is
overexpressed in the majority of human epithelial cancers, including esophageal, breast, and lung
cancers [73, 75]. Five doses will be studied in the trial. Toxicity will be graded according to the
NCI-CTCAE version 4.03, with a 21-day assessment window using the scale of 5 grades. The dose
limiting toxicity (DLT) is defined as toxicity with grade 3 or higher. Tumor response will be evaluated using RECIST version 1.1, scored as complete remission (CR), partial remission (PR), stable
disease (SD), and progressive disease (PD). Response is defined as CR/PR. TROP2 expression will
be measured on day 8, after dosing, to provide a biomarker for measuring the biological activity of
the drug.
Here, we develop a utility-based seamless Phase I/II design to find the OBD. We jointly
model toxicity and efficacy using a multinomial-Dirichlet model and employ a utility function to
measure dose risk-benefit trade-off. We show that the utility approach is flexible and more general,
in that it contains the existing marginal toxicity-efficacy trade-off methods as a special case. The
design consists of two seamlessly connected stages. In stage I, the Bayesian optimal interval (BOIN)
design [65] is used to quickly explore the dose space and collect preliminary toxicity and efficacy
data. In stage II, in light of accumulating efficacy and toxicity from both stages I and II, we
continuously update the posterior estimate of the utility for each dose after each cohort, and use
this information to direct the dose assignment and selection. We refer to the resulting design as
the utility-based BOIN (U-BOIN) design. To accommodate the delayed efficacy observed in some
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targeted and immunotherapy trials, we extend the U-BOIN design and use the short-term endpoint
(e.g., immune activity or other biological activity of targeted agents) to predict the delayed efficacy
outcome to facilitate real-time decision making.
Numerous Phase I/II trial designs have been proposed. Thall and Russell [97] developed
a Bayesian Phase I/II design that characterizes patient outcomes using a trinary variable that
accounts for both toxicity and efficacy. Braun [6] generalized the continual reassessment method
(CRM [77]) to accommodate toxicity and efficacy simultaneously. Thall and Cook [96] presented
the EffTox design, based on the trade-offs between toxicity and efficacy. Yin et al. [109] proposed
a Phase I/II design that uses the odds ratio of the efficacy and toxicity as a measure of desirability.
Yuan and Yin [118] described a Phase I/II design that jointly models toxicity and efficacy as timeto-event outcomes. Jin et al. [44] proposed a Phase I/II design that accommodates late-onset
toxicity and efficacy. Liu and Johnson [62] proposed a robust Bayesian Phase I/II design, based on
a flexible Bayesian dynamic model. Guo and Yuan [31] proposed a personalized Bayesian Phase
I/II design that accounts for patient characteristics and biomarker information. Zang et al. [120]
proposed several practical Phase I/II trial designs to find the OBD. Liu et al. [61] proposed a
Bayesian Phase I/II trial design for immunotherapy that considers the immune response, toxicity,
and efficacy. Yuan et al. [113] provided a comprehensive coverage of Phase I/II designs.
Compared to existing Phase I/II designs, the proposed U-BOIN design has several strengths.
First, the U-BOIN is simple and easy to implement. It is a model-assisted design in that it uses
a model for efficient decision making, but its decision rule for dose escalation/de-escalation can
be tabulated and included in the trial protocol before a trial starts [105, 114, 125]. Once the
trial is designed, it can be easily implemented using the predetermined decision table. No complicated computation or model estimation is needed. In contrast, most existing Phase I/II designs
are model-based designs, and require complicated model fitting and estimation after treating each
cohort. Second, the U-BOIN is robust, because it models toxicity and efficacy at each dose independently, without imposing any parametric structure on dose-toxicity and dose-efficacy curves.
In contrast, most existing designs assume that the dose-toxicity and dose-efficacy curves follow
certain parametric forms (e.g., logistic model), and thus are susceptible to the influence of model
mis-specification.
Third, most existing Phase I/II designs use the trade-off in the marginal toxicity and efficacy
probabilities of a dose to measure the desirability of the dose, while the U-BOIN design uses the
utility, which is not only easier to elicit from physicians, but also more flexible and general. We
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prove that the trade-off based on marginal toxicity and efficacy probabilities is a special case of the
utility approach. Although utility has been used in previous designs [35, 71, 72], to the best of our
knowledge, this work is the first to formally show that the utility approach contains the trade-off
based on marginal toxicity and efficacy probabilities as a special case. This provides a theoretical
justification for using the utility approach. Lastly, the U-BOIN is capable of accommodating delayed
efficacy, whereas most existing designs assume that the efficacy endpoint is quickly observed.
The remainder of this chapter proceeds as follows. Section 4.2 introduces the statistical
model, utility function, dose-finding algorithm, and software to implement the U-BOIN design.
Section 4.3 uses simulation to compare the U-BOIN design with an existing Phase I/II design, and
also assesses the robustness of the design using sensitivity analysis. Section 4.4 provides a brief
summary.

4.2
4.2.1

Method
Efficacy-toxicity model
Consider a Phase I/II trial with J doses under investigation. Let yE = 0, · · · , R − 1 denote

the categorical efficacy endpoint with R levels, where a higher level represents a more desirable
treatment response; and yT = 0, · · · , Q − 1 denote the categorical toxicity endpoint with Q levels,
where a higher level represents a more severe toxicity. The bivariate outcomes (YE , YT ) can be
equivalently represented by a single variable Y with K = R × Q levels, where each level of Y maps
to a distinct value of (YE , YT ).
As an example, consider the conventional setting that both YE and YT are binary. Let
YE = 1 denote response, 0 otherwise. Similarly, let YT = 1 denote DLT, 0 otherwise. Then,
Y has K = 4 levels, with Y = 1, if (YE , YT ) = (0, 1); Y = 2, if (YE , YT ) = (0, 0); Y = 3, if
(YE , YT ) = (1, 1); and Y = 4, if (YE , YT ) = (1, 0). The value of Y ascribed to each possible
(YE , YT ) is not critical, as long as we keep track of the mapping. Without loss of generality, we
assume that Y = 1 denotes the least favorable clinical outcomes, and Y = K denotes the most
favorable clinical outcomes.
Define πjk = Pr(Y = k | d = j), k = 1, · · · , K and j = 1, · · · , J, with

PK

k=1

πjk = 1, where

d denotes the dose level. We assume that Y follows a Dirichlet-multinomial model as follows:

Y |d=j

∼

(πj1 , · · · , πjK ) ∼

Multinomial(πj1 , · · · , πjK ).
Dirichlet(a1 , · · · , aK ),
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where a1 , ..., aK > 0 are hyper-parameters. We set

PK

k=1

ak = 1, such that the prior is vague and

equivalent to a prior sample size of 1.
At an interim decision time, assume that nj patients have been treated at dose d = j,
PK
among which njk patients had outcome Y = k, where nj = k=1 njk . Given the observed interim

data Dj = (nj1 , · · · , njK ), the posterior distribution of π j = πj1 , · · · , πjK is

π j | Dj ∼ Dirichlet(a1 + nj1 , · · · , aK + njK ).

4.2.2

Utility
We measure the desirability of the investigational doses using utility. Let ψk denote the

utility ascribed to outcome Y = k, k = 1, · · · , K. The utility ψk should be elicited from physicians
to reflect the risk-benefit trade-off underlying their medical decisions, which can be done using the
following procedure:
(1) Fix the value of the utility for the least desirable outcome Y = 1 as ψ1 = 0, and for the
most desirable outcome Y = K as ψK = 100. For example, for binary YE and YT , the least
desirable outcome is (YE = 0, YT = 1), i.e., (no response, DLT), and the most desirable
outcome is (YE = 1, YT = 0), i.e., (response, no DLT).
(2) Ask the clinician to use these two utilities as a reference to score the utility values ψ2 , · · · , ψK−1
for the other K − 2 possible outcomes Y = 2, · · · , K − 1 to quantify the risk-benefit trade-off
under each outcome.
Table 4.1 shows three examples of the utility function. The first two examples consider
the scenario where both toxicity and efficacy are binary outcomes. Example 1 has utility values
{ψ1 = 0, ψ2 = 30, ψ3 = 50, ψ4 = 100} for the outcomes {(YE = 0, YT = 1), (YE = 0, YT = 0), (YE =
1, YT = 1), (YE = 1, YT = 0)}. Compared to example 1, example 2 rewards the response (i.e.,
YE = 1) more, in the presence of DLT (i.e., YT = 1), by assigning a larger value to ψ3 (65 versus
50). This is appropriate for the trial where toxicity can be well managed and response is highly
desirable (e.g., leading to long survival). Example 3 shows the case where YT has three levels (i.e.,
minor, moderate, and severe toxicity), and YE has also three levels (i.e., PD, SD, and CR/PR).
In our experience, clinicians quickly understand what the utilities mean and provide values
for ψk ’s, since the values reflect the actual clinical practice. After completing this process, simulation
should be performed to verify the operating characteristics of the design. In some cases, the
simulation results may motivate slight modification of some of the numerical utility values, although
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Table 4.1: Examples of utility

(a) Example 1
YE = 0
YE = 1

YT = 1
ψ1 = 0
ψ3 = 50

YT = 0
ψ2 = 30
ψ4 = 100

YT = 1
ψ1 = 0
ψ3 = 65

YT = 0
ψ2 = 30
ψ4 = 100

YT = severe
ψ1 = 0
ψ4 = 0
ψ7 = 15

YT = moderate
ψ2 = 15
ψ5 = 30
ψ8 = 45

(b) Example 2
YE = 0
YE = 1
(b) Example 3
YE = PD
YE = SD
YE = PR/CR

YT = minor
ψ3 = 30
ψ6 = 50
ψ9 = 100

Note. PD: partial disease, SD: stable disease, PR: partial remission, CR: complete remission.
such modification typically has little or no effect on the design’s operating characteristics. One
possible criticism for using the utility values is that they require subjective input. However, we
are inclined to view this as a strength, rather than a weakness. The process of specifying the
utility requires clinicians to carefully consider the potential risks and benefits of the treatment that
underlie their clinical decision making in a more formal way and incorporate that into the trial. In
addition, our simulation study and previous studies [31, 61, 72] show that the design is generally
not sensitive to the numerical values of the utility, as long as it reflects a similar trend.
Given the values of ψk , the true mean utility for dose j is given by

(4.1)

Uj =

K
X

ψk πjk ,

k=1

Since the true mean utility Uj depends on πjk , which is unknown, we need to estimate it, based on
the observed data. Given the interim data D = {Dj }, the estimate of mean utility is given by

(4.2)

Ûj =

K
X

ψk E(πjk | D).

k=1

For the conventional setting with binary YT an YE , another common approach to defining
the efficacy-toxicity trade-off is directly based on the marginal efficacy probability πE,j = Pr(YE =
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1|d = j) and marginal DLT probability πT ,j = Pr(YT = 1|d = j), which can be expressed as

(4.3)

UjM = πE,j − wπT ,j ,

where w is a prespecified weight [113]. This trade-off function says that patients are willing to
trade an increase of w in the DLT probability for a unit increase in the efficacy probability. If
w = 0, we obtain the special case that the dose with the highest efficacy is the most desirable.
The following theorem shows that this marginal-probability-based approach is a special case of the
utility approach described above. The proof is provided in the Appendix.
Theorem 1. Marginal-probability-based trade-off UjM , defined in (4.3), is a special case
of the utility method defined in (4.1), in the sense that for a prespecified weight w, we can find
(ψ2 , ψ3 ), such that Uj = ξUjM , where ξ is a non-zero constant.
In the Supplementary Material available at https://onlinelibrary.wiley.com, we provide an
example to show how to map Uj with UjM by choosing appropriate values of (ψ2 , ψ3 ).
Liu and Johnson [62] proposed another marginal-probability-based trade-off function

(4.4)

UjM 2 = πE,j − w1 πT ,j − w2 πT ,j I(πT ,j > ρ),

where w1 and w2 is a prespecified weight, I(·) is an indicator function, and ρ is a prespecified
toxicity threshold deemed of substantial concern. Compared to UjM in (4.3), this trade-off function
is more flexible and allows to impose a higher penalty (i.e., w1 + w2 ) when the true DLT probability
πT ,j exceeds the threshold ρ. UjM 2 becomes UjM when w2 = 0. It is not clear if trade-off function
UjM 2 can be expressed equivalently in the form of Uj as (4.1). Nevertheless, the proposed U-BOIN
design can be used with different types of utility/trade-off, including UjM 2 . We plan to incorporate
this functionality in our software provided later.

4.2.3

Optimal biological dose (OBD)
To define the OBD, we first define the admissible dose to safeguard patients from toxic or

futile doses. As the objective here is to rule out toxic or futile doses, it is more natural to start with
the definition of an inadmissible dose. Let π̄T denote the maximum tolerable DLT probability, and
π E the lowest acceptable response rate. We define that dose j is inadmissible, if it meets either one
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or both of the following two criteria:

(4.5)

(Toxic)

Pr(πT ,j > π̄T | D) > CT ,

(4.6)

(Futile)

Pr(πE,j < π E | D) > CE ,

where CE and CT are probability cutoffs. In general, CT = 0.95 and CE = 0.9 work well, but
should be calibrated using simulation to ensure desirable operating characteristics. This can be
done easily using the software provided.
The admissible dose is then defined as the dose for which none of the criteria (4.5) and
(4.6) is satisfied. When YT has more than 2 categories (e.g., grade 0-2, grade 3, and grade 4-5),
for the purpose of defining the admissible dose, YT can be temporarily collapsed into DLT/no DLT
(i.e., DLT = grade 3 and higher). This dichotomization simplifies the definition of the admissible
dose and is often adequate to safeguard patients from overly toxic doses. While it is not necessary,
more complicated safety criteria could be entertained to accommodate multiple categories. Similar
dichotomization (i.e., response/no response) is also applied to YE , when it has more than two
categories. Note that although we dichotomize YT and YE for defining the admissible dose, our
model and utility are still based on their original scales. We define the OBD as the dose that is
admissible and has the highest utility value, i.e.,

OBD = argmaxj∈A (Uj ),

where A denotes the set of admissible doses.

4.2.4

Phase I/II OBD finding algorithm
The U-BOIN design consists of two seamless, connected stages (Figure 4.1). The objective

of stage I is to quickly explore the dose space to identify a set of admissible doses that are reasonably
efficacious and safe for stage II. In stage I, we conduct dose escalation based on only the toxicity
outcome, but efficacy data are also collected and will be used for decision making in stage II. Given
the exploratory nature of stage I, if YT has more than two categories, we dichotomize it as DLT/noDLT to facilitate the exploration of the dose space. This is in line with the clinical practice and
serves well for the purpose of stage I. Note that for the estimation and finding the OBD (i.e., the
primary objective of the trial), we retain the original scale of YT .
Stage I dose escalation/de-escalation is guided by the BOIN design [65], which has been
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Figure 4.1: Diagram of the U-BOIN design
well-validated and widely used in a variety of oncology trials [1, 51, 54, 104] and treatment agents
[41, 52, 66, 82]. Due to very limited data and large uncertainty, for patient safety, we set the target
DLT probability φT = π̄T − 0.05, slightly lower than the maximum tolerable DLT probability π̄T ,
to ensure that stage I dose exploration concentrates around up to, but not exceeding π̄T . Let π̂T ,j
denote the empirical (or maximum likelihood) estimate of πT ,j , given by π̂T ,j = mj /nj , where mj
is the number of patients who experienced DLT at the dose level j; and λe and λd denote the
predetermined optimal escalation boundary and de-escalation boundary. Table 4.2 provides the
values of λe and λd for the commonly used target DLT probability φT , see Liu and Yuan [65] for
the derivation and formula to calculate λe and λd .
Table 4.2: Dose escalation and de-escalation boundaries of the BOIN design

Boundaries
λe (escalation)
λd (de-escalation)

0.15
0.118
0.179

Target DLT probability (φT )
0.20
0.25
0.30
0.157
0.197
0.236
0.238
0.298
0.358
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0.35
0.276
0.419

0.40
0.316
0.480

The dose-finding algorithm in stage I proceeds as follows.
A1 Patients in the first cohort are treated at dose level 1 or a prespecified starting dose.
A2 Suppose j is the current dose, use the following rules to assign a dose to the next cohort of
patients.
• Escalate the dose to j + 1 if π̂T ,j ≤ λe .
• De-escalate the dose to j − 1 if π̂T ,j ≥ λd .
• Otherwise, stay at the current dose j.
A3 Repeat step A2 until the number of patients treated on one of the doses reaches s1 , and then
move to stage II. We recommend s1 = 12 as the default value, while s1 = 9 to 15 generally
yields good operating characteristics.
Stage II proceeds as follows:
B1 Let j ∗ denote the highest dose level that has been tried. If π̂j ∗ ,T ≤ λe and j ∗ is not the
highest dose in the trial, escalate the dose to j ∗ + 1 for treating the next cohort of patients;
otherwise, proceed to step B2.
B2 Given the observed interim data D collected in both stages I and II, determine the admissible
dose set A. If no dose is admissible, terminate the trial and no dose should be selected as the
OBD. Otherwise, assign the next cohort of patients to the admissible dose (i.e., ∈ A) that
has the largest posterior mean utility, which can be pre-tabulated.
B3 Repeat steps B1 and B2 until reaching the prespecified maximum sample size N or the
number of patients treated at one of the doses reaches s2 (> s1 ), and then select the OBD as
the admissible dose (i.e., ∈ A) that has the largest posterior mean utility. For most trials, a
value between 18 to 24 is a reasonable choice for s2 .
In stage I, following the BOIN design, we impose an overdose control rule as follows: if
Pr(πT ,j > π̄T | mj , nj ) > 0.95 and nj ≥ 3, dose level j and higher are eliminated from the trial;
the trial is terminated if the lowest dose level is eliminated, where Pr(πT ,j > π̄T | mj , nj ) > 0.95
is evaluated based on a beta-binomial model with the uniform prior. Once the trial move to stage
II, this overdose control rule is seamlessly merged as the inadmissible rule (4.5). In the overdose
control rule, we use π̄T , rather than φT , as the DLT probability threshold to ensure that the overdose
control rule seamlessly connects with the inadmissible rule.
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For stage II step B1, the reason that we perform dose escalation when π̂T,j ∗ ≤ λe is to allow
the trial to continue exploring the dose space, given that the highest tried dose is safe, to reduce
the risk of being stuck at a local suboptimal dose, due to a large variation caused by a small sample
size. Besides the pick-the-winner (PW) approach (i.e., deterministically assigning the next cohort
of patients to dose j ∈ A that has the largest posterior mean utility), other strategies can also be
used to assign patients. For example, we can adaptively randomize the next cohort of patients to
dose j ∈ A, with probability ωj proportional to its posterior mean utility, i.e.,

(4.7)

Uj

ωj = P

j∈A

Uj

.

The adaptive randomization (AR) approach can reduce the risk of being stuck at a suboptimal
dose, but as a trade-off, it tends to treat fewer patients at the OBD. Another approach is equal
randomization (ER), where the next cohort of patients are assigned to the admissible doses with
equal probability, i.e.,

(4.8)

ωj = P

1

j∈A

1

.

We compare the performance of PW, AR, and ER in our simulation study. None of the methods
dominates the others. Thus, we generally recommend the PW approach because of its simplicity.
Unlike most existing Phase I/II designs, which require complicated model fitting and estimation after each cohort to make the decision of dose assignment, one prominent advantage of the
U-BOIN is that its dose assignment rules can be pre-tabulated in decision tables and included in
the trial protocol before the trial starts. To conduct the trial, no complicated calculation is needed.
The investigator can simply use the decision tables to determine dose assignment, e.g., determine
whether escalation/de-escalation is needed (steps A2 and B1) or identify admissible doses (step B2).
Because of this feature, the U-BOIN can be classified as a model-assisted design [105, 114, 125].
Section 1 in the online Supplementary Material (at https://onlinelibrary.wiley.com) provides
an example of using the decision tables in a hypothetical Phase I/II trial.

4.2.5

Delayed efficacy response
In some trials, efficacy endpoint YE requires a long time to be ascertained. In our motivating

example, it takes three months to evaluate YE . The long assessment window causes a major logistics

72

issue for decision making in stage II. For example, given that the accrual rate is three patients per
month, and that patients are treated in cohorts of three, on average, six new patients will be accrued
while waiting to evaluate the previous three patients’ outcomes. This begs the question: how can
new patients receive timely treatment, when the previous patients’ outcomes are not yet observed?
Statistically, this means that D are not fully observed, as some YE ’s are unavailable. As
a result, the mean utility estimate (4.2) and the inadmissible criterion (4.6) cannot be evaluated
for making interim decisions. This issue is known as the late-onset or delayed-outcome issue,
which has been studied in literature. Cheung and Chappell [14] proposed a weighting method
to handle late-onset toxicity for Phase I clinical trials. Yuan and Yin [118] modeled toxicity and
efficacy as time-to-event outcomes that accommodate the unobserved as censored events. Liu et
al. [64] and Jin et al. [44] treated unobserved outcomes as missing data, and proposed a Bayesian
data augmentation approach to predict unobserved toxicity and/or efficacy outcomes to facilitate
decision making. Cai et al. [8] took the multiple imputation approach to handle unobserved efficacy
outcomes in Phase II trials.
We follow the approach of Cai et al. [8] and use multiple imputation to handle unobserved
YE . The innovation here is that we use the measure of biological activity, which is routinely recorded
in targeted and immunotherapy trials, as an ancillary variable to help predict (or impute) YE .
Examples of the measure of biological activity include immune response (e.g., CD8+ T cell count)
in immunotherapy trials and gene expression related to the pathway targeted by the treatment
agent. The measure of biological activity is often quickly observable after drug administration and
correlated with the clinical response. Daud et al. [18] showed that the abundance of CD8+ T
cells predict response to anti-PD1 therapy, and advocated using the immune activity to predict the
likelihood of achieving a clinical response to the PD-1 pathway inhibitor. For ease of exposition,
hereafter we use the immune response, denoted by YI , as the example to illustrate our approach, but
YI can be any reasonable biological activity measure predictive of treatment efficacy. We assume
that YI is quickly observable, thus its value is always available at the time of decision making.
Given the observed value of YI , we predict the unobserved YE , based on the following scaled
logistic regression model:

(4.9)

logit

π

E,j

λ



= β0 + β1 YI ,

where πE,j is the probability of efficacy for dose j, β0 and β1 are regression parameters, and
0 < λ ≤ 1 is a plateau (or scale) parameter used to reflect that the probability of clinical response

73

often levels out after the immune activity reaches a certain level. Under this model, the probability
of efficacy πE,j increases with YI , and then plateaus at the value of λ when YI is sufficiently large.
When λ = 1, it becomes a standard logistic regression model. We do not include dose level j in
the model, because the treatment effect of immunotherapy is mediated by the immune response,
and thus it is often reasonable to assume that, conditional on YI , πE,j is independent of j. If
this assumption is not plausible in some situations, one can simply add j as a covariate to the
model. In addition, more biomarkers, when available, can be added to model (4.9) as predictors
to improve the prediction accuracy. One attractive property of our imputation approach is that,
when the imputation model (4.9) is misspecified, its impact on the design diminishes over time
and eventually goes away when the trial is completed. This is because, as the trial proceeds, more
and more patients’ YE become observed, and accordingly fewer and fewer percentage of YE needs
prediction. As a result, our method is generally robust to model misspecification, as shown later in
the sensitivity analysis.
In terms of prior specifications in model (4.9), following Gelman et al.,[27] we assume that
the model parameters (λ, β0 , β1 ) are independent and have their own prior distributions. We specify
a uniform distribution for the scale parameter λ ∼ unif (0, 1). The magnitude of the coefficients
(β0 and β1 ) could be very large or small, depending on different trials. This makes it difficult to
specify standard prior distributions for the coefficients. To tackle this problem, we first standardize
the variable YI . In our application, YI is continuous; we standardize it to have a mean of 0 and a
standard deviation of 0.5. We regulate the prior distributions to make sure that a typical change
in a covariate should not lead to a dramatic change in the efficacy probability.
After standardizing data, a change of 2.5 on the logit scale can move the probability of
a favorable response to the therapy from 0.2 to 0.75. We assume that the effect of the immune
response is unlikely to be more dramatic than that. This typically is true for immunotherapy trials,
as the efficacy probability is rarely outside of that range. We assign a normal distribution with a
mean of 0 and a standard deviation 1.25 for β0 : β0 ∼ N (0, 1.252 ). The parameter β1 is supposed
to be positive, due to the positive relationship between immune response and tumor response, and
thus we assign a gamma distribution with a shape parameter of 1 and a rate parameter of 1.2:
β1 ∼ Gamma(shape = 1, rate = 1.2). The priors ensure that a change in the covariate YI from
one standard deviation below the mean to one standard deviation above the mean will lead to an
absolute change that is mostly less than 2.5 on the logit scale.
Let f (β0 , β1 , λ) denote the joint prior distribution of (β0 , β1 , λ). The posterior distribution
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of (β0 , β1 , λ) is given by
(4.10)
f (β0 , β1 , λ|D) ∝ f (β0 , β1 , λ)

nj
J Y
Y

λeβ0 +β1 yI,ji

j=1 i=1

1 + eβ0 +β1 yI,ji

!yE,ji

1 + (1 − λ)eβ0 +β1 yI,ji

!1−yE,ji
,

1 + eβ0 +β1 yI,ji

where yI,ji is the immune response for the ith patient treated with dose j and yE,ji is the tumor
response for this patient.
At an interim decision time, let YE,obs and YE,mis denote the observed and missing parts
of YE . We impute the value of YE,mis using multiple imputations as follows.
1) Conditional on observed data (YE,obs , YI ) , sample L draws of (λ, β0 , β1 ) from their posterior
distribution (4.10) using the adaptive rejection Metropolis sampling [29]. A certain number of
burn-in iterations are typically needed before collecting the posterior draws. In our simulation,
we set the number of burn-in iterations as L0 = L/2.
2) Thin the posterior draws by taking a sample after every L0 /H draw, resulting in a total of H




(1)
(1)
(H)
(H)
sets of posterior draws of (λ, β0 , β1 ), denoted as λ(1) , β0 , β1 , · · · , λ(H) , β0 , β1
.
3) Impute YE,mis for H times, where the hth imputed value is generated by drawing a random
sample from Bernoulli(q), where h = 1, . . . , H and q = λeβ0 +β1 YI /(1+eβ0 +β1 YI ). We denoted
(1)

(H)

the H sets of imputed values as YE,imp , · · · , YE,imp .
After filling in YE,mis with each of the H imputed values, we obtained an H imputed
(h)

complete dataset, D(1) , · · · , D(H) , where D(h) is obtained by filling in YE,mis with YE,imp , h =
1, · · · , H. Then, the estimate of mean utility (4.2) is given by

Ûj =

H
4


1 XX
ψk E πjk | D(h) ,
H
h=1 k=1

and the left side of the inadmissible criterion (4.6) is calculated as

Pr πE,j < π E | D



=

H

1 X 
Pr πE,j < π E | D(h) .
H
h=1

The dose finding follows the same algorithm described in section 4.2.4. Little and Rubin [58]
suggested that, for practical use, the number of multiple imputation (H) can be sufficient when
H = 5 or greater. In our simulation, we perform H = 20 imputations.
To further improve the efficiency of the design, YI can also be used to refine the admissible
rule. The rationale is that when YE takes a long time to be observed, the inadmissible criterion
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(4.6) is not effective for screening out ineffective doses, because a high percentage of YE may not
be observed at the time of making interim decisions. Since YI is quickly observable, it can be used,
supplementary to YE , to improve the power of identifying effective doses or safeguard patients from
ineffective doses. Specifically, define µI,j = E(YI |d = j), and let µI denote the lowest acceptable
mean immune response. We define dose j inadmissible if it meets at least one of the toxicity and
futility criteria in (4.5) and (4.6), and

(4.11)

(Insufficient activity)

Pr(µI,j < µI | D) > CI ,

where CI is a prespecified probability threshold. In other words, if a dose has little activity to
activate immune system, it is deemed unpromising and inadmissible. Again, the admissible dose is
defined as the dose that is not inadmissible. The posterior probability Pr(µI,j < µI | D) can be
evaluated based on the Bayesian normal model:
YI | d = j ∼ N (µI,j , σj2 )
f (µI,j , σj2 ) ∝ σj−2 .
4.2.6

Software and trial implementation
To facilitate the use of the U-BOIN design, we develop an easy-to-use web-based applica-

tion, which is freely available at http://www.trialdesign.org. Figure 4.2 shows the graphical
user interface of the app. Extensive help files are available by clicking on the yellow question mark
at the upper right corner of each tab.
To design a trial, follow the steps:
• Specify the design parameters (e.g., dose information, sample size, cohort size, utility function,
admissible criteria, etc.), under the Trial Setting tab. After parameters are entered, design
diagram and decisions tables will be provided under the tab.
• Generate the operating characteristics of the design by supplying different scenarios (under
the Simulation tab).
• Download trial protocol under Trial Protocol tab. The protocol includes (1) a brief description of the U-BOIN design, (2) decision tables based on input under Trial Setting, and (3)
operating characteristics for the scenarios entered under Simulation.
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Figure 4.2: The user interface of the U-BOIN software
To conduct a trial, use the decision tables generated under Trial Setting or use the Trial
Conduct tab. The app will return the dose for treating the next cohort of patients if the data
provided indicates that the trial is not completed, and it will select the OBD if the trial is completed.
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4.3
4.3.1

Numerical study
Simulation A
Simulation A considers the case that YT and YE are quickly ascertainable. Following

our motivating trial, we consider J = 5 doses, and the total sample size N = 54 patients with
s1 = 12. The minimum acceptable efficacy probability is π E = 0.2, and the maximum acceptable
DLT probability is π̄T = 0.30. We set πT∗ = 0.25 by using δ = 0.05. For the inadmissible criteria
(i.e., equations (4.5) and (4.6)), probability cutoffs are set as CT = 0.95 and CE = 0.9, based on
simulation calibration. The elicited utility is presented in Table 4.1 as example 1.
We consider 8 representative scenarios that differ in the shape of the dose-toxicity and doseefficacy curves, and the location of the OBD. The scenarios are shown in Figure 4.3. In scenarios
1 and 2, the dose-response curve increases with the dose level, and then plateaus. In scenarios 3
and 4, the dose-response curve increases to an optimal point, and then decreases. In scenario 5,
the dose-response curve levels off at the first dose level. In scenarios 6, 7, and 8, all dose-response
curves monotonically increase. Scenario 6 has the last dose level being the OBD. Scenario 7 has
two OBDs, located at dose level 2 and 3. Scenario 8 has no OBD since the doses are either futile
or overly toxic. Under each scenario, we generate (YT , YE ), based on a Gumbel model:
Pr(YT = yT , YE = yE | d = j) =(πE,j )yE (1 − πE,j )1−yE (πT ,j )yT (1 − πT ,j )1−yT
 c

e −1
+ πE,j (1 − πE,j )πT ,j (1 − πT ,j )(−1)yE +yT
,
ec + 1
where yE , yT ∈ {0, 1}, and the association parameter c was set as 0.2. The values of πE,j and πT ,j
(i.e., the marginal efficacy probability and DLT probability) for each dose level are provided in
Table 4.3. We compare the proposed U-BOIN design with the EffTox design[96]. We consider the
two most important metrics for comparison: (1) percentage of correct selection (PCS), which is
the probability of correctly identifying the OBD, and (2) patient allocation, which referred to the
average number of patients assigned to each dose. In the EffTox design, the toxicity-efficacy tradeoff is constructed based on three equally desirable trade-off target probabilities: (πE = 0.2, πT =
0), (πE = 1, πT = 0.7), and (πE = 0.45, πT = 0.3). Under each scenario, we performed 2,000
simulations.
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Figure 4.3: Simulation scenarios. The dash-dotted line (blue) is the dose-toxicity curve, the solid
line (red) is the dose-efficacy curve, and the dashed line (black) is the dose-immune response curve.
The OBD is highlighted by red asterisk in the x-axis. Simulation A considers only the efficacy and
toxicity curves, while simulation B considers efficacy, toxicity, and immune response.
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Table 4.3: Results of Simulation A, including the selection percentage (Selection %), the average
number of patients treated at each dose (No. of patients), and the percentage of early stopping.
The optimal biological dose (OBD) is bolded. In scenario 8, the OBD does not exist, and thus the
percentage of early stopping is bolded.
Dose Level
Design

1

2

3

% of early
4

5

stopping

Scenario 1

EffTox
U-BOIN

DLT probability
Efficacy probability
Utility

0.02
0.20
43.0

0.15
0.65
69.0

0.30
0.65
63.0

0.45
0.65
56.0

0.60
0.65
50.0

Selection %
No. of patients
Selection %
No. of patients

2.0
4.3
1.7
6.2

50.0
22.7
72.9
29.9

45.0
23.8
22.4
13.8

2.0
2.8
2.8
3.5

0.0
0.4
0.0
0.5

0.0
0.2

Scenario 2

EffTox
U-BOIN

EffTox
U-BOIN

DLT probability
Efficacy probability
Utility

0.03
0.10
36.0

0.08
0.22
43.0

0.15
0.60
66.0

0.28
0.60
60.0

0.40
0.60
55.0

Selection %
No. of patients
Selection %
No. of patients

0.0
3.4
1.1
4.9

4.0
4.9
3.2
7.5

60.0
26.4
65.7
24.4

29.0
14.2
24.9
12.7

7.0
5.1
4.3
4.3

DLT probability
Efficacy probability
Utility

0.05
0.08
34.0

0.15
0.46
56.0

Scenario 3
0.30
0.45
0.25
0.20
37.0
29.0

0.60
0.10
18.0

Selection %
No. of patients
Selection %
No. of patients

12.0
10.8
1.2
6.6

70.0
25.5
92.2
34.7

10.0
11.5
4.0
8.9

1.0
2.9
0.4
2.6

0.0
1.0
0.0
0.4

0.0
0.8

7.0
2.1

Scenario 4

EffTox
U-BOIN

DLT probability
Efficacy probability
Utility

0.15
0.15
36.0

0.25
0.45
52.0

0.40
0.30
36.0

0.45
0.25
32.0

0.50
0.20
27.0

Selection %
No. of patients
Selection %
No. of patients

36.0
19.4
11.9
15.0

47.0
19.0
74.1
29.5

5.0
7.5
3.7
5.1

2.0
2.6
0.4
1.1

2.0
2.3
0.0
0.2

Scenario 5
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9.0
9.9

Table 4.3 Continued:
Dose Level
Design

EffTox
U-BOIN

% of early

1

2

3

4

5

DLT probability
Efficacy probability
Utility

0.10
0.45
58.0

0.30
0.45
50.0

0.50
0.45
42.0

0.55
0.45
40.0

0.65
0.45
36.0

Selection %
No. of patients
Selection %
No. of patients

69.0
29.7
75.4
33.1

27.0
17.3
22.8
16.5

2.0
4.9
1.5
3.7

0.0
1.0
0.2
0.5

0.0
0.3
0.0
0.1

stopping

2.0
0.2

Scenario 6

EffTox
U-BOIN

DLT probability
Efficacy probability
Utility

0.05
0.35
53.0

0.07
0.45
59.0

0.10
0.50
61.0

0.12
0.55
64.0

0.16
0.75
75.0

Selection %
No. of patients
Selection %
No. of patients

10.0
8.6
5.9
7.0

12.0
7.9
11.7
8.8

26.0
14.2
13.1
9.0

24.0
11.1
13.6
9.1

29.0
12.1
55.7
20.1

0.0
0.0

Scenario 7

EffTox
U-BOIN

DLT probability
Efficacy probability
Utility

0.03
0.15
40.0

0.16
0.38
51.0

0.27
0.45
51.0

0.45
0.60
53.0

0.55
0.70
55.0

Selection %
No. of patients
Selection %
No. of patients

1.0
4.2
2.0
5.1

33.0
13.8
45.0
20.4

54.0
25.9
41.0
20.0

9.0
7.0
10.0
6.7

1.0
2.3
1.0
1.2

2.0
1.0

Scenario 8

EffTox
U-BOIN

DLT probability
Efficacy probability
Utility

0.22
0.03
25.0

0.45
0.10
23.0

0.55
0.20
25.0

0.65
0.35
30.0

0.70
0.40
31.0

Selection %
No. of patients
Selection %
No. of patients

1.0
4.6
0.8
14.3

6.0
6.2
5.5
9.7

6.0
6.3
1.7
1.6

0.0
2.3
0.0
0.1

0.0
1.2
0.0
0.0

87.0
92.0

Table 4.3 summarizes the operating characteristics for the designs. The U-BOIN design
outperforms EffTox as it has a larger PCS and allocates more patients on the OBD. In scenarios 1
and 2, the dose-response curve increases first, and then plateaus, and the OBDs (dose level 2 and 3,
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respectively) are one dose level lower than the MTD (i.e., dose level with DLT probability closest to
the target DLT probability). The U-BOIN has a 23% higher PCS and assigns seven more patients
on the OBD than EffTox does in scenario 1. Similarly, the U-BOIN has a larger PCS in scenario
2, for which the two designs have comparable patient allocation. In scenarios 3 and 4 where the
dose-response curve increases to an optimal point and then decreases, U-BOIN has 22% and 27%
higher PCS than EffTox, respectively. Moreover, U-BOIN assigns nine and ten more patients on
the OBD, respectively in the two scenarios. In scenario 5 where the OBD is located on the first
dose, and the response rate does not change with dose levels, U-BOIN has a 6% higher PCS and
assigns three more patients on the OBD. In scenario 6, where all doses are safe and the OBD is the
last dose level, the U-BOIN has a 27% higher PCS and assigns eight more patients on the OBD.
This is because EffTox cannot distinguish well the suboptimal doses from the OBD in this scenario,
subsequently assigning more patients on dose level 3 and 4 and selecting one of the dose levels as
the OBD 55% of the time. U-BOIN has comparable performance to EffTox when there are two
OBDs (scenario 7), in terms of PCS and patient allocation. When there is no OBD due to toxicity
or futility (scenario 8), U-BOIN has a larger chance to stop the trial early.

4.3.2

Simulation B
Simulation B considers the case that YT is quickly ascertainable, but YE takes a long time

to be scored with the assessment window of 3 months. We assume that patient accrual follows a
Poisson process, with the rate of 3 patients per month. We simulated YT and YE based on the
same Gumbel model and 8 scenarios, as described in Simulation A. The reason we chose the same
simulation scenarios is that, by doing so, the results from Simulation A (i.e., YE is always observed)
can be used as a benchmark to evaluate the performance of the design in Simulation B (i.e., YE
is partially observed, due to delayed response). To generate a delayed response, for patients who
experience efficacy in the assessment window (i.e., YE = 1), we simulate their time to efficacy from
a truncated Weibull distribution with a support of (0, 3) months. The shape and scale parameter
for the Weibull distribution are chosen such that the efficacy probability at the end of assessment
time matches those in Table 4.3, and that 90% of the responses occur in the latter half of the
assessment window (i.e., (1.5, 3) months). The immune response YI is generated from N (µI,j , 1),
where µI,j is plotted in Figure 4.3. We set CI = 0.9. Under each scenario, 2,000 simulations are
performed.
Table 4.4 shows the simulation results. The PCS of the OBD and the number of patients
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allocated to the OBD are generally comparable to the results in Simulation A (i.e., the optimal
benchmark with fully observed data) and U-BOIN still outperforms the EffTox design. The results
indicate that U-BOIN efficiently handles the delayed efficacy response. Because the U-BOIN design
does not need to suspend accrual to wait YE to be fully observed and allows real-time decision
making, it has great potential to shorten the trial duration.
Table 4.4: Results of Simulation B, including the selection percentage (selection %), the average
number of patients treated at each dose (No. of patients), the percentage of early stopping, and
the trial duration. The optimal biological dose (OBD) is bolded. In scenario 8, the OBD does not
exist, and thus the percentage of early stopping is boldeded.
Dose Level
Design

1

2

3

% of early

Duration

4

5

stopping

(month)

2.0
2.8
2.9
3.6

0.0
0.4
0.3
0.5

0.0

45.9

2.8

20.8

29.0
14.2
22.4
12.1

7.0
5.1
4.9
4.1

0.0

43.8

8.3

20.0

1.0
2.9
0.8
2.9

0.0
1.0
0.0
0.4

7.0

45.6

2.8
2.8

20.7

2.0
2.6
0.4
1.0

2.0
2.3
0.0
0.2

9.0

47.8

19.1
19.1

18.8

0.0
1.0
0.2
0.5

0.0
0.3
0.0
0.0

2.0

50.0

2.0
2.0

20.7

Scenario 1
EffTox
U-BOIN

Selection %
No. of patients
Selection %
No. of patients

2.0
4.3
0.9
6.4

50.0
22.7
68.9
29.2

45.0
23.8
24.1
13.7

Scenario 2
EffTox
U-BOIN

Selection %
No. of patients
Selection %
No. of patients

0.0
3.4
0.0
4.3

4.0
4.9
0.2
6.1

60.0
26.4
64.1
24.5
Scenario 3

EffTox
U-BOIN

Selection %
No. of patients
Selection %
No. of patients

12.0
10.8
0.8
6.7

70.0
25.5
89.6
33.6

10.0
11.5
6.0
9.5

Scenario 4
EffTox
U-BOIN

Selection %
No. of patients
Selection %
No. of patients

36.0
19.4
6.8
13.6

47.0
19.0
70.4
27.9

5.0
7.5
3.4
4.7

Scenario 5
EffTox
U-BOIN

Selection %
No. of patients
Selection %
No. of patients

69.0
29.7
72.9
32.9

27.0
17.3
22.7
16.4

2.0
4.9
2.2
3.7
Scenario 6
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Table 4.4 Continued:
Dose Level
Design

EffTox
U-BOIN

Selection %
No. of patients
Selection %
No. of patients

% of early

Duration

1

2

3

4

5

stopping

(month)

10.0
8.6
4.2
6.5

12.0
7.9
10.3
8.6

26.0
14.2
12.2
9.5

24.0
11.1
13.6
9.9

29.0
12.1
59.2
19.4

0.0

43.4

0.4
0.4

21.0

43.0
9.0
10.5
5.2

40.0
1.0
1.7
0.8

0.0
2.4
0.0
0.1

0.0
1.3
0.0
0.0

Scenario 7
EffTox
U-BOIN

Selection %
No. of patients
Selection %
No. of patients

33.0
1.0
5.0
8.5

45.0
33.0
45.6
22.7

45.0
54.0
33.1
15.6

46.5
2.0
4.1
4.1

20.7

87.00

16.6

99.10

8.8

Scenario 8
EffTox
U-BOIN

Selection %
No. of patients
Selection %
No. of patients

1.0
4.7
0.0
11.1

6.0
6.1
0.4
4.7

6.0
6.3
0.4
1.3

To examine the performance of U-BOIN when there are delayed outcomes at a relatively smaller sample size, we conduct the simulation again using N = 39. Results show that
U-BOIN still maintains its great operating characteristics, even when sample size is relatively
small. The simulation results are provided in Table S8 of the Supplementary Material (at https:
//onlinelibrary.wiley.com). We also provide operating characteristics for eight additional representative scenarios (Scenarios A1-A8) for both Simulation A (Table S9) and Simulation B (Table
S10). The results, again, show that U-BOIN has robust performance in various scenarios in comparison to EffTox.

4.3.3

Sensitivity analysis
We conduct sensitivity analyses to assess the robustness of the U-BOIN design by using a

different set of utility values ψ 0 = {ψ1 = 0, ψ2 = 20, ψ3 = 55, ψ4 = 100}, which assigns a lower score
for (YE = 0, YT = 1) and a higher score for (YE = 1, YT = 1), indicating that patients are willing to
tolerate a higher toxicity risk in order to attain a higher efficacy. We also evaluate the performance
of U-BOIN using different patient allocation strategies (i.e., step B2 of Stage II of the dose finding
algorithm): PW, AR, and ER.
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The simulation results (see Figure 4.4) show that the U-BOIN design performs well with
comparable PCS and patient allocations for the two different utilities. This characteristic is important, since two clinicians might have slightly different opinions about the specific utility value
assigned to an outcome combination. Our design shows robustness for this type of deviation.
Figure 4.5 shows the results under different patient allocation strategies. The PCS is
comparable among the PW, AR, and ER strategies. The difference among the three strategies
mainly lies in the number of patients treated on OBD. The PW approach, on average, assigns
significantly more patients on the OBD than both the ER and AR approaches, while it has larger
variability. Since the variation is more towards the higher end (i.e., more patients are treated on
OBD), the PW approach is desirable in this simulation study.
Note that in this Simulation A, we specify s2 = N for fair comparison with the EffTox
design, which does not stop the trial early on the basis of the number of patients treated on a dose.
A sensitivity analysis using s2 = {18, 21} is provided in Section 5 of the Supplementary Material (at
https://onlinelibrary.wiley.com). The result in Figure S1 shows that using the recommended
values, the change in the percentage of correct selection is negligible, but the saving in sample size
is substantial.
For the case with delayed YE , we performed three additional sensitivity analyses by (1) assuming that the efficacy assessment window is two months or four months; (2) specifying more vague
prior distributions for the coefficients β0 and β1 with β0 ∼ N (0, 3.752 ) and β1 ∼ Gamma(shape =
1, rate = 0.4), both of which have standard deviations that are three times the previous values
in section 4.2.5; and (3) considering two additional scenarios (scenarios B1 and B2 in Table S11),
where YI and YE are weakly associated with Pearson’s correlation coefficients -0.15 and 0.2, respectively. The results show that the U-BOIN design is also robust to the length of assessment window,
prior distribution of the prediction model (Figure S2), and the association between YI and YE .

4.4

Summary
We proposed the U-BOIN, a seamless Phase I/II model-assisted design, to identify the

OBD for targeted and immunotherapy trials. The U-BOIN design accounts for the efficacy-toxicity
trade-off using a utility function. Unlike most existing Phase I/II designs that require complicated
real-time model fitting and estimation to make dose assignment decisions, the U-BOIN is simple
and easy to implement. The dose assignment rules of the U-BOIN can be pre-tabulated in decision
tables and included in the trial protocol before the onset of a trial. To conduct the trial, no
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Figure 4.4: Results of sensitivity analysis for different utilities. Scenario 8 is not included, as the
OBD does not exist in that scenario.
complicated calculation is needed. The investigator can simply use the decision tables to determine
dose assignment. Simulation studies show that compared to a more complicated model-based Phase
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Figure 4.5: Results of sensitivity analysis for different patient allocation strategies: pick-the-winner
(PW), adaptive randomization (AR), and equal randomization (ER). Scenario 8 is not included, as
the OBD does not exist in that scenario.
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I/II design, the U-BOIN has higher accuracy to identify OBD and is more robust. To facilitate the
use of the U-BOIN design in clinical trials, we develop a user-friendly software freely available at
www.trialdesign.org. Readers can find the U-BOIN design in the “BOIN suite” under Phase I
applications.
While this project focuses on immunotherapy and targeted trials, U-BOIN also can be used
for conventional cytotoxic agent trials. In such cases, both toxicity and efficacy typically increase
with the dose, but may do so at different rates. It is likely that increasing the dose causes much
higher toxicity, with limited efficacy gain. The idea of risk-benefit trade-off, and thus finding the
optimal dose, is still generally applicable here for use in most medical decisions in practice.
Like most model-assisted designs, U-BOIN models efficacy and toxicity at each dose independently, whereas model-based Phase I/II designs (e.g., EffTox design) model efficacy and toxicity
across all doses, through imposing a parametric dose-efficacy and -toxicity curve model. As a result,
one may worry about the potential efficiency loss for U-BOIN. Our numerical study and previous
studies show that, for the purpose of dose finding, the efficiency loss caused by using only local
data (in model-assisted designs, such as U-BOIN) is minimal or negligible. This can be explained
as follows. First, although U-BOIN models only the local data at the current dose, its dose-finding
algorithm (e.g., escalate the dose if the current dose is safe, and de-escalate the dose if the current
dose is toxic) implicitly uses the dose-toxicity order information across the doses. In addition, in
practice, the parametric dose-efficacy and -toxicity model assumed by model-based designs is more
likely to be miss-specified than correctly specified. Thus, on average, borrowing information across
doses through the parametric model leads to rather limited efficiency gain. Furthermore, such limited efficiency gain does not necessarily translate into performance gain. This is because, to make
correct decisions of dose assignment and selection, we only need to correctly estimate the rank of
utility across the doses. A slightly more variability on the estimate of the utility has no or negligible
impact on the performance of the design.
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A

Appendix

Theorem 1. Marginal-probability-based trade-off UjM , defined in (4.3), is a special case
of the utility method defined in (4.1), in the sense that for a prespecified weight w, we can find
(ψ2 , ψ3 ), such that Uj = ξUjM , where ξ is a non-zero constant.
Proof

If there is a constant ξ, such that UjM = ξ Ũj , then, Ũj is a special case of UjM .
To fix scale for utility, we propose that ψ1 = 0,ψ4 = 100. Then UjM is a function of only

ψ2 and ψ3 .
UjM = ψ2 πj2 + ψ3 πj3 + 100πj4
It is obvious that UjM > 0 by definition. Denote Ũj (w) = Ũj = πE,j − wπT ,j . If UjM = ξ Ũj ,
then ξ 6= 0, Ũj (w) 6= 0, and ψ2 πj2 + ψ3 πj3 + 100πj4 = ξ Ũj (w). Since 0 < ψ2 πj2 + ψ3 πj3 <
100(πj2 + πj3 ), we have

100πj4
Ũj (w)

<ξ<

100(1−πj1 )
,
Ũj (w)

which is nonzero constant.

In summary, for a prespecified w and Ũj (w) 6= 0, we can find (ψ2 , ψ3 ) and a non-zero
constant ξ, such that UjM = ξ Ũj , which says that Ũj is a special case of Uj .
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CHAPTER 5

Versatile software platforms for the implementation of novel
model-assisted designs in early phase clinical trials

5.1

Introduction
The main purpose of Phase I studies is to evaluate the safety of a new drug and identify

a maximum tolerated dose (MTD), defined as the highest dose with acceptable level of toxicity.
Typically, the primary endpoint in Phase I trial is binary, i.e., whether or not a patient experiences
dose-limiting toxicity (DLT) while receiving a dose in the trial. The corresponding parameter of
interest is the proportion of patients who experience DLTs (i.e., DLT probability). The designs used
to identify the MTD can be classified into three types according to their statistically foundations
and implementation approaches: algorithm-based (also known as rule-based), model-based, and
model-assisted [115]. Algorithm-based designs guide dose assignment through a set of prespecified
rules without assuming any parametric assumption on the dose-toxicity curve. Thus, they are
simple to implement. But the downside is that they are rigid and have poor accuracy [117]. A
classical example is the 3+3 design [19]. Model-based designs often assume a dose-toxicity model
and guide the dose escalation and de-escalation by continuously updating the estimate of dosetoxicity model based on the accumulated data. Typical examples of the model-based designs are
the continual reassessment method (CRM [77]) and its variations, such as escalation with overdose
control (EWOC[2]), Bayesian logistic regression model (BLRM [74]), and Bayesian model averaging
CRM (BMA-CRM [111]). Model-based designs yield better performance than the 3+3 design in
identifying the MTD and allocating more patients to the MTD [124, 125]. However, model-based
designs are not straightforward for clinicians to comprehend, which has limited their use in practice.
Model-assisted designs are a class of recent designs that enjoy both the simplicity of
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algorithm-based designs and the satisfactory performance of model-based designs. Similar to modelbased designs, model-assisted designs use a statistical model (e.g., the binomial model for the number of DLTs) to assist the derivation of the design for efficient decision making; and like algorithmbased designs, model-assisted designs can pre-tabulate the dose escalation and de-escalation rules
before the onset of a trial, making it as simple as the 3+3 to implement. Classic examples of modelassisted designs in Phase I clinical trials include the Bayesian optimal interval (BOIN) design [65],
keyboard design [105], and modified DLT probability interval design (mTPI [42]) and its extension
mTPI-2 [31].
Zhou et al. [124, 125] compared the BOIN design to other model-assisted and model-based
designs. They found that BOIN and keyboard designs both perform better than 3+3 in terms of
accuracy, safety, and reliability, and are safer than CRM and mTPI. We also compared BOIN to
i3+3, and further shows its superiority over algorithm-based designs in Chapter 2.1. The BOIN and
keyboard designs have been extended to accommodate commonly encountered challenges in Phase
I clinical trials, such as fast accrual, delayed toxicity, and evaluation of drug combinations. There
is a well-validated BOIN R package to implement the BOIN designs. But using R package requires
a certain level of statistical programming. Thus, it remains a challenge for practitioners to evaluate
the operating characteristics of the designs in a timely manner without programming skills. There is
no R package for the keyboard design and its extensions, making it even harder for non-statisticians
to evaluate the accuracy and reliability of the designs. Despite the well-documented flaws of 3+3,
it is still the dominant method used in Phase I clinical trials. The lack of reliable, robust, and easyto-use software has limited the use of the more superior novel designs such as BOIN and Keyboard.
Lee and Chu [39] suggested that “the availability of accompanying software for the implementation
of Bayesian methods is crucial for the use of these methods in clinical trials”.
The R package Shiny has become a popular tool for software development. It enables R
users to develop interactive web applications directly in R [10], and has revolutionized the way
statisticians share their analytic results and research methods. Applications developed using Shiny,
referred to as shiny apps hereafter, typically have interactive point-and-click interface that are
self-explanatory and accessible to a broader audience. It can empower people without statistical
programming skills to explore the performance of a novel design easily without knowing statistical
programming. For this reason, shiny apps have gain a lot of popularity in both industry and
academia. Many industry companies, such as Novartis and Eli Lilly and Company, have a team
specializing in analyzing, visualizing, and reporting clinical trial data using Shiny apps. In academia,
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shiny apps have been used to facilitate the understanding and use of novel methods. Examples
include the web applications for model-based dose escalation/de-escalation design [79, 102] and for
planning and simulating adaptive platform trials [100], among others. To facilitate the use of modelassisted designs for designing and conducting Phase I clinical trials and make it more accessible for
clinicians who may not have expertise in statistical programming, we develop a software platform
for BOIN designs (BOIN suite) and keyboard designs (Keyboard suite), respectively.
One distinct feature of our software is that each of the two suites includes multiple shiny
apps for model-assisted designs, each tackling a different challenge in Phase I clinical trials. BOIN
suite include apps for single-agent trials using non-informative prior (standard BOIN [65]), incorporating historical data (iBOIN [127]), and having fast accrual or delayed toxicity (TITE-BOIN
[116]); for drug-combination (BOIN COMB) to find single MTD [56] or MTD contour [121]; and
for utility-based single-agent Bayesian optimal interval design (U-BOIN [126]) to identify optimal
biological dose (OBD). Keyboard suite includes apps for single-agent trials without delayed toxicity
(KEYBOARD) [105]) or with deplayed toxicity (TITE-KEYBOARD [57]); and for combination
trials to find single MTD (KEYBOARD COMB [80]). Another unique feature of the two software
suite is that the designs considered are all model-assisted and thus provide simple-to-use decision
rules like those in 3+3, which is easy for practitioners familiar with 3+3 to adopt these new adaptive
designs.
Functionality-wise, all the shiny apps have a simple and user-friendly interface to carry
out the following tasks: (1) generate decision tables and design flowchart; (2) simulate operating
characteristics such as probability of selecting the MTD (or OBD), percentage (or number) of
patients allocated to each dose, and early stopping probability; (3) prepare trial protocol; (4)
compute the recommended dose level for the next cohort of patients, based on data obtained; and
(5) estimate MTD (or OBD) when a study is completed.
The greatest contribution of this work is that, the software platform empowers clinicians
and even statisticians to easily evaluate the performance of the designs and aid them to choose
appropriate designs for their intended trials. Through simulation information on the interactive
shiny apps, clinicians can evaluate the accuracy and safety of the novel designs in a timely manner.
That is, they can change the trial specifications and get real time feedback on how the designs would
perform in various trial settings. The availability of these software will not only make the designs
easier to access and enable a more efficient collaboration between statisticians and clinicians, but
will also have a profound impact on early phase drug development, as the availability of these shiny
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apps will substantially increase the use of Bayesian adaptive designs in early phase clinical trials.

5.2

Method
The software platform we developed for Phase I clinical trial design consists of two versatile

suites: BOIN suite and Keyboard suite. We first describe the designs under each suite, respectively,
and then provide information on the statistical tools used to developed the two software suites.
5.2.1

BOIN suite
The BOIN suite includes shiny apps for single-agent trials using non-informative prior (the

standard BOIN) or informative prior (iBOIN); single-agent trials with fast accrual or delayed toxicity (TITE-BOIN); combination trials (BOIN COMB) to find a single MTD or the MTD contour;
and utility-based Bayesian optimal interval design (U-BOIN) to identify the OBD.
Standard BOIN design for single-agent trials
The BOIN design was constructed to minimize the chance of making incorrect dose assignment decisions in order to effectively treat patients, i.e., minimizing the probability of exposing
patients to overly toxic or sub-therapeutic doses. The implementation of the design can be done by
simply comparing the observed DLT probability to a pair of optimal escalation and de-escalation
boundaries (λe , λd ), which are derived given the specification of target DLT probability (derivation
can be found in Liu and Yuan [65]). Let p̂j = yj /nj denote the observed dose limiting toxicity
(DLT) probability at dose j = 1, · · · , J, where yj is the number of observed DTLs and nj is the
number of patients treated at dose j. A trial using BOIN can be conducted as simple as below.
Suppose the current dose is j, then the dose used for next cohort of patients is determined based
on the following rule.
• escalate to dose j, if p̂j ≤ λe and j 6= J;
• de-escalate to dose j − 1, if p̂j ≥ λd and j 6= 1
• stay at the current dose, otherwise.
The decision rule is similar to that in the cumulative cohort design (CCD [37]), which was developed
based on the asymptotic distribution of patient allocation of the group up-and-down design [28]
using the Markov chain theory [57]. In comparison, the advantage of BOIN is that it has better
finite sample performance, which is desirable in Phase I trials given the typically small sample size.

93

For the purpose of overdose control, doses j and higher levels will be eliminated from further
examination if Pr(pj > φ | data) > δ and at least three patients are treated on dose j, where pj
is the true DLT probability of dose level j, j = 1, · · · , J, φ is the target DLT probability, and δ is
a probability cutoff (typical values are 0.9 and 0.95). This posterior probability is evaluated based
on the beta-binomial model yj | pj ∼ binomial(nj , pj ) with pj ∼ uniform(0, 1). When the lowest
dose is eliminated, stop the trial for safety.
The BOIN app tabulates decision rules using the aforementioned algorithm and makes the
implementation of the design as simple as the traditional 3+3. Suppose the target DLT probability
is 0.3, with the default setting of the BOIN design, the shiny app will produce the decision table
as shown Table 5.1. Thus, conducting a trial simply requires comparing the number of observed
DLTs at the current dose to the boundaries provided in the table.
Table 5.1: Dose escalation/de-escalation and elimination boundaries in BOIN design with target
DLT probability of 0.3
Number of patients treated at current dose
1
2
3
4
5
6
7
8
9
10
11
12
Escalate if # of DLT ≤
0
0
0
0
1
1
1
1
2
2
2
2
Deescalate if # of DLT ≥
1
1
2
2
2
3
3
3
4
4
4
5
Eliminate if # of DLT ≥
NA
NA
3
3
4
4
5
5
5
6
6
7
Note. The NA’s in the third row means that the elimination rule will not be triggered when
the number of patients treated on current dose is less than three.
In addition to the decision boundaries, the shiny app also provides design flowchart and
simulation results for use in protocol preparation, upon users’ input of trial parameters. To minimize
the workload of trial planning for statisticians and clinicians, the app is also equipped to output
well-organized template that includes a brief description of the design, followed by the design
flowchart, decision tables, and simulation results. To enable a fast comparison between BOIN and
3+3 designs, the app also provides the option for users to select whether the 3+3 design is simulated
while running simulation for the BOIN design (a concrete example for using this app is provided
in section 5.3.2).
BOIN for single-agent trials using informative prior (iBOIN)
Model-assisted designs (e.g., BOIN) were developed assuming non-informative prior distribution on the parameter of interest. Little research has been done regarding to how informative
prior information that is obtained from historical trials or real-world evidence can be incorporated
into the model-assisted designs without compromising their simplicity for trial implementation.
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This has led to the misconception that model-assisted designs cannot incorporate informative prior
information, which is sometimes cited as their weakness, compared to model-based designs. We
recently proposed a unified framework to incorporate informative prior information into modelassisted designs, including BOIN and keyboard/mTPI-2 designs (details provided in Chapter 3).
Numerical studies show that incorporating appropriate prior information can improve the performance of the model-assisted designs in a similar way as in the CRM. We found that BOIN with
informative (referred to as iBOIN) has the most desirable accuracy and reliability. Specifically,
iBOIN utilizes the skeleton approach same as in the CRM, combined with the concept of prior
effective sample size [69]. The dose assignment is based on similar algorithm described for the
standard BOIN, except that by incorporating informative prior, the escalation and de-escalation
boundaries (λe , λd ) in iBOIN vary with the dose levels and the number of patients treated at the
doses. However, the iBOIN app can provide decision table similar to that in Table 5.1 for trial implement, maintaining the simplicity feature of the BOIN design. Numerical studies have shown that
when prior information of good quality is available, the iBOIN can greatly increase the accuracy to
identify MTD and allocates more patients at the MTD.
The iBOIN app requires similar input as the standard BOIN, except that it also requires
the specifications of prior DLT probability and prior effective sample size for all doses in the trial.
Additionally, it has the flexibility for users to determine if the prior DLT probabilities are used to
select the MTD at the end of the trial. The app also has the options for simulation and protocol
preparation.

BOIN for single-agent trial with delayed toxicity (TITE-BOIN)
The typically long duration of drug development has posed great challenges in meeting
the ever increasing need of effective therapies. To speed up drug development, increasing the pace
of patient accrual and using novel adaptive designs have become the two most common strategies
[56, 115, 116]. BOIN design is one of the novel adaptive designs and has been validated and used in
many recent trials [115], but it is not a panacea. BOIN requires the toxicity outcomes to be quickly
ascertainable in order to have complete observed data for decision making at an interim time. With
the development of novel molecularly targeted agents and immunotherapy, late-onset (delayed)
toxicity has become a common problem encountered in Phase I trials. A trial with delayed toxicity
outcome causes major logistic difficulty when using existing adaptive Phase I trial designs that
require quick observance of toxicity to determine the dose assignment for next cohort of patients.
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The same logistic difficulty arises when the accrual is faster than the toxicity evaluation window.
To address these challenges, Yuan et al. [116] proposed the time-to-event Bayesian optimal interval
(TITE-BOIN) design that allows real-time dose assignment decisions for new patients despite the
existence of pending toxicity data. The essential idea of TITE-BOIN is to impute the DLT outcome
for patients whose DLT data are pending, by using data from all patients and their follow-up times
in a time-to-event model. The TITE-BOIN has comparable accuracy to identify the MTD, when
compared to the more complex model-based time-to-event continuous reassessment method (TITECRM [14]), but it is simpler to implement with substantially better overdose control.
TITE-BOIN can also pre-tabulates dose-escalation/de-escalation rules before the onset of
a trial. To conduct a trial, it requires only the number of patients treated on each dose, the
corresponding number of patients who experience DLT, the number of patients whose DLT data is
pending, and the standard total follow-up times (STFT), which is determined using the sum of the
follow-up times for all pending patients at the current dose divided by the DLT assessment window.
The TITE-BOIN app provides three different time-to-event models for predicting pending toxicities.
Users can choose any of them to determine the decision table for trial conduct. It also has a built-in
calculation to calculate the STFT value to assist in the use of the decision table. Users can also use
the app to assess the accuracy and safety of the design through its built in simulation functions.
Protocol templates can be downloaded for trial planning as well. Thus, compared to TITE-CRM
[14] that requires repeat model fitting during the trial, the TITE-BOIN is more transparent and
also more straightforward to use with the availability of the shiny app. The rolling six (R6) design
[90], an algorithm-based design, has often used to address the logistic difficulties caused by either
fast accrual or delayed toxicity. The TITE-BOIN app also provides an option for users to determine
if they want to include R6 design in the simulation.

BOIN for drug-combination trials (BOIN COMB)
The traditional paradigm that one drug for one disease may fail in circumstances where
more than one pathways drive the malignant process of the tumor under investigation [78]. Designing combination trials could be the most desirable way to pursue greater clinical benefits for
patients in this case. It is more difficult to design drug-combination than single-agent trials due
to two main challenges: (1) the drug combinations are only partially ordered in terms of their
toxicity probabilities, and (2) there could exist a MTD contour (i.e., more than one MTD). While
there are numerous model-based Bayesian Phase I trials for combination trials, their use is limited
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due to the complexity of their statistical foundation and computation as well as their sensitivity
to prior specifications. To address the first challenge, Lin and Yin [56] extended the BOIN design
that addresses one-dimensional dose space to explore the two-dimensional dose space for MTD
identification. Zhang and Yuan [121] developed the waterfall design, which is also built upon the
BOIN design, to simultaneously address both of the two challenges aforementioned. The two designs also belong to the model-assisted class and provide simple and robust alternatives for Phase
I combination trials. An overview of the two designs are provided below.

(1) BOIN for finding a single MTD in drug-combination trials
Suppose there are two drugs (A and B) under investigation. Drug A has J dose levels
while B has K dose levels. Let pjk denote the true DLT probability of the combination doses (j, k),
where j, j = 1, · · · , J and k, k = 1, · · · , K. And denote the corresponding observed DLT probability
p̂jk = yjk /njk , where njk is the number of patients treated on the dose combination (j, k) and yjk
is the number of patients who experience DLT. The design proposed by Lin and Yin [56] makes the
decision of dose escalation/de-escalation based on a similar rule as the single-agent BOIN design
described above. To implement the trial, it just needs to compare the observed DLT probability to
a pair of escalation and de-escalation boundaries: (λe , λd ), which are optimized by minimizing the
probability of incorrect dose assignment (see Lin and Yin [56] for more details).
The difference between single-agent BOIN and the design proposed by Lin and Yin [56]
for combination trials is that there is more than one neighboring doses to move to when escalation
(when p̂jk ≤ λe ) or de-escaltion (when p̂jk ≥ λd ) decision is made. Suppose the current dose
combination is (j, k), to determine the assignment of the dose for next cohort of patients, the
design first defines an admissible escalation set AE = {(j + 1, k), (j, k + 1)} and de-escalation set
AD = {(j − 1, k), (j, k − 1)}, and then decide which dose to use for next cohort of patients based on
the value of pAT , which is the posterior probability that the DLT probability of a dose combination
(j 0 , k 0 ) falls within the acceptable toxicity interval (λe , λd ), where (j 0 , k 0 ) belongs to the escalation
set AE or the de-escalation set AD . The dose assignment proceeds as follows given the observed
data.
• Escalate to the dose combination in AE that has the largest value of pAT , if p̂jk ≤ λe ;
• De-escalate to the dose combination in AD that has the largest value of pAT , if p̂jk ≥ λd ;
• Stay at current dose combination, otherwise.
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(2) BOIN for finding the MTD contour in drug-combination trial
Due to drug-drug interaction, it is of intrinsic interest to find multiple MTDs for many
drug-combination. The MTDs can be further evaluated in subsequent Phase II trials to identify the
one with the highest efficacy. To adequately explore the two-dimensional dose space requires a large
sample size, because the toxicity probabilities in the dose space is partially ordered. This poses
a great challenge in Phase I combination trials because Phase I trials typically have small sample
size. To overcome the problem, Zhang and Yuan [121] proposed the waterfall design. The basic
idea of the waterfall design is straightforward: divide the two-dimensional dose-finding problem into
a series of simpler one-dimensional dose-finding subtrials. In each of the subtrials, dose toxicity
probabilities are fully ordered and the standard BOIN is used to identify the MTD in each of the
subtrials. The innovation of the waterfall designs is that the subtrials are conducted in a certain
order such that the precedent subtrial will inform the conduct of the subsequent trial. The sequence
of the subtrials efficiently borrows information across subtrials and thus saves sample size.
Suppose that the two drugs A and B has 3 and 5 dose levels, respectively. Figure 5.1
provides an example to illustrate the waterfall design. As shown, the waterfall design divides the
3 × 5 dose space into three subtrials. As shown in panel (a), the trial starts by conducting the
first subtrial with the starting dose (1,1). After the first subtrial identifies (3,1) as the candidate
MTD, waterfall design proceeds to the second subtrial with the starting dose (2,2) as shown in
panel (b). After the second subtrial identifies (2,4) as the candidate MTD, the design conducts the
third subtrial with the starting dose (1,5) (see panel (c)). After all the subtrials are completed,
select the MTD contour based on the data from all the subtrials (panel (d)) using matrix isotonic
regression [7].
The BOIN COMB shiny app gives users the option to select if the trial aims at finding
a single MTD or a MTD contour. For either option, a decision table table (similar to Table 5.1)
for implementing the designs will be provided for trial conduct. If the purpose is to find the MTD
contour, the app also provides the design chart (as shown in Figure 5.1) given the number of dose
levels for drug A and drug B, and the starting dose combination of the two drugs. Like BOIN,
iBOIN, and TITE-BOIN, the BOIN COMB app also have functions to conduct simulation and
download trial protocol.
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（a）
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（b）
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（c）
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（d）
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Drug B
Figure 5.1: The waterfall design for finding the MTD contour in drug-combination trials (adapted
from Figure 1 in Zhang and Yuan [121]). For panels (a)-(c), the circles surrounded by a rectangle
is a subtrial. In panels (b)-(c), the filled circle is the MTD candidate selected from the previous
subtrial. The MTD candidate for the third subtrial in panel (c) is indicated in the third row of
panel (d).
Utility-based BOIN design (U-BOIN) to identify optimal biological dose
Traditional dose-finding designs for chemotherapy aim to find the maximum tolerated dose
(MTD). The underlying assumption is that both toxicity and efficacy monotonically increase with
the dose, and thus the MTD presents the most efficacious dose that is safe. This assumption,
however, is often questionable for immunotherapy and targeted agents. Although it is reasonable
to assume that toxicity increases with the dose, the same is not necessarily true for efficacy. To
optimize the treatment benefit of immunotherapy and targeted therapy, therefore, it is important
to consider toxicity and efficacy simultaneously and their risk-benefit trade-off during dose finding.
The objective of dose finding for targeted therapy and immunotherapy is to identify the optimal
biological dose (OBD), defined as the dose that has the highest desirability in terms of the riskbenefit trade-off.
Zhou et al. [126] developed the U-BOIN design, a utility-based seamless Phase I/II design
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to find the OBD. In stage I, the BOIN design [65] is used to quickly explore the dose space and collect preliminary toxicity and efficacy data. In stage II, in light of accumulating efficacy and toxicity
from both stages I and II, U-BOIN jointly models toxicity and efficacy using a multinomial-Dirichlet
model and employs a utility function to measure dose risk-benefit trade-off. Dose assignment is
guided using the contiguously updated posterior estimate of the utility for each dose after each
cohort. To accommodate the delayed efficacy observed in some targeted and immunotherapy trials,
the U-BOIN is capable of predicting the delayed efficacy using a short-term endpoint (e.g., immune
activity or other biological activity of targeted agents) to facilitate real-time decision making. Extensive simulation studies showed that U-BOIN is not only simple to use with its pre-tabulated
decision tables, but also has superior performance than model-based Phase I/II designs (such as
the EffTox design [96]).
With the U-BOIN app, users can simply input trial parameters to obtain readily available
decision boundaries to implement the trial for stage I and stage II. The app also provides a trial
conduct function to determine dose assignment if users prefer using the app over decision tables.
To use this function, users just need to upload a file with observed patient outcomes according to
a prespecified format, which is provided in the app. Then, the app will automatically determine
which dose to use for next cohort of patients. Like any other apps in the BOIN suite, the U-BOIN
app can be used to run simulations and prepare trial protocol.

5.2.2

Keyboard suite
The Keyboard suite includes shiny apps for single-agent trials without delayed toxicity

(KEYBOARD) or with delayed toxicity (TITE-KEYBOARD), and drug-combination trials (KEYBOARD COMB). The three model-assisted designs have comparable performance to their counterpart BOIN designs: standard BOIN, TITE-BOIN, and BOIN COMB. The difference is that the
decision rules derived in the keyboard designs are based on different statistical approach. Although
keyboard designs are considered not as transparent as BOIN designs [115], they still provide good
alternatives for conducting Phase I trials. Thus, it is worthwhile to provide user-friendly applications.

Keyboard for single-agent trials
Keyboard design was developed to overcome the limitation of the modified toxicity interval
(mTPI) design that is likely to overdose patients in a trial. The dose assignment in keyboard relies
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on a prespecified proper dosing interval (referred to as the target key) and the calculation of a
strongest key based on the posterior distribution of the DLT probability. The posterior distribution
is determined by a beta-binomial model with uniform(0,1) prior distribution.
yj | nj , pj ∼ Binom(nj , pj )
(5.1)

pj ∼ Beta(1, 1)
pj | Dj = (yj , nj ) ∼ Beta(yj + 1, nj − yj + 1)

The strongest key refers to a probability interval that has the same width as the target key and
that also has the largest posterior probability density based on accumulated data on current dose.
Specifically, suppose the target DLT probability is 0.25 and (0.2, 0.3) is considered as the proper
dosing interval (the target key). Then the probability intervals (0, 0.2) and (0.3, 1) on the two sides
of the target key are divided into intervals with length 0.1, equal to that of the target key. As
shown in Figure 5.2, this ends up with two and seven keys on the left and right sides of the target
key, respectively. Suppose the current dose is j, the dose assignment for next cohort of patients is
determined by comparing the location of the strongest key and the target key.
• Escalate to j + 1, if the strongest key is on the left side of target key;
• De-escalate to j − 1, if the strongest key is on the right side of the target key;
• Stay at the current dose, if the strongest key overlaps with the target key.

Figure 5.2: Illustration of dose escalation and de-escalation in keyboard design
With the shiny app, users do not need to calculate the posterior probability and the
strongest key. Instead, the app will do all the calculations behind the scene and output a de-
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cision table similar to that for BOIN (e.g., Table 5.1). This greatly simplifies the implementation
of the trial design. The app can also be used to evaluate the accuracy and safety of the keyboard
design through simulations and to prepare statistical protocols for trial planning.

Keyboard for single-agent trial with delayed toxicity (TITE-KEYBOARD)
The keyboard design requires the calculation of posterior distribution of toxicity rate at
each dose that has been used to treat patients. The derivation of the posterior distribution requires
fully observed toxicity outcomes for all patients enrolled in the trial as shown in (5.1). When
fast accrual or delayed toxicity occurs, the likelihood that used to derive the posterior becomes
a complicated product of the likelihood for patients who have finished the follow-up time (i.e,
the toxicity evaluation window) with their toxicity outcomes evaluated and that for those whose
toxicity outcome is still pending. This leads to a posterior distribution whose inference depends on
Markov Chain Monte Carlo simulation and makes the decision rules impossible to tabulate before
the onset of a trial. This feature loses the most important property of the model-assisted design:
simplicity. To circumvent the issue, Lin and Yuan [57] proposed the TITE-keyboard, which uses an
approximated likelihood for patients whose toxicity outcomes are pending, i.e., the toxicity outcomes
for these patients have not been observed at the decision time. With the approximation, the joint
likelihood for all the patients in the trial becomes the standard binomial likelihood. Specifically,
to determine the posterior distribution of DLT probability, in the beta-binomial model (5.1), nj is
replaced by ESSj = yj + m̃j , where ESSj is known as the effective sample size at dose j, and m̃j
is the effective number of patients who have not experienced DLT. The value of m̃j is determined
as below.

m̃j =The number of patients who have completed the assessment without experiencing DLT at dose j
+

Total follow-up time for patients with pending toxicity outcome at dose j
Length of assessment window
For patient safety, TITE-keyboard does not permit dose escalation unless at least two

patients have completed toxicity assessment at the current dose level. Thus, to conduct the trial
with the TITE-Keyboard, no real-time model fitting is needed. Investigators only need to count
the number of patients treated at current dose, the number of patients who have completed toxicity
assessment, the number of patients with pending outcome, and calculate the effective sample size
(ESS) at current dose. The TITE-KEYBOARD app not only provides a calculator for determining
the ESS, but also returns a decision table to ease the implementation of the design. Similar to
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other apps in the software platform, TITE-KEYBOARD app can also be used for simulation and
protocol preparation.

Keyboard for drug-combination trials (KEYBOARD COMB)
The keyboard combination design [80] provides an alternative for drug-combination trials,
as it has comparable operating characteristics to the BOIN combination design. The main difference
between Keyboard combination design and BOIN combination design is the statistical principle used
to determine the rules for dose escalation and de-escalation. The keyboard combination design relies
on the calculation of posterior distribution for the DLT probability whereas the BOIN combination
directly uses observed DLT probability.
There are five escalation and de-escalation schemes proposed in Pan et al. [80]. We only
include the escalation and de-escalation scheme that is similar to that of BOIN combination as it
yields the best operating characteristics under various scenario setting in the simulation studies
in the original paper. Specifically, once escalation (or de-escalation) decision is made, keyboard
combination determine the dose for next cohort of patients as the one with the largest posterior
probability falling into the proper dosing interval (λe , λd ) in the admissible escalation set AE (or deescalation set AD ). Unlike the BOIN combination design where the values (λe , λd ) are determined
by minimizing incorrect decisions, the keyboard combination designs use the values directly elicited
from clinicians. Pan et al. also established the statistical properties of the Keyboard combination
design such as optimality, coherence, and consistence, which assure clinicians that the design for
sure will yield desirable operating characteristics.
The Keyboard combination design maintains the simplicity of the original single-agent
keyboard design, which can tabulate decision rules before the onset of a trial. The KEYBOARD
COMB app requires the number of dose levels for the drugs and their respective starting dose levels,
as well as the target DLT rate and the proper dosing interval. All the other settings are similar to
that in BOIN COMB app. With the input, the app will provide decision tables for trial conduct.
Users can use the app to conduct simulation studies and prepare trial protocols.

5.2.3

Tools for software development
The BOIN suite and Keyboard suite were developed using R programming [95], primarily

with the R shiny package [10]. Additional packages were used to enhance the appearance and
functionality of the software. We used ShinyBS to add pop-up windows to show scenarios uploaded
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or to save scenarios entered; Shinyjs to improve user experience of shiny apps by hiding, disabling,
or enabling certain input elements as necessary; rhandsontable to make complicated trial settings
(such as two-dimensional dose toxicity probabilities) in nice and concise table format; DT to output simulation results in HTML tables that can be saved in the formats of pdf, csv, excel, etc;
XLConnect and XLConnectJars to write Microsoft Excel files that can be downloaded from the
app; and rmarkdown to produce protocol template.

5.3
5.3.1

Results
Features of the applications
Different from most published shiny applications that only contain a single app for a specific

model-based design, the software platform we developed includes two classes of model-assisted
Bayesian adaptive designs: the Bayesian optimal interval (BOIN) suite and the Keyboard suite,
shown in Figure 5.3 panels A and B, respectively. The BOIN suite contains BOIN design for
single-agent trials with non-informative prior (standard BOIN) and informative prior (iBOIN); for
single-agent trials with fast accrual or delayed toxicity (TITE-BOIN); for single-agent trials to
identify optimal biological dose using utility-based approach (U-BOIN), and for drug-combination
trials (BOIN COMB). Similarly, the Keyboard suite contains designs for single-agent trials without
delayed toxicity (standard Keyboard) and with delayed toxicity (TITE-KEYBOARD), and for
drug-combination (KEYBOARD COMB).
For the BOIN suite, a click on the icon for “BOIN” will bring out a sub-panel containing
standard BOIN and iBOIN apps. All the app interfaces in the two suites are user-friendly and trial
inputs are self-explanatory. Users do not need to have statistical programming skills to evaluate
the operating characteristics of the trial designs. The evaluations can be done in a point-and-click
fashion. Extensive help files are also available in each app. Panel C in Figure 5.3 provides a decision
tree to help users determine which design is appropriate under specific trial settings in case they
are not familiar with the designs.
The strengths of the BOIN suite and Keyboard suite lie in the versatile platform and
use-friendly features as below.
1) Contain multiple novel designs, each addressing a different challenge in Phase I clinical trials.
2) Run under different operating systems.
3) Do not require any installation.
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Figure 5.3: Bayesian optimal interval (BOIN) and Keyboard suite available at www.trialdesign.org.
4) Do not require statistical programming skills to use.
5) Provide comprehensive user help files.
6) Regularly maintained and free to use.
All the shiny applications in the two suites have capability to implement the following three
main tasks.
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Trial planning At the planning stage, users can use the app to conduct simulation for
various trial settings and obtain decision rules based on their specified trial setting. All the
information is well-organized in a trial protocol template that are available in both html and
word format. For the BOIN suite, the templates are available in both English and Chinese.
Trial conduct To determine dose assignment during a trial, users can simply comparing the
observed data to the decision boundaries obtained using the apps. Alternatively, for more
complicated designs such as U-BOIN, BOIN combination, and Keyboard combination, the
apps also provide an option to determine the dose for next cohort of patients. Users can
simply type in or upload trial data to the app to get the recommended dose for next cohort
of patients.
MTD (or OBD) estimation After a trial completes accrual and has outcomes evaluated,
the apps can be used to determine the MTD or OBD.
5.3.2

Implementation with a trial example
All the shiny applications include the following core statistical specifications for trial plan-

ning and conduct.
1) Target toxicity (or DLT) probability and toxicity intervals required by a design.
2) Number of doses and starting dose level.
3) Sample size and cohort size.
4) Early stopping criteria.
5) Prior specifications (applicable for iBOIN, TITE-BOIN, and TITE-KEYBOARD).
To demonstrate the ease of trial planning and trial conduct using the shiny apps, we use
the BOIN app (Figure 5.4 shows part of the user interface) as an example. Suppose the target
DLT probability in the trial we plan is 0.3. A dose with DLT probability of 0.18 is considered
sub-therapeutic and of 0.48 is over-toxic. The information happens to be the default setting of
BOIN design, and is used to obtain dose escalation and de-escalation boundaries. In the BOIN
app, check the box for “Use the default alternative to minimize decision error (recommended)” to
obtain dose escalation and de-escalation boundaries. A maximum of 30 patients will be enrolled
and are treated in a cohort size of three. We enter this information in the “Sample Size” panel.
To save sample size, we determine that the trial will be stopped if any of the doses have been used
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Figure 5.4: Design setting and flowchart for the trial example using the BOIN app.
to treat 12 patients. To prevent from exposing patients to overly toxic doses, we impose the safety
rule that a dose and its higher dose levels will be eliminated if we find that there is 95% chance that
the dose has a DLT probability that is greater the target probability of 0.3, given at least three
patients are treated. The safety criteria is entered under the “Overdose Control” panel.

Trial planning

Under the “Trial setting” of the BOIN app, we entered our trial settings as

shown in Figure 5.4. Click on “Get Flow Chart and Decision Table”, the app returns the BOIN
diagram and decision tables (shown in Figure 5.4 and Figure 5.5, respectively), which can be directly
included in trial protocol. ‘
It is critical to assess the accuracy and the safety of design before using it in the actual
trial. To do this, we first construct several scenarios that may represent the true dose-toxicity curve.
Then we use the “Simulation” tab in the BOIN app to evaluate the probability of correctly selecting
the true MTD and the percentage (or number) of patients allocated to each dose. A design with
good operating characteristics should have a desirable probability to identify the true MTD and
treat a large proportion (or number) of patients at the MTD across various scenarios.
In this example, we consider four scenarios with the MTD located at dose level 1, 2, 3, and
4, respectively, as shown in Figure 5.6. To enter the scenarios, the BOIN app allows a direct input
(i.e., type in) and also provides an option for users to upload the scenarios using a prespecified
template. If ”Upload scenario file” is selected, users will see the template. We choose “Type in” to
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Figure 5.5: Decision table for the trial example using the BOIN app.
enter the scenarios manually. We can conveniently add or remove a scenario through the “Add a
Scenario” and “Remove a Scenario” tabs. We can also save our scenarios for future use by clicking
on the “Save Scenarios” tab . After scenarios are entered, we set the number of simulated trials
(e.g., 1000) for each scenario. To ensure reproducible results of our simulation, we set the random
number generator seed as 6 (any other number is fine) under “Set Seed”. At the end, we click
“Run Simulation”. On the right panel of the app are displayed the simulation results, including
the percentage of selecting a dose as MTD (Selection %) and the percentage of patients treated at
each dose (% Pts treated). Additionally, the results also contain the average number of patients
(Number of Patients) and the percentage of stopping the trial early without selecting MTD (%
Early Stopping). As shown, if we want, we can copy or print the simulation results, or save them
in CSV and Excel format. We find this to be a friendly feature that enables easy sharing of the
simulation results within a collaboration team. The BOIN app provides a very handy tab to help

Figure 5.6: Simulation example using the BOIN app.
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prepare trial protocol. After running our simulation, we click on “Trial protocol” to download a
template to prepare our protocol. The template includes a well-written description of the dose
finding algorithm of BOIN design, along with the design diagram, decision table, and simulation
results. The template is available in html and word formats. The app also provide Chinese template
to meet the ever increasing demand for the BOIN design in China. The English protocol template
for our trial example is provided in the Appendix.

Trial conduct

To conduct the trial, the decision table (shown in Figure 5.5) obtained during

our trial planning is all we need. We treat the first cohort of patients at the lowest dose as specified
and use the decision table to determine the dose for subsequent cohorts of patients. Suppose there
are no toxicity observed for the first three patients, we will escalate to dose level 2 for next cohort of
patients. At any time, we simply count the number of patients treated on that dose and the number
of patients who experience toxicity to determine whether escalation or de-escalation is triggered or
the current dose should be eliminated. For example, suppose 6 patients were treated at current
dose, we would de-escalate the dose if 3 of them experienced toxicity or eliminate the dose and
its higher doses if 4 or more patients experienced toxicity. The trial continued until the maximum
sample size is reached.

MTD estimation

BOIN design uses the isotonic estimate of toxicity rate to select MTD. This

can be easily done using the shiny app. Suppose at the end of the trial, we have treated 3, 6, 12, 3
on dose level 1, 2, 3, and 4, but no patients have been treated on dose level 5. The corresponding
numbers of patients who experienced toxicity are 0, 1, 3, and 2, respectively. We entered the trial
data into the BOIN app under the “Select MTD” tab as shown in Figure 5.7. A click on “Estimate
the MTD” will give us the selection result, as shown on the right side of the app, where we see the
estimated MTD, and the dose-limiting toxicity (DLT) estimate for all doses used to treat patients
and their corresponding 95% credible intervals.

5.4

Summary
To facilitate the use of the novel model-assisted designs and accelerate drug development

in early phase trials, we developed two versatile software platforms: BOIN suite and Keyboard
suite. Each suite includes multiple well-performed model-assisted designs that can be used to
tackle different challenges in Phase I clinical trials. The availability of these software provides
timely and interactive simulation information to help clinicians and reviewers to understand the
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accuracy and the safety of the novel designs without the need of programming skills. This work
is of greatest importance, as it not only facilitates the ease of collaborations between statisticians
and clinicians, but also will advance the development of novel methods in clinical trials by making
them more accessible to a broader audience.

A

Appendix

The protocol template (a pdf file) for the trial example using BOIN app is attached below.
This file demonstrates how the app can save the time used to write a statistical protocol by using
the readily available template from the shiny app.
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Template for Protocol Preparation

NOTE: If you would like a Microsoft Word version of this protocol document template, simply select (highlight) this entire
document, copy it, open a new Word document, and paste the protocol document template into the Word document. On
Windows machines this can conveniently be accomplished by pressing CTRL-A to select (highlight) the entire document,
CTRL-C to copy it, and CTRL-V to paste it. Alternatively, opening the saved HTML file in Microsoft Word may produce
better results.

Template for Protocol Preparation
We will employ the Bayesian optimal interval (BOIN) design (Liu and Yuan, 2015; Yuan et al., 2016) to find the MTD. The
BOIN design is implemented in a simple way similar to the traditional 3+3 design, but is more flexible and possesses
superior operating characteristics that are comparable to those of the more complex model-based designs, such as the
continual reassessment method (CRM) (Zhou et al., 2018).
The target toxicity rate for the MTD is ϕ = 0.3 and the maximum sample size is 30. We will enroll and treat patients in
cohorts of size 3. DLTs are defined in Section ###, and only those DLTs that occur within the first cycle will be used for
dose finding. As shown in Figure 1, the BOIN design uses the following rule, optimized to minimize the probability of
incorrect dose assignment, to guide dose escalation/de-escalation:
if the observed DLT rate at the current dose is ≤ 0.236, escalate the dose to the next higher dose level;
if the observed DLT rate at the current dose is ≥ 0.359, de-escalate the dose to the next lower dose level;
otherwise, stay at the current dose.
For the purpose of overdose control, doses j and higher levels will be eliminated from further examination if Pr(pj

>

0.3 |

data) > 0.95, where pj is the true DLT rate of dose level j, j = 1,⋯, 5. This posterior probability is evaluated based on
the beta-binomial model yj ∣ pj ∼ binomial(pj ) with pj ∼ uniform(0, 1) , where yj is the number of patients
experienced DLT at dose level j . When the lowest dose is eliminated, stop the trial for safety. The probability cutoff 0.95 is
chosen to be consistent with the common practice that when the target DLT rate <=1/6, a dose with 2/3 patients
experienced DLT is eliminated.
The steps to implement the BOIN design are described as follows:
1. Patients in the first cohort are treated at dose level 1.
2. To assign a dose to the next cohort of patients, conduct dose escalation/de-escalation according to the rule
displayed in Table 1, which is equivalent to the rule described above. When using Table 1, please note the
following:
a. “Eliminate” means eliminate the current and higher doses from the trial to prevent treating any future patients
at these doses because they are overly toxic.
b. When we eliminate a dose, automatically de-escalate the dose to the next lower level. When the lowest dose
is eliminated, stop the trial for safety. In this case, no dose should be selected as the MTD.
c. If none of the actions (i.e., escalation, de-escalation or elimination) is triggered, treat the new patients at the
current dose.
d. If the current dose is the lowest dose and the rule indicates dose de-escalation, treat the new patients at the
lowest dose unless the number of DLTs reaches the elimination boundary, at which point terminate the trial
for safety.
e. If the current dose is the highest dose and the rule indicates dose escalation, treat the new patients at the
highest dose.
3. Repeat step 2 until the maximum sample size of 30 is reached, or stop the trial if the number of patients treated at
the current dose reaches 12 and the decision according to Table 1 is to stay at the current dose.

file:///C:/Users/yanhong zhou/Downloads/protocol template - 2020-03-20T191907.567.html
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Figure 1. Flowchart for trial conduct using the BOIN design

Table 1. Dose escalation/deescalation rule for the BOIN design
The number of patients treated at the current dose
1

2

3

4

5

6

7

8

9

10

11

12

Escalate if # of DLT <=

0

0

0

0

1

1

1

1

2

2

2

2

Deescalate if # of DLT >=

1

1

2

2

2

3

3

3

4

4

4

5

Eliminate if # of DLT >=

NA

NA

3

3

4

4

5

5

5

6

6

7
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Note. # of DLT is the number of patients with at least 1 DLT. When none of the actions (i.e., escalate, de-escalate or
eliminate) is triggered, stay at the current dose for treating the next cohort of patients.
After the trial is completed, select the MTD based on isotonic regression as specified in Liu and Yuan (2015). This
computation is implemented by the shiny app “BOIN” available at http://www.trialdesign.org (http://www.trialdesign.org).
Specifically, select as the MTD the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity
rate. If there are ties, select the higher dose level when the isotonic estimate is lower than the target toxicity rate and
select the lower dose level when the isotonic estimate is greater than or equal to the target toxicity rate.

Operation Characteristics
Table 2 shows the operating characteristics of the trial design based on 1000 simulations of the trial using shiny app
“BOIN” available at http://www.trialdesign.org (http://www.trialdesign.org). The operating characteristics show that the
design selects the true MTD, if any, with high probability and allocates more patients to the dose levels with the DLT rate
closest to the target of 0.3.
Table 2. Operating characteristics of the BOIN design
Dose Level
1

2

3

4

5

True DLT Rate

0.3

0.46

0.5

0.54

0.58

Selection %

69.7

15.5

2.3

0.6

0

% Pts Treated

61.3

31.3

6.2

0.9

0.2

True DLT Rate

0.16

0.3

0.47

0.54

0.6

Selection %

27.2

54.8

15.2

1.8

0

% Pts Treated

34.4

42

19.7

3.5

0.4

True DLT Rate

0.04

0.15

0.3

0.48

0.68

Selection %

0.9

26.1

57.2

15.6

0.2

% Pts Treated

15

29.2

36.7

17.3

1.9

True DLT Rate

0.02

0.07

0.12

0.3

0.45

Selection %

0.1

1.8

20.4

58.5

19.2

% Pts Treated

12.1

14.6

24.8

32.6

15.9

Number of Patients

% Early Stopping

Scenario 1

11.9
16.8

Scenario 2

1
22.1

Scenario 3

0
25.3

Scenario 4

0
27
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Appendix 1

： Trial and Design Specifications
Parameter

Value

Number of doses

5

Starting dose

1

Max sample size

30

Cohort size

3

Stop trial if # patients assigned to single dose reaches

12

Use accelerated titration

False

Target toxicity probability

0.3

Use the default alternatives to minimize decision errors

True

Alternative (unacceptable high toxicity) for optimization

Default

Alternative (unacceptable low toxicity) for optimization

Default

Eliminate dose threshold

0.95

Number of repetitions per scenario

1000

Random number generator seed

6
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Appendix 2. Alternative BOIN decision table
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Figure 5.7: Design setting of trial example and flowchart produced in the BOIN app.
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CHAPTER 6

The use of local and nonlocal priors in Bayesian test-Based
monitoring for Phase II clinical trials

6.1

Introduction
Phase II clinical trials play a critical role in drug development. The objective of phase II

clinical trials is to evaluate the therapeutic effect of a new treatment and screen out inefficacious
agents. Phase II trials commonly use a short-term and dichotomous endpoint to characterize the
patient clinical response to treatment. For example, a binary objective response endpoint can
be used to indicate whether the patients have achieved a complete or partial response within a
predefined treatment course. If the new treatment shows a promising treatment effect, further
large-scale confirmatory trials can be conducted.
In general, phase II studies can be performed using either frequentist or Bayesian designs
[4, 117]. The frequentist approaches treat the response probability of the new treatment as a
fixed, yet unknown parameter [9, 23, 26]. The most well-known frequentist phase II design is the
Simon’s optimal two-stage design [88]. In this design, n1 patients are enrolled in stage I, if there
are r1 or fewer responses, terminate the trial early and conclude that the drug is not promising;
otherwise, enroll an additional n2 patients in stage II and claim the drug is promising if more than r
responses are observed. The parameters of Simon’s design are optimized to minimize the expected
sample size (the optimal design) or the maximum sample size (the minimax design) under the null
hypothesis that the treatment is not efficacious, with the type I and type II error rates being well
controlled. Simon’s two-stage design is widely adopted in phase II trials. Numerous generalizations
or extensions of Simon’s two stage design have been proposed. Examples include the three-stage
design [11], the design based on a composite null hypothesis [59], the optimal adaptive design [87],
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and the multiple-arm design [123] among others.
Most of the frequentist phase II designs only have two or three stages, with the design
parameters determined based on numerical searching. However, when the number of interim looks
exceeds three or continuous monitoring is considered, it is computationally infeasible to determine
the optimal design parameters for frequentist designs. Moreover, frequentist designs are rigid in
the sense that they do not allow any deviation from the original design. For example, for the
Simon’s design, the “go/no-go” decisions can only be made at the predetermined interim time,
and the design will not stop the trial early, even when observed data have already indicated that
the drug is indeed ineffective. To safe guard patients from futile treatments and accelerate the
development of efficacious drugs, it is critical to make adaptive decisions based on the accumulated
data throughout the trial in a timely fashion, such that the trial can be stopped earlier for futility or
efficacy. Typically, the more interim looks, the greater the chance of detecting futile or efficacious
treatments; in turn, the smaller the sample size, the more efficient the trial.
When more interim analyses are desired, Bayesian methods become particularly appealing
due to their “we learn as we go” nature [39]. Bayesian inference universally follows three steps:
(1) Elicit the prior distribution of the unknown response parameter, based on historical or external
trials, as well as expert opinions. (2) Obtain the likelihood function based on the data collected
during the study. (3) Synthesize the prior information and the observed data likelihood into a
posterior distribution of the parameter of interest using Bayes theorem. In Bayesian phase II
designs, the treatment effect is considered as an unknown random variable, and the Bayesian
inference can be adaptively and timely made, as long as new data are observed. As a result,
Bayesian designs usually are more flexible in facilitating multiple interim decisions. In addition,
frequentist methods require a penalty for each look of the data, but there are no such hurdles for
interim analyses in a Bayesian perspective [3].
Due to the appealing feature of flexibility, recent years have witnessed vast developments
in Bayesian phase II clinical trial designs [32, 45, 49, 86, 94, 98, 99, 103, 107, 122]. Overall,
existing Bayesian sequential monitoring approaches can be divided into two categories: posterior (or
predictive) probability based (PB) or Bayesian hypothesis test based (TB). For the PB approach, the
“go/no-go” decisions are made based on the Bayesian posterior (or predictive) probability that the
treatment is futile or effective. If such a probability is greater than a prespecified upper probability
cutoff, then the trial can be terminated early, as the experimental treatment is likely to be futile
or promising. If this probability is small, however, then there is inadequate information to deliver
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a conclusion and the trial continues to collect more data. On the other hand, the TB approach
adaptively makes the “go/no-go” decisions based on the Bayesian hypothesis testing framework
with the Bayes factor. Although [45] argued that the use of Bayes factor in sequential monitoring
can gain more efficiency compared to the PB approach, while also eliminating a potential source
of bias often caused by prior-data conflict, the research on the TB approach for phase II trials is
lacking. Limited examples include the two-stage Bayes factor based design [20] and the design to
identify the maximum effective dose [30]. To get more insight into TB monitoring, in the first part
of this chapter, we are interested in studying the connection between the TB and PB approaches.
In particular, we show that TB sequential monitoring is essentially a special case of PB monitoring,
with a data-adaptive stopping cutoff.
Although the Bayesian approaches have gained popularity in phase II clinical trials, an issue
that was largely overlooked is the choice of prior distributions. For the TB monitoring approach, a
prior distribution is required to quantify the initial uncertainty of the unknown parameter under the
alternative hypothesis. According to [46], the prior distributions can be classified into local priors
and nonlocal priors. A local prior refers to a probability density that assigns positive probability
to regions of the parameter space that are consistent with the null hypothesis. The commonly
used Beta distribution for the response rate falls into the category of local priors. [46] also showed
that the problem with using the local prior is that it accumulates evidence in favor of the true null
hypothesis at a much slower rate, as compared to favoring a true alternative hypothesis. To address
this issue, a class of nonlocal prior was proposed. One such nonlocal prior is the flexible inverse
moment (iMOM) density [45, 46]. In the second part of this paper, we extensively examine the
effects of local and nonlocal priors on the TB monitoring procedure. We demonstrate that when
the treatment is truly futile, using an iMOM prior has a greater probability of stopping a trial early
for futility vs using a Beta prior, while the probabilities to claim efficacy when the treatment is
truly efficacious are comparable between the two. This, in turn, leads to a smaller average number
of patients enrolled when the iMOM prior is used.
The rest of this chapter is organized as follows. In section 6.2, we first provide an overview
of different Bayesian monitoring approaches and then show the relationship between PB monitoring
and TB monitoring. In section 6.3, we describe prior specification for Beta distribution and iMOM
density, and we propose a procedure to estimate the associated effective sample size for iMOM
density. In section 6.4, we conducted extensive simulation to examine the operating characteristics
of the TB monitoring using Beta and iMOM priors. In section 6.5, we provide tutorials on the
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newly developed web-based software for phase II sequential monitoring. We conclude the study in
section 6.6.

6.2
6.2.1

Sequential monitoring
Bayesian posterior (or predictive) probability based (PB) monitoring
In a phase II trial, let n denote the number of patients and y denote the number of responses

observed. The treatment effect is quantified by the probability of clinical response, p, and thus the
number of response y is usually modeled as a binomial random variable, i.e., y ∼ Binom(n, p). Given

the observed value D = (y, n), the binomial likelihood function is f (D | p) = ny py (1 − p)n−y . In
Bayesian inference, all the information about the parameter is contained in the posterior distribution
of p, which can be calculated using the Bayes’ theorem as follows,

(6.1)

π(p | D) = R

f (D | p)π(p)
, 0 ≤ p ≤ 1.
f (D | p)π(p)dp

Here, π(p) is the prior distribution for the unknown parameter p, which characterizes all available
information before conducting the trial. Once the posterior distribution is obtained, we can make
inference about the true parameter p.
Let p0 denote a clinically uninteresting response rate or the response rate of the standard
control, and let p1 represent a desirable target response rate. In general, the “go/no-go” decisions for
the PB approach can be made based on either the posterior probability or the predictive probability
that the experimental drug has a higher response rate than the clinically uninteresting rate p0 .
Specifically, if posterior probability is used, the posterior probability that the treatment effect of
the experimental drug exceeds the standard effect by a prespecified improvement δ, i.e., Pr(p >
(p0 + δ) | D), can be calculated continuously at each interim decision-making time when the data
are accumulated. Here, we can assign either a point mass or a prior probability distribution based
on historical data to p0 . In this paper, we only consider p0 as a prespecified point, and fix δ = 0.
For a trial with sequential monitoring, we can determine whether to early stop or continue
the trial by comparing the posterior probability Pr(p < (p0 + δ) | D) with a probability cutoff [98].
For example, the trial can be stopped early for futility if Pr(p < (p0 + δ) | D) > rf , where rf is a
probability cutoff for futility stopping. If this Bayesian monitoring rule is not satisfied, then there
is not adequate information to deliver any conclusion, so the trial continues to collect more data
until the prespecified sample size is reached. Similarly, if efficacy monitoring is considered, then the
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trial can be stopped early for efficacy, if the posterior probability Pr(p > (p0 + δ) | D) is greater
than the efficacy stopping boundary re . In most cases, the probability cutoffs rf and re take fixed
values at 0.90 or 0.95. Alternatively, calibration procedures can also be conducted to calibrate the
cutoff values of rf and re to satisfy certain prespecified type I/II error constraints. Generalization
of this Bayesian monitoring procedure can be found in [32], [99], and [122] among others.
In addition to the posterior probability, Bayesian predictive probability serves as a good
alternative tool to conduct interim decision monitoring. Unlike the posterior probability monitoring
approach, which is based on the posterior distribution of p, the predictive probability monitoring
procedure uses the predictive distribution of p for decision making. Suppose the maximum sample
size is N , at the interim time with n patients treated, let Y ∗ denote the future number of responses
among the remaining N − n patients. Given the observed data, the predictive distribution of the
R1
number of responses among the total sample size can be obtained as Pr(Y ∗ | D, N − n) = 0 f (D∗ |
p)π(p | D)dp, where D∗ = (Y ∗ , N − n) denotes the unobserved future data, f (D∗ | p) is the
Binomial likelihood function based on the future data D∗ , and π(p | D) is the posterior distribution
of p based on the observed data D.
The Bayesian predictive probability procedure continuously calculates the predictive probability of a positive conclusion (e.g., accept the alternative hypothesis) or of a negative conclusion
(e.g., accept the null hypothesis), and makes timely adaptive “go/no-go” decisions as the trial
moves on [49]. By continuously comparing the predictive probabilities with respect to the cutoffs,
the decision rules of the predictive probability monitoring procedure mimics that of the posterior
probability monitoring procedure. As shown in [49], the sequential monitoring based on the predictive probability not only accounts for uncertainty among observed data, but also variability for
outcomes that may be observed in the future for a trial. Like posterior probability monitoring,
the predictive probability monitoring is more adaptable than traditional multi-stage designs and
conceptually appealing. It has been generated to more complex trial settings, such as randomized
phase II trials [107], trials with time-to-event endpoints [108], and platform trials [34].

6.2.2

Bayesian hypothesis test based (TB) monitoring
An alternative Bayesian monitoring approach is developed on the basis of the Bayesian

hypothesis testing procedure [45]. Specifically, consider the following hypotheses,

(6.2)

H0 : p ≤ p0

versus
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H1 : p > p0 ,

where under the null hypothesis H0 , the treatment effect is deemed unpromising. Under the
Bayesian framework, the Bayes factor serves as a natural quantity to measure the strength of
evidence for a hypothesis relative to another one. Specifically, the Bayes factor in favor of H1
(denoted as BF10 ) can be calculated as

(6.3)

BF10

R1
f (D | p)π(p | H1 )dp
Pr(D | H1 )
p
=
= R p00
,
Pr(D | H0 )
f (D | p)π(p | H0 )dp
0

where f (D | p) is the data likelihood and π(p | Hj ) is the prior distribution of p under Hj , j = 0, 1.
That is, the Bayes factor is the ratio of likelihood averaged over the prior under H1 and H0 . When
no or little prior information can be borrowed, it is natural to assume a priori that the hypotheses
are equally likely a priori, i.e., the prior hypothesis probabilities Pr(H0 ) = Pr(H1 ) = 1/2. In this
case, the Bayes factor BF10 is equivalent to the posterior odds in favor of H1 .
Under the Bayesian hypothesis testing framework, a decision to reject the null hypothesis
occurs only when the Bayes factor in favor of the alternative hypothesis exceeds a prespecified
evidence level. Thus, it can quantify evidence in favor of the null hypothesis when the null hypothesis
is not rejected [55]. A greater BF10 indicates a stronger evidence for H1 . Alternatively, we can
define Bayes factor as BF01 = Pr(D | H0 )/Pr(D | H1 ). In this case, a larger BF01 indicates a
greater evidence for H0 .
At each interim decision-making time, the TB monitoring procedure adaptively tests the
hypotheses (6.2) and makes the “go/no-go” decisions as follows:
• Efficacy stopping: if BF10 > γe , stop the trial to claim efficacy of the new treatment.
• Futility stopping: if BF01 > γf , stop the trial to claim futility of the new treatment.
where γe and γf are prespecified values that respectively represent substantial evidence in favor of
H1 and H0 . Table A6.1 shows the interpretation of Bayes factor as the strength of evidence for
hypothesis testing [47]. [45] showed that the Bayes factor in favor of the alternative hypothesis will
almost always be smaller than it could have been with a correctly-specified prior under H1 . As a
result, compared to the PB monitoring that is based on the posterior probability intervals, the TB
monitoring based on Bayes factor can automatically adjust the bias induced by overly optimistic
priors. This property is of practical use, especially from a regulatory perspective.

122

6.2.3

Relationship between PB monitoring and TB monitoring
As aforementioned, PB monitoring is based on the posterior probability that the response

rate is greater than the reference response rate given observed data, while the TB monitoring is
based on the evidence contained in the data in favor of one hypothesis relative to another one. We
show here that the two monitoring approaches are closely related, and TB monitoring can essentially
be viewed as a special case of PB monitoring. Let π(p) = Pr(H0 )π(p | H0 ) + Pr(H1 )π(p | H1 ) be
the overall prior distribution, and let π(p | D) be the overall posterior distribution of p, which is
calculated based on the observed data D and the overall prior π(p). Then the posterior probability
R
of Hj can be computed as Pr(Hj | D) = Hj π(p | D)dp, j = 0, 1. According to the definition of
Bayes factor, for futility monitoring, we have

⇐⇒
⇐⇒
⇐⇒

Pr(D | H0 )
> γf
Pr(D | H1 )
Pr(H0 | D) Pr(H1 )
> γf
Pr(H1 | D) Pr(H0 )
γf Pr(H0 ) Pr(H1 | D)
Pr(H0 | D) >
Pr(H1 )
γf Pr(H0 ) Pr(p > p0 | D)
Pr(p ≤ p0 | D) >
≡ rf0 (D)
Pr(H1 )

Here, rf0 (D) depends on the observed data D. Thus TB monitoring can be viewed as a special case
of PB monitoring with δ = 0 and a data-adaptive stopping cutoff. A similar proof can be done for
efficacy monitoring.
Compared to the fixed cutoff that remains unchanged over the course of the trial, the dataadaptive cutoff rf0 (D) varies with the interim sample size n and the observed number of responses
y. For example, suppose the data are generated under the null hypothesis H0 , then in general, the
cutoff function rf0 (D) decreases with the number of patients treated. This is due to the fact that
the posterior probability Pr(p > p0 | D) decreases as the sample size increases when the data are
simulated from H0 . As a result, at the beginning of the trial, data are sparse and a more stringent
stopping rule with a larger value of λ0f (D) may be preferred to avoid accidentally terminating the
trial. As the trial proceeds and information accumulates, there is less uncertainty regarding the
response rate and a smaller stopping boundary would be produced based on Pr(p > p0 | D), making
the trial easier to stop for futility. This is similar to Bayesian posterior monitoring, in which the
probability cutoff λe is generalized into decreasing function of sample size [98]. [122] showed that
allowing the cutoff to change with the sample size increases the power of a design. Indeed, [45]

123

showed an extensive simulation study where TB monitoring exhibited higher efficiency than PB
monitoring.

6.3

Prior specification
Prior specification is critical to the performance of Bayesian inference. Especially in early-

phase trials when the sample size is typically small, different prior distributions may lead to varied
interim decisions or final conclusions [110]. During a study, the Bayesian method updates the prior
to form the posterior distribution coherently and continuously based on the accumulated data.
The use of prior information for Bayesian designs could be a double-edged sword. If the prior is
consistent with the current data, proper use would increase the trial efficiency and render more
accurate decision making. In contrast, improper use of the prior may be subject to biased inference
and incorrect decisions. Hence, the choice of prior distribution should be carefully made according
to the clinical setting, expert knowledge, and sufficient simulation studies. Recently, the US Food
and Drug Administration [22] has also announced a draft guideline for industry and highlighted
the importance of the evaluation of prior distribution on innovative trial designs. For Bayesian
phase II trial designs, a largely overlooked issue is the choice of prior distributions. In this section,
we describe two different types of prior distributions that will be thoroughly examined in the TB
monitoring procedure.

6.3.1

Beta distribution
Since the primary endpoint in phase II trials is usually binary, a natural choice of the

prior for the response rate (p) is the Beta prior due to the conjugacy. The use of a conjugate
prior simplifies the computation for posterior distribution, as it gives a closed-form expression
for the posterior. Suppose that the prior distribution is p ∼ Beta(a, b), where a and b are the
hyperparameters. The quantity a/(a + b) reflects the prior mean, while the size of a + b indicates
how informative the prior is. The larger the value of a+b, the more informative the prior, indicating
a stronger belief. In many cases, a Beta(1, 1) is used as a non-informative prior, which is equivalent
to the Uniform (0,1) distribution. Given the observed data D = (y, n), the posterior distribution
of p is still a Beta distribution, i.e., p | D ∼ Beta(y + a, n − y + b). Such a beta-binomial model has
been widely applied in early-phase trial designs [91, 49, 59, 40, 33].
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6.3.2

The inverse moment (iMOM) density
All beta densities assign non-negligible probability to the parameter space that is consistent

with the null hypothesis. Thus, the beta distribution is the so-called local prior. In Bayesian
hypothesis testing using the Bayes factor, [46] showed that the problem of using the local prior
is that it accumulates evidence in favor of the true null hypothesis at a much slower rate vs a
true alternative hypothesis. To address this problem, the nonlocal priors that assign zero prior
probability to the null space are advocated. One representative example is the class of inverse
moment (iMOM) prior densities. In particular, when the parameter of interest is response rate (p),
the iMOM density takes the form:

(6.4)

 
−k 




2


kτ ν/2 

 (p − p0 ) 
2 −(ν+1)/2
π (p; p0 , k, ν, τ ) =
(p − p0 )
exp − 



Γ(ν/2k)
τ





where p0 is the null value, p ∈ [0, 1], and k > 0, ν > 0, τ > 0 are the parameters that jointly define
the iMOM density. The iMOM density is not a conjugate prior, as the posterior distribution does
not have a standard distributional form. Inference on the unknown parameter p, if needed, can be
made by drawing posterior samples using Markov Chain Monte Carlo (MCMC) algorithms.
The iMOM density assigns zero density at the point null hypothesis and its neighborhood.
We refer to the area that has zero mass as the “null region” hereafter. The null region increases
with k and τ and decreases with ν (as shown in Figure A6.1). In terms of the tail behavior, a
heavier tail is accompanied by a larger value of τ or a smaller value of ν.
One difference between iMOM and Beta is their robustness to Bayesian inference when
prior-data conflicts exist. [25] showed that, in Bayesian inference, a Beta prior is not a robust prior
in comparison to a Cauchy prior when there is prior-data conflict. We also checked the iMOM
against the Beta and Cauchy priors when a prior-data conflict exits, using the same settings in [25],
and we found that iMOM has similar robustness to Cauchy, indicating that iMOM is a more robust
prior than Beta in the prior-data conflict setting (Figure A6.2).

6.3.3

Prior effective sample size
A fundamental aspect of using the Bayesian approach is to quantify the amount of infor-

mation contained in the prior [70]. This is measured by effective sample size (ESS), which is defined
as the number of hypothetical patients associated with the prior distribution. It is straightforward
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to determine ESS in many commonly used models. For example, it can be argued that a Beta(a, b)
distribution has an ESS of a + b. While it is straightforward to determine ESS for a Beta distribution, it is not obvious for an iMOM prior. Following [69], we use the following procedure to obtain
ESS for an iMOM prior π(p; p0 , k, τ, ν).
1. Specify the mode (pm ) of the iMOM prior π(p; p0 , k, τ, ν) or determine it using the following
equation:
pm = p0 +

√


τ

2k
ν+1

1/2k
.

2. Sample T (e.g., T = 104 ) data points (p(1) , · · · , p(T ) ) from π(p; p0 , k, τ, ν) and calculate the
variance of the samples

σp2

PT
=

− p̄)2
, where p̄ =
T −1

t=1 (p

(t)

PT

t=1

T

p(t)

.

3. Specify a Beta(c, d) such that the mode and variance of this Beta distribution matches those
of the iMOM prior, i.e., set

pm =

c−1
cd
, and σ̂p2 =
.
c+d−2
(c + d)2 (c + d + 1)

4. Solve the two nonlinear equations in step 3 to obtain c and d, and determine effective sample
size as
ESS = c + d.

One of the main tasks in our study is to assess the influence of different priors on the
operating characteristics of a phase II study with TB monitoring based on the Bayes factor. For
a fair comparison, we first make sure that the priors have the same ESS, given that they have the
same mean or mode. It is intuitive and easy to specify a Beta prior with a desired ESS. For instance,
if a Beta prior with mode 0.5 and ESS=10 is needed, a Beta(5, 5) will satisfy the specification.
The corresponding specification for iMOM, however, is not straightforward. In this study,
we use a numerical calibration procedure to specify an iMOM prior. First, we specify the following
three elements for the iMOM prior: (1) the uninteresting response rate p0 under H0 ; (2) the prior
mode (pm ) of response rate for the new treatment under H1 ; and (3) the prior effective sample size.
Based on the three prefixed quantities outlined above, we determine the (k, τ, ν) for the iMOM prior
through a grid search. Specifically, we set up a wide range for k (e.g., k ∈ (0.01, 10)), and ν = 2k,
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as recommended in [45, 46]. Each combination of k and ν, along with p0 and pm , determines a
unique τ , and thus a unique iMOM density. Using methods outlined in steps 1-4 above, the values
of (k, ν, τ ) with ESS= c + d closest to the prespecified ESS will be selected to determine the iMOM
prior.
To facilitate the use of the iMOM in phase II TB monitoring, we develop an easy-to-use
web-based application, which is freely available at www.trialdesign.org. This application can be
used to conduct interim monitoring for efficacy, futility, or both, based on the Bayes factor. More
details on this application are provided in Section 6.5.

6.4
6.4.1

Simulation
Simulation setting
In this paper, we studied the prior influence on the performance of TB monitoring proce-

dure, while the comparisons between TB and PB monitoring have been extensively made in [45]
and thus are omitted. On the other hand, our simulation study can be viewed as a complement to
the study in [45].
A new drug is under development with the expectation to improve the likelihood of increasing patients’ response to a treatment. The response rate for a standard of care was 0.2 and
the new treatment was anticipated to have a larger response rate of 0.4, based on external trial
information and preliminary results. A trial was planned and the investigator intended to use the
TB monitoring design to conduct this trial. The trial was expected to (1) stop early to safeguard
patients from futile drug, if the treatment is not promising compared to the standard of care; (2)
stop early to accelerate the development of the new treatment, if early evidence indicates highly
possibility of success; and (3) enroll fewer patients, given the correct decision is made. To help
the investigator design this trial with a suitable prior, we conducted extensive simulations to assess
the operating characteristics of 10, 000 simulated trials for various scenarios under different prior
specifications.
Assume that the trial would enroll at most N patients (N = 50, 100). Patients entered the
trial with a cohort size of five. The first interim analysis was carried out when 10 patients were
treated and had their outcomes evaluated, then an interim analysis was conducted after every five
additional patients. The trial was early terminated for efficacy if BF10 ≥ 9; early terminated for
futility if BF01 ≥ 9; and otherwise continued until the maximum sample size (N ) was reached.
We assigned a point mass density with p = 0.2 under the null hypothesis H0 and test
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various prior densities under the alternative H1 . The prior densities under H1 include the standard
Beta prior, the truncated Beta prior, the Uniform prior, and the iMOM prior. The first three belong
to the class of local priors, while iMOM is a nonlocal prior. The iMOM and Beta priors ascribed
to H1 had the mode of 0.4. The strength of the prior was reflected by prior ESS. We considered
both a weakly informative prior with ESS=5 and a strongly informative prior with ESS=20. For
the weakly informative prior, we specified the nonlocal prior iMOM as π(p; k = 0.325, ν = 0.65, τ =
0.7029)[0.2,1] , and the local prior Beta(2.2, 2.8), based on the algorithm in section 6.3.3. To mimic
the behavior of iMOM, i.e., assigning non-zero density at the parameter space with p < 0.2, we
included a truncated beta prior Beta(2.2, 2.8)[0.2,1] , denoted as tBeta, for comparison. We also note
that this truncated beta prior is still a local prior, as it has positive density at p = 0.2. We then
considered the most commonly used Uniform distribution to see how the informative prior would
perform in comparison to the non-informative prior. The Uniform distribution was also truncated
in (0.2, 1) and denoted as tUniform. For the strongly informative prior ESS=20, the priors were
iMOM π(p; k = 1.685, ν = 3.37, τ = 0.0467), Beta(8.2, 11.8), and Beta(8.2, 11.8)[0.2,1] .
We considered 13 scenarios with the true response rate ranging from 0 to 0.6, with an
interval space of 0.05. For each scenario, we considered three different metrics for the comparison
between the nonlocal iMOM and the three local Beta priors. (1) The probability of claiming efficacy,
which was defined as the percentage of simulated trials claiming that the treatment is efficacious if
the criteria BF10 ≥ 9 is satisfied during or at the end of the trial. (2) The probability of claiming
futility, which was defined as the percentage of simulated trials claiming that the treatment is
futile if BF01 ≥ 9 is satisfied. (3) The average number of patients treated in the 10, 000 simulated
trials for each scenario. In addition to the overall probability of claiming efficacy or futility, we
also summarize such a probability at each interim look, as well as at the final analysis. If larger
probabilities of making a correct decision are observed at earlier interim analyses, it indicates a
more efficient design. Here, the correct decision refers to claiming efficacy under H1 and claiming
futility under H0 .
6.4.2

Simulation results

(a) Monitoring with a weakly informative prior

Figure 6.1 shows the operating char-

acteristics of the TB monitoring procedure with different prior distributions assumed under H1 .
With the weakly informative prior, the use of an iMOM prior yields a comparable probability of
claiming efficacy in comparison to the use of tUniform and Beta, while the use of tBeta has the
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largest probability of claiming efficacy (panel a1). The iMOM prior outperforms local priors in
terms of futility monitoring. As shown in panel a2, the design with the iMOM prior has a greater
probability to claim futility when the treatment is indeed not better than the standard of care.
For instance, when the true response rate is 0.2, there is a probability of 0.86 to claiming futility
under the use of an iMOM prior. On the other hand, the use of tUniform and tBeta yields smaller
probabilities of claiming futility. Notably, the use of a Beta prior causes abysmal behavior, i.e., the
trial never terminates for futility, regardless of the true response rate. Such a finding showcases the
shortcoming of using a local prior in test-based monitoring.
In terms of average sample size, the design using the iMOM prior requires fewer patients on
average. As shown in panel a3, when the true response rate is 0.2, the average number of patients
enrolled is only 23 under the use of an iMOM prior, while this number is 32, 39, and 50 when
tUniform, tBeta, and Beta are used, respectively.

(b) Monitoring with a strongly informative prior

When a strongly informative prior (e.g.,

ESS=20) is used, we find that the use of iMOM, tBeta, and Beta priors have similar probabilities
of claiming efficacy, and all outperform the use of the tUniform prior in terms of the probability
of claiming efficacy when the true response rate is greater than 0.2. This indicates that when
the prior is congruent with the data, the larger the ESS, the greater the power to make a correct
decision. Like that with a weakly informative iMOM prior, the design with a strongly informative
iMOM prior also has the greatest probability to claim futility when the treatment is indeed not
better than the standard of care. The use of Beta with ESS=20 greatly increases the probability
of claiming futility when the treatment is not promising (panel b2), compared to panel a2. Despite
such an improvement, the design using a Beta prior still has a much lower probability of claiming
futility than found with iMOM. As shown, with a Beta prior, when the true response rate is 0.2, the
probability to claim futility is 0.55, much smaller than found with an iMOM prior (0.89). In terms
of the number of patients treated, the use of a strongly informative iMOM prior still performs the
best among the considered priors.

(c) Probability of making a correct decision at each interim

The advantage of the

iMOM prior is more prominent, as demonstrated by the probability of making correct decisions at
each interim analysis. For example, the design with the iMOM prior stops much earlier for claiming
futility when the response rate is 0.2 under both weakly and strongly informative priors (Figures 6.2
and A6.4, respectively). When H1 is true (i.e., the response rate is 0.4), the behavior of the iMOM
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Figure 6.1: Efficacy and futility sequential monitoring using Bayes factor with weakly informative
prior (ESS=5, left panels) and strongly informative prior (ESS=20, right panels). When ESS=5,
the iMOM has parameters k = 0.325, ν = 0.65, τ = 0.7029 and the local prior is Beta(2.2, 2.8).
When ESS=20, the iMOM has parameters k = 1.685, ν = 3.37, τ = 0.0467 and the local prior is
Beta(8.2, 11.8). The maximum sample size is 50.
prior is comparable to that of tBeta and Beta in terms of stopping the trial earlier for efficacy.
In Supplementary Material, we detail the sensitivity analysis we conducted to assess the
operating characteristics of the design using different priors with maximum sample size (N ) varying
from 20 to 200 and a prior effective sample size that varies from 5 to 20 (section A6.0.4). In summary,
the use of iMOM is more efficient than the use of the other local priors, due to the fact that iMOM
yields a smaller average sample size with a comparatively probability of claiming efficacy, when
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Figure 6.2: Probabilities of claiming efficacy when H1 is true (i.e., panel a), and probabilities
of claiming futility when H0 is true (i.e., panel b) at each interim time and final analysis when
maximum sample size N = 50 and prior effective sample size is 5. The numbers in parentheses
represent the overall probabilities of claiming futility or efficacy in the trial.
the treatment is truly effective, and a higher probability of claiming futility, when the treatment is
truly ineffective.

6.5

Software application
To facilitate the use of an iMOM prior for TB monitoring in phase II trials, we developed

a user-friendly Shiny application. Figure 6.3 shows the app interface of the Trial setting for both
efficacy and futility TB monitoring using an iMOM prior. Users can use the app to get full stopping
boundaries, run simulations, and download a formatted trial protocol template.
To obtain full stopping boundaries, users first set up the Trial setting by (1) entering the
response rate under null and alternative hypothesis, respectively; (2) determining stopping rules
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Figure 6.3: Shiny app interface of the TB monitoring procedure based on the iMOM prior.
under Interim monitoring; (3) supplying cohort size, maximum number of patients, and minimum
number of patients to enroll before the first monitoring under Sample size; and (4) providing the
prior effective sample under Prior information. After the setup, click on the “calculate stopping
boundaries” button . The full stopping boundaries will be shown and can be downloaded as csv,
excel, or pdf files, as shown in Figure A6.8. For the example with settings presented in Figure 6.3,
the full stopping boundaries are as shown in Table 6.1.
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Number
Stop for futility if
Continue the trial if
Stop for efficacy if
of patients number of responses is number of responses is number of responses is
10
0-1
2-5
6-10
15
0-2
3-6
7-15
20
0-4
5-8
9-20
25
0-5
6-10
11-25
30
0-6
7-11
12-30
35
0-8
9-13
14-35
40
0-9
10-14
15-40
45
0-11
12-16
17-45
50
0-12
13-17
18-50
Table 6.1: Full stopping boundaries for efficacy and futility monitoring using Bayes factor. The null
response rate is 0.2 and the alternative response rate is 0.4. The trial stops for futility if BF01 > 9
and for efficacy if BF10 > 9. The prior effective sample size for the iMOM prior is 10. Patients
enter the trial with a cohort size of five and the first interim is conducted after ten patients are
treated.
Suppose at current interim analysis, where 20 patients are treated and seven responses
are observed, the trial should continue to enroll more patients based on the stopping boundaries
provided.
To run the simulation for various scenarios, users can use the Simulation tab after calculating stopping boundaries under Trial setting. As shown in Figure A6.9, enter the true response
rate and the desired number of simulated trials for each scenario, click on the “Simulate” button.
The simulation results will be shown on the right side of the app under the tab Operating characteristics. If users want to save their current parameter input for future use, they can easily do that
under the Summary of parameter input next to Operating characteristics. The simulation results
for our example are shown in Table 6.2. The results summarize the probabilities of claiming efficacy
and futility under each scenario, the average number of patients treated, and some quantiles that
may be of interest.
To generate the trial protocol, click on Protocol and a protocol template with full stopping
boundaries and simulation results can be downloaded as either an html or word file. The protocol
template for the current example can be seen in Figure A6.10. We also provide an extensive user
guide to illustrate the methods and how to use the app. This information is available under the
User guide tab.
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True response
Pr(claim efficacy)
Pr(claim futility)
Patients allocation*
0.20
0.0282
0.8910
22(10,10,20,30,45)
0.30
0.3210
0.4154
31(10,15,30,50,50)
0.40
0.8014
0.0976
25(10,15,20,35,50)
0.50
0.9796
0.0126
17(10,10,15,20,30)
0.60
0.9984
0.0014
13(10,10,10,15,15)
*Patients allocation: average number of patients and quantiles (10%, 25%,50%,
75%, 90%)
Table 6.2: Operating characteristics for a phase II study with sequential monitoring for both efficacy
and futility using Bayes factor with iMOM prior. The null response rate is 0.2 and the alternative
response rate is 0.4. The trial stops for futility if BF01 > 9 and for efficacy if BF10 > 9. The prior
effective sample size for the iMOM prior is 10. Patients enter the trial with a cohort size of five.
The first monitoring is conducted after ten patients are treated and subsequent interim monitoring
is carried out after every five patients. The maximum number of patients enrolled is 50.

6.6

Summary
In this study, we first investigated the connection between the TB and PB approaches. In

particular, we showed that TB sequential monitoring is essentially a special case of PB monitoring
with a sample-size-dependent stopping cutoff. In the second part of this chapter, we extensively
examined the effect of local and nonlocal priors on TB monitoring through simulation studies under
various settings with different maximum sample sizes and prior effective sample sizes. When the
treatment is indeed efficacious, using iMOM yields comparable probability of claiming efficacy in
comparison to the use of local priors, and the average number of patients are also comparable across
the use of the different priors. When the treatment is futile, the use of an iMOM prior has a much
greater probability to claim futility. The TB monitoring with iMOM also has a larger probability
of claiming futility at earlier interim analyses, which in turn results in a much smaller number of
patients enrolled, reducing the number of patients exposed to futile treatment.
In addition, we also noted that a phase II trial with an iMOM prior for TB monitoring
requires fewer patients to claim futility than to claim efficacy. This finding is consistent with what
was observed in the original reference [46] in which it was shown that the Bayes factor converges
faster to the true null hypothesis than to the true alternative hypothesis. Another important
observation is that the use of a Beta prior never results in claiming of futility when ESS is small,
even when the treatment is actually futile. With the increase in ESS, the probability of claiming
futility using a Beta prior will greatly increase, although it is still smaller than that of using an
iMOM prior.
In summation, we recommend the use of the iMOM prior for TB monitoring with Bayes

134

factor. To facilitate the use of an iMOM prior in trial monitoring, we developed a user-friendly web
app, which is freely available at www.trialdesign.org.

A
A6.0.1

Appendix

Interpretation of Bayes factor as the strength of evidence
Under the Bayesian hypothesis testing framework, a decision to reject the null hypothesis

occurs only when the Bayes factor in favor of the alternative hypothesis exceeds a prespecified
evidence level. Thus, it can quantify evidence in favor of the null hypothesis when the null hypothesis
is not rejected [55]. Table A6.1 provides the interpretation of the strength of evidence in terms of
both BF10 and log(BF10 ).
Table A6.1: Interpretation of Bayes factor(BF10 ) and its log scale as the strength of evidence for
H1 over H0 [47]
BF10
<1:1
1:1 to 3:1
3:1 to 20:1
20:1 to 150:1
>150:1

A6.0.2

log(BF10 )
<0
0 to 1
1 to 3
3 to 5
>5

Strength of evidence for H1
Support H0
Barely worth mentioning
Substantial
Strong
Very strong

iMOM density with varying parameters
We show the iMOM density as a function of (k, τ, ν) in Figure A6.1. It is noted that an

iMOM with larger values of k and τ has a wider null region and a heavier tail. In contrast, an
iMOM with a larger value of ν tends to have lighter tails.
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Figure A6.1: iMOM density with a null value at 0.2 under different parameter (k, τ, ν) settings.
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A6.0.3

The relative robustness of iMOM versus Beta
We show here, under the setting described in [25] that iMOM has similar performance to

the robust Cauchy prior (Figure A6.2).

Figure A6.2: Plot of prior, likelihood, and posterior distribution for the setting described in [25].
All the prior distributions have the same mode. The prior mean response rate is 0.2, corresponds
to a prior log(odds) of −1.39, but the observed response rate is 0.8 with a sample size of 20.

A6.0.4

Sensitivity analysis
We conducted a sensitivity analysis to assess the operating characteristics of the design

using different priors with maximum sample size (N ) varying from 20 to 200 and prior effective
sample size varying from 5 to 20. We show the results at N = 100 and ESS= (5, 20) in Figure
A6.3. As expected, the rise in both N and ESS escalates the probability of claiming efficacy when
the treatment is promising, and increases the probability of claiming futility when the treatment is
futile. Under all settings, the use of an iMOM prior requires much fewer patients (panels a3 and
b3 in Figure A6.3). This is because the trial always stops at earlier interim analyses for futility
(e.g., panel b in Figures A6.4-A6.7), thus requiring much fewer patients. We note that while under
the Beta prior, ESS changes from 5 to 20 will increase the probability of claiming futility from 0 to
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0.55 when N = 50 and from 0 to 0.79 when N = 100, but the stopping occurs at the later interim
analyses compared to that under iMOM (panel b in Figures A6.4 and A6.7).
In terms of trial efficiency, we found that iMOM was more desirable for futility monitoring
through all specifications of maximum sample size and prior effective sample size (e.g., Figures
A6.4- A6.7). Given a fixed ESS (e.g., 5), the use of iMOM has a comparable probability of claiming
efficacy in comparison to tBeta and beta when sample size is smaller, while it yields slightly smaller
probability of claiming efficacy when sample size is larger. For instance, when sample size decreases
to 25 (Figure A6.5), iMOM, tBeta, and Beta have the same probability of claiming efficacy (0.5),
which is slighter larger than that under tUniform (0.46); when sample size increases to 100 (Figure
A6.6), we note that iMOM has a smaller probability of claiming efficacy: 0.06%, 0.08%, 0.09%
smaller than tUniform, tBeta, and Beta, respectively. Given a fixed sample size (e.g., 50), the
larger the ESS, the smaller the difference between using iMOM and using tBeta in terms of the
probability of claiming efficacy. For example, when ESS=5 (Figure 6.2), the difference between
iMOM and tBeta is 0.08, but when ESS=20 (Figure A6.4), the difference is slightly smaller (0.03).
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Figure A6.3: Efficacy and futility sequential monitoring using Bayes factor with weakly informative
prior distributions (ESS=5) and a strongly informative prior (ESS=20). When ESS=5, the iMOM
has parameters k = 0.325, ν = 0.65, τ = 0.7029 and the local prior is Beta(2.2, 2.8). When ESS=20,
the iMOM has parameters k = 1.685,ν = 3.37, τ = 0.0467 and the local prior is Beta(8.2, 11.8).
The maximum sample size is 100.
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Figure A6.4: Probability of claiming efficacy under H1 and probability of claiming futility under
H0 at each interim or final analysis when maximum sample size N = 50 and prior effective sample
size is 20. The numbers in parentheses represent the overall probabilities of claiming futility or
efficacy in the trial.
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Figure A6.5: Probability of claiming efficacy under H1 and probability of claiming futility under H0
at each interim or final analysis when maximum sample size N = 25 and prior effective sample size
is 5. The numbers in parentheses represent the overall probabilities of claiming futility or efficacy
in the trial.
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Figure A6.6: Probability of claiming efficacy under H1 and probability of claiming futility under
H0 at each interim or final analysis when maximum sample size N = 100 and prior effective sample
size is 5. The numbers in parentheses represent the overall probabilities of claiming futility or
efficacy in the trial.
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Figure A6.7: Probability of claiming efficacy under H1 and probability of claiming futility under
H0 at each interim or final analysis when maximum sample size N = 100 and prior effective sample
size is 20. The numbers in parentheses represent the overall probabilities of claiming futility or
efficacy in the trial.
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A6.0.5

Output for the shiny application example
In this section, we show examples of the typical outputs for TB monitoring using iMOM

prior with the web-based app available at www.trialdesign.org. Figure A6.8 shows the full
stopping boundaries and the corresponding iMOM prior given trial parameters set in Figure 6.3.
Figure A6.9 displays the output for simulations when a trial is planned. And Figure A6.10 showcases
the formatted protocol for the example provided in the main text.

Figure A6.8: Full stopping boundaries and iMOM prior determined by the input under Trial
setting in the Shiny app, as shown in Figure 6.3.
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Figure A6.9: Example of simulation output.

Figure A6.10: An example for the template of protocol.
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CHAPTER 7

Conclusion

In Chapter 2, we reviewed the the designs available for Phase I clinical trials, and elucidated
the similarity and difference between the recently proposed algorithm-based i3+3 design and the
model-assisted BOIN design. We showed that the i3+3 design adopted very similar decision rules
as the BOIN design, but because of taking the algorithm-based design framework, it suffers from a
series of scientific and logical deficiencies inherited in algorithm-based designs. We further showed
that the “de-escalation modification rule” used by i3+3 to differentiate it from BOIN does not
improve, but often impair the design performance. Simulation study shows that compared to the
i3+3 design, the BOIN design has better accuracy to correctly identify the MTD and is safer with
lower risk of overdosing patients. In addition, BOIN is also simpler, more transparent and has been
widely validated in a variety of clinical trials, thus provides a better choice for Phase I oncology
trials.
Although BOIN has been well-validated and used in a wide range of Phase I clinical trials,
it has been perceived by many that it, as a model-assisted design, cannot incorporate historical
information or real-world evidence into trial planning and conduct. Similar concerns are true for
other model-assisted designs, such as mTPI and Keyboard/mTPI-2. To improve the efficiency of
the model-assisted Phase I designs, in Chapter 3, we proposed a systematic way to incorporate prior
estimated DLT probabilities obtained from historical data, external trials, or real-world evidence
into the designs. The proposed method takes a similar approach as the CRM skeleton and combines
it with the concept of prior effective sample size to incorporate informative prior information into
the model-assisted designs, including BOIN and keyboard. The resulting designs are referred to as
iBOIN and iKeyboard, respectively. The approach is readily applicable to mTPI. The reason why
we did not include it here is that this design has a severe problem of overdosing patients and thus
not a good alternative for Phase I clinical trials. A robust prior is also proposed to accommodate
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the case where clinicians are not very certain about the prior estimate of DLT probabilities for the
doses under investigation. Additionally, in this chapter, we also quantified the effective sample size
induced by the normal distribution on the hyper-parameter in CRM, using a more straightforward
approach. CRM using informative prior is denoted as iCRM. Our simulation results demonstrate
that when prior MTD is correctly specified, all the informative designs greatly improve both the
percentage of correctly selecting the true MTD and the percentage of assigning patients to the
MTD, with the largest improvement observed in iBOIN. Both iCRM and iKeyboard are riskier than
iBOIN. The iKeyboard is also the most sensitive design to prior specification. We recommended
iBOIN for Phase I clinical trials when good prior information is available, due to the simplicity and
superior performance of the design. iBOIN with robust prior or standard BOIN should be used if
it is anticipated that the prior may not well approximate the true DLT probability curve.
In Chapter 4, we proposed the U-BOIN, a seamless Phase I/II model-assisted design, to
identify the optimal biological dose (OBD) for targeted and immunotherapy trials. The U-BOIN
design accounts for the efficacy-toxicity trade-off using a utility function. Unlike most existing
Phase I/II designs, which require complicated real-time model fitting and estimation to make dose
assignment decisions, the U-BOIN is simple and easy to implement. The dose assignment rules of
the U-BOIN can be pre-tabulated in decision tables and included in the trial protocol before the
onset of a trial. To conduct the trial, no complicated calculation is needed. The investigator can
simply use the decision tables to make the decision of dose escalation/de-escalation. Simulation
studies show that compared to a more complicated model-based Phase I/II design, the U-BOIN
has higher accuracy to identify OBD and is more robust. Besides immunotherapy and targeted
trials, U-BOIN also can be used for conventional cytotoxic agent trials. In such cases, both toxicity
and efficacy typically increase with the dose, but may do so at different rates. It is likely that
increasing the dose causes much higher toxicity, with limited efficacy gain. The idea of risk-benefit
trade-off is still generally applicable here for use in most medical decisions in practice. Like most
model-assisted designs, U-BOIN models efficacy and toxicity at each dose independently, whereas
model-based Phase I/II designs (e.g., EffTox design) model efficacy and toxicity across all doses,
through imposing a parametric dose-efficacy and -toxicity curve model. As a result, one may worry
about the potential efficiency loss for U-BOIN. Our numerical study and previous studies show that,
for the purpose of dose finding, the efficiency loss caused by using only local data (in model-assisted
designs, such as U-BOIN) is minimal or negligible. This is because, to make correct decisions of
dose assignment and selection, we only need to correctly estimate the rank of utility across the
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doses. A slightly more variability on the estimate of the utility has no or negligible impact on the
performance of the design.
In addition to our extensions of the BOIN to incorporate informative prior (iBOIN) and to
identify OBD by measuring dose desirability using utility function (U-BOIN), there are many other
designs that have built upon the BOIN design to address different challenges in Phase I clinical
trials. For instance, it has been extended to address the issues brought by fast accrual, delayed
outcome, and evaluation of drug combinations. Keyboard has been shown to have comparable
operating characteristics to BOIN in numerous studies and it also has been extended to address delayed toxicity problems and to identify MTD in drug-combination trials. However, the use of these
designs is limited due to the lack of reliable, robust, and user-friendly software. To facilitate the use
of the model-assisted designs for designing and conducting Phase I clinical trials and make it more
accessible for clinicians who may not have expertise in statistical programming, we developed a software platform for BOIN designs (BOIN suite) and keyboard designs (Keyboard suite), respectively,
in Chapter 5. The BOIN suites include designs for single-agent trials using non-informative prior
(standard BOIN) or using informative prior derived from historical data (iBOIN); for single-agent
trials with fast accrual or delayed toxicity (TITE-BOIN); for drug-combination (BOIN COMB) to
find a single MTD or a MTD contour; and for utility-based BOIN design (U-BOIN) to find OBD for
immunothearpy and targeted therapy trials. Keyboard suite includes designs for single-agent trials
without delayed toxicity (KEYBOARD [105]) or with delayed toxicity (TITE-KEYBOARD [57]);
and for drug-combination trials to find a single MTD (KEYBOARD COMB [80]). The strengths
of the BOIN suite and Keyboard suite are that they (1) run under different operating systems;
(2) do not require any installation; (3) do not require statistical programming skills to use: (4)
provide comprehensive user help files; and (5) are regularly maintained and free to use. Another
unique feature of the two software suite is that all the designs are model-assisted and thus provide
simple-to-use decision rules like that in 3+3, which is easy for practitioners familiar with 3+3 to
adopt these new adaptive designs.
In Chapter 6, we first studied the connection between the Bayesian hypothesis test based
(TB) and posterior/predictive probability based (PB) approaches for sequential monitoring in Phase
II clinical trials. In particular, we showed that the TB sequential monitoring (using Bayes factor)
is essentially a special case of the PB monitoring with a sample-size-dependent stopping cutoff. In
the second part of this chapter, we extensively examined the effect of local and nonlocal prior on
TB monitoring through simulation studies under various settings with different maximum sample
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sizes and prior effective sample sizes. The TB monitoring with nonlocal prior (e.g., iMOM prior)
has larger probability of claiming futility at earlier interim analyses when the treatment under
investigation is indeed futile, which in turn result in much smaller number of patients enrolled,
reducing the number of patients exposed to futile treatment. Additionally, we also noted that a
Phase II trial with iMOM prior for TB monitoring requires fewer patients to claim futility than
to claim efficacy. This finding is consistent with what observed in the original reference, in which
it was shown that the Bayes factor converges faster to the true null hypothesis than to the true
alternative hypothesis. Another important observation is that the use of local prior (e.g., Beta
prior) never results in claiming of futility when ESS is small, even when the treatment is actually
futile. With the increase in ESS, the probability of claiming futility using Beta prior will greatly
increase, although it is still smaller than that using nonlocal prior. For the above reasons, we
recommended the use of iMOM prior for TB monitoring with Bayes factor. To facilitate the use of
iMOM prior in trial monitoring, we also developed a user-friendly web-based app, which is freely
available at www.trialdesign.org.
To sum up, chapters 2-6 contain five projects that make significant contributions to drug
development, as these projects advance the research of early phase clinical trial designs by providing
novel model-assisted designs and facilitate a broader use of efficient model-assisted designs in early
phase clinical trials by constructing user-friendly apps.
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